<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Fluoxetine for adults who are overweight or obese - Serralde-Zúñiga, AE - 2019 | Cochrane Library</title> <meta content="Fluoxetine for adults who are overweight or obese - Serralde-Zúñiga, AE - 2019 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011688.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Fluoxetine for adults who are overweight or obese - Serralde-Zúñiga, AE - 2019 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011688.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD011688.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Fluoxetine for adults who are overweight or obese" name="citation_title"/> <meta content="Aurora E Serralde-Zúñiga" name="citation_author"/> <meta content="Instituto Nacional de Ciencias Medicas y Nutrición Salvador Zubirán" name="citation_author_institution"/> <meta content="Alejandro G Gonzalez Garay" name="citation_author"/> <meta content="Instituto Nacional de Pediatría" name="citation_author_institution"/> <meta content="pegasso.100@hotmail.com" name="citation_author_email"/> <meta content="Yanelli Rodríguez-Carmona" name="citation_author"/> <meta content="University of Michigan School of Public Health" name="citation_author_institution"/> <meta content="Guillermo Melendez" name="citation_author"/> <meta content="Hospital General de Mexico Dr. Eduardo Liceaga" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="10" name="citation_issue"/> <meta content="10.1002/14651858.CD011688.pub2" name="citation_doi"/> <meta content="2019" name="citation_date"/> <meta content="2019/10/15" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011688.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011688.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011688.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011688.pub2&amp;doi=10.1002/14651858.CD011688.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011688.pub2&amp;doi=10.1002/14651858.CD011688.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011688.pub2&amp;doi=10.1002/14651858.CD011688.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011688.pub2&amp;doi=10.1002/14651858.CD011688.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011688.pub2&amp;doi=10.1002/14651858.CD011688.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011688.pub2&amp;doi=10.1002/14651858.CD011688.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011688.pub2&amp;doi=10.1002/14651858.CD011688.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011688.pub2&amp;doi=10.1002/14651858.CD011688.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011688.pub2&amp;doi=10.1002/14651858.CD011688.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011688.pub2&amp;doi=10.1002/14651858.CD011688.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011688.pub2&amp;doi=10.1002/14651858.CD011688.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011688.pub2&amp;doi=10.1002/14651858.CD011688.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011688.pub2&amp;doi=10.1002/14651858.CD011688.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011688.pub2&amp;doi=10.1002/14651858.CD011688.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011688.pub2&amp;doi=10.1002/14651858.CD011688.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011688.pub2&amp;doi=10.1002/14651858.CD011688.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011688.pub2&amp;doi=10.1002/14651858.CD011688.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011688.pub2&amp;doi=10.1002/14651858.CD011688.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011688.pub2&amp;doi=10.1002/14651858.CD011688.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011688.pub2&amp;doi=10.1002/14651858.CD011688.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011688.pub2&amp;doi=10.1002/14651858.CD011688.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011688.pub2&amp;doi=10.1002/14651858.CD011688.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011688.pub2&amp;doi=10.1002/14651858.CD011688.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774054000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774081000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000"}};Liferay.authToken="xNbeAU8n";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD011688\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD011688\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011688\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011688\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1559916434000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","de","zh_HANS","zh_HANT","ru","pt","ko","ms","hr","fa","fr","pl"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD011688.pub2",title:"Fluoxetine for adults who are overweight or obese",firstPublishedDate:"Oct 15, 2019 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Metabolic and Endocrine Disorders Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738735355000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=xNbeAU8n&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011688.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD011688.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD011688.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD011688.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011688.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD011688.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD011688.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD011688.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD011688.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD011688.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;초록&quot;},{&quot;language&quot;:&quot;pt&quot;,&quot;title&quot;:&quot;Resumo&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Zusammenfassung in einfacher Sprache&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;쉬운 말 요약&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;pl&quot;,&quot;title&quot;:&quot;Streszczenie prostym językiem&quot;},{&quot;language&quot;:&quot;pt&quot;,&quot;title&quot;:&quot;Resumo para leigos&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;淺顯易懂的口語結論&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD011688.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD011688.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD011688.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD011688.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>13390 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD011688.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011688.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011688.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011688.pub2/full#CD011688-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011688.pub2/full#CD011688-sec-0115"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011688.pub2/full#CD011688-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011688.pub2/full#CD011688-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011688.pub2/full#CD011688-sec-0015"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011688.pub2/full#CD011688-sec-0016"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011688.pub2/full#CD011688-sec-0055"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011688.pub2/full#CD011688-sec-0109"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD011688.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011688.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011688.pub2/appendices#CD011688-sec-0120"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011688.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011688.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD011688.pub2/media/CDSR/CD011688/supinfo/CD011688StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD011688.pub2/media/CDSR/CD011688/supinfo/CD011688StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011688.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011688.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011688.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD011688.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD011688.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2022 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD011688.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Fluoxetine for adults who are overweight or obese</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011688.pub2/information#CD011688-cr-0004">Aurora E Serralde-Zúñiga</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011688.pub2/information#CD011688-cr-0005"><i class="icon corresponding-author fa fa-envelope"></i>Alejandro G Gonzalez Garay</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011688.pub2/information#CD011688-cr-0006">Yanelli Rodríguez-Carmona</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011688.pub2/information#CD011688-cr-0007">Guillermo Melendez</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD011688.pub2/information/en#CD011688-sec-0139">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 15 October 2019 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD011688.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD011688.pub2">https://doi.org/10.1002/14651858.CD011688.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD011688-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD011688-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD011688-abs-0019">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD011688-abs-0014">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD011688-abs-0016">Français</a> </li> <li class="section-language"> <a class="" href="full/ko#CD011688-abs-0010">한국어</a> </li> <li class="section-language"> <a class="" href="full/pt#CD011688-abs-0008">Português</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD011688-abs-0004">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD011688-abs-0001" lang="en"> <section id="CD011688-sec-0001"> <h3 class="title" id="CD011688-sec-0001">Background</h3> <p>Fluoxetine is a serotonin reuptake inhibitor indicated for major depression. It is also thought to affect weight control: this seems to happen through appetite changes resulting in decreased food intake and normalisation of unusual eating behaviours. However, the benefit‐risk ratio of this off‐label medication is unclear. </p> </section> <section id="CD011688-sec-0002"> <h3 class="title" id="CD011688-sec-0002">Objectives</h3> <p>To assess the effects of fluoxetine for overweight or obese adults.</p> </section> <section id="CD011688-sec-0003"> <h3 class="title" id="CD011688-sec-0003">Search methods</h3> <p>We searched the Cochrane Library, MEDLINE, Embase, LILACS, the ICTRP Search Portal and ClinicalTrials.gov and World Health Organization (WHO) ICTRP Search Portal. The last date of the search was December 2018 for all databases, to which we applied no language restrictions . </p> </section> <section id="CD011688-sec-0004"> <h3 class="title" id="CD011688-sec-0004">Selection criteria</h3> <p>We included randomised controlled trials (RCTs) comparing the administration of fluoxetine versus placebo, other anti‐obesity agents, non‐pharmacological therapy or no treatment in overweight or obese adults without depression, mental illness or abnormal eating patterns. </p> </section> <section id="CD011688-sec-0005"> <h3 class="title" id="CD011688-sec-0005">Data collection and analysis</h3> <p>Two review authors independently screened abstracts and titles for relevance. Screening for inclusion, data extraction and risk of bias assessment was performed by one author and checked by the second. We assessed trials for the overall certainty of the evidence using the GRADE instrument. For additional information we contacted trial authors by email. We performed random‐effects meta‐analyses and calculated the risk ratio (RR) with 95% confidence intervals (95% CI) for dichotomous outcomes and the mean difference (MD) with 95% CI for continuous outcomes. </p> </section> <section id="CD011688-sec-0006"> <h3 class="title" id="CD011688-sec-0006">Main results</h3> <p>We identified 1036 records, scrutinized 52 full‐text articles and included 19 completed RCTs (one trial is awaiting assessment). A total of 2216 participants entered the trials, 1280 participants were randomly assigned to fluoxetine (60 mg/d, 40 mg/d, 20 mg/d and 10 mg/d) and 936 participants were randomly assigned to various comparison groups (placebo; the anti‐obesity agents diethylpropion, fenproporex, mazindol, sibutramine, metformin, fenfluramine, dexfenfluramine, fluvoxamine, 5‐hydroxy‐tryptophan; no treatment; and omega‐3 gel). Within the 19 RCTs there were 56 trial arms. Fifteen trials were parallel RCTs and four were cross‐over RCTs. The participants in the included trials were followed up for periods between three weeks and one year. The certainty of the evidence was low or very low: the majority of trials had a high risk of bias in one or more of the risk of bias domains. </p> <p>For our main comparison group — fluoxetine versus placebo — and across all fluoxetine dosages and durations of treatment, the MD was −2.7 kg (95% CI −4 to −1.4; P &lt; 0.001; 10 trials, 956 participants; low‐certainty evidence). The 95% prediction interval ranged between −7.1 kg and 1.7 kg. The MD in body mass index (BMI) reduction across all fluoxetine dosages compared with placebo was −1.1 kg/m² (95% CI −3.7 to 1.4; 3 trials, 97 participants; very low certainty evidence). Only nine placebo‐controlled trials reported adverse events. A total of 399 out of 627 participants (63.6%) receiving fluoxetine compared with 352 out of 626 participants (56.2%) receiving placebo experienced an adverse event. Random‐effects meta‐analysis showed an increase in the risk of having at least one adverse event of any type in the fluoxetine groups compared with placebo (RR 1.18, 95% CI 0.99 to 1.42; P = 0.07; 9 trials, 1253 participants; low‐certainty evidence). The 95% prediction interval ranged between 0.74 and 1.88. Following fluoxetine treatment the adverse events of dizziness, drowsiness, fatigue, insomnia and nausea were observed approximately twice as often compared to placebo. A total of 15 out of 197 participants (7.6%) receiving fluoxetine compared with 12 out of 196 participants (6.1%) receiving placebo experienced depression. The RR across all fluoxetine doses compared with placebo was 1.20 (95% CI 0.57 to 2.52; P = 0.62; 3 trials, 393 participants; very low certainty evidence). All‐cause mortality, health‐related quality of life and socioeconomic effects were not reported. </p> <p>The comparisons of fluoxetine with other anti‐obesity agents (3 trials, 234 participants), omega‐3 gel (1 trial, 48 participants) and no treatment (1 trial, 60 participants) showed inconclusive results (very low certainty evidence). </p> </section> <section id="CD011688-sec-0007"> <h3 class="title" id="CD011688-sec-0007">Authors' conclusions</h3> <p>Low‐certainty evidence suggests that off‐label fluoxetine may decrease weight compared with placebo. However, low‐certainty evidence suggests an increase in the risk for dizziness, drowsiness, fatigue, insomnia and nausea following fluoxetine treatment. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD011688-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD011688-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/de#CD011688-abs-0003">Deutsch</a> </li> <li class="section-language"> <a class="" href="full/es#CD011688-abs-0020">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD011688-abs-0015">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD011688-abs-0017">Français</a> </li> <li class="section-language"> <a class="" href="full/hr#CD011688-abs-0013">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/ko#CD011688-abs-0011">한국어</a> </li> <li class="section-language"> <a class="" href="full/ms#CD011688-abs-0012">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/pl#CD011688-abs-0018">Polski</a> </li> <li class="section-language"> <a class="" href="full/pt#CD011688-abs-0009">Português</a> </li> <li class="section-language"> <a class="" href="full/ru#CD011688-abs-0007">Русский</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD011688-abs-0005">简体中文</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD011688-abs-0006">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD011688-abs-0002" lang="en"> <h3>Fluoxetine for overweight or obese adults</h3> <p><b>Review question</b><br/>What are the effects of fluoxetine treatment in overweight or obese adults? </p> <p><b>Background</b><br/>Fluoxetine is a medicine used for the treatment of depression, which reduces appetite as a side effect. Therefore, it is suspected that fluoxetine could be used as a treatment for overweight or obese people. In this group of people administration of fluoxetine means an off‐label treatment which means it is not licensed for treating obesity. </p> <p><b>Study characteristics</b><br/>We found 19 randomised controlled trials (clinical studies where people are randomly put into one of two or more treatment groups) evaluating mainly women receiving different doses of fluoxetine. A total of 1280 overweight or obese participants received fluoxetine and 936 participants received mainly placebo or another anti‐obesity medication. The participants in the included studies were followed up for periods varying between three weeks and one year. </p> <p><b>Key results</b><br/>For our main comparison group — fluoxetine compared with placebo — and for all fluoxetine doses there was a 2.7 kg weight loss in favour of fluoxetine. We are uncertain, however, if an additional study would again show a benefit for fluoxetine. A total of 399 out of 627 participants (63.6%) receiving fluoxetine compared with 352 out of 626 participants (56.2%) receiving placebo experienced a side effect. Dizziness, drowsiness, fatigue, insomnia and nausea were observed approximately twice as often after fluoxetine compared to placebo. A total of 15 out of 197 participants (7.6%) receiving fluoxetine compared with 12 out of 196 participants (6.1%) receiving placebo experienced depression. The studies did not report on death from any cause, health‐related quality of life and socioeconomic effects. </p> <p>This evidence is up to date as of December 2018.</p> <p><b>Certainty of the evidence</b><br/>The overall certainty of the evidence was low or very low, mainly because of the small number of studies per outcome measurement and the small number of participants. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD011688-sec-0115" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD011688-sec-0115"></div> <h3 class="title" id="CD011688-sec-0116">Implications for practice</h3> <section id="CD011688-sec-0116"> <p>Approved indications for use of fluoxetine are major depression, obsessive behaviours, panic disorders and bulimia. We observed low‐certainty evidence suggesting that off‐label fluoxetine may produce a modest weight loss compared with placebo at any dose, especially when given at a dose of 60 mg/day. However, we found low‐certainty evidence of a small increase in the risk for specific adverse events, such as dizziness, drowsiness, fatigue, insomnia and nausea following fluoxetine consumption. With respect to other findings of our review, there were limited data from other comparator anti‐obesity agents and non‐pharmacological therapies were scarce. </p> </section> <h3 class="title" id="CD011688-sec-0117">Implications for research</h3> <section id="CD011688-sec-0117"> <p>Further research is required to determine whether the administration of fluoxetine has any effect on morbidity, socioeconomic effects and health‐related quality of life in overweight and obese people, as well as whether this intervention might be useful in combination with other anti‐obesity agents or with non‐pharmacological interventions to reduce weight. To ensure the efficacy and safety of fluoxetine in overweight or obese adults high‐certainty evidence is needed to analyse the effects of long‐term use of fluoxetine to promote weight loss and to determine the severity of adverse events. On the other hand, researchers should improve their efforts to reduce high attrition rates in these types of long‐term therapies. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD011688-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD011688-sec-0008"></div> <div class="table" id="CD011688-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Summary of findings: fluoxetine compared with placebo</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Fluoxetine compared with placebo</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Population:</b> overweight or obese adults </p> <p><b>Settings:</b> outpatients </p> <p><b>Intervention:</b> fluoxetine </p> <p><b>Comparison:</b> placebo </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Placebo</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Fluoxetine</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>No of participants<br/>(trials)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Weight loss (kg)</b> </p> <p>(a) All fluoxetine dosages</p> <p>(b) Fluoxetine 60 mg/d<br/>(c) Fluoxetine 40 mg/d<br/>(d) Fluoxetine 20 mg/d </p> <p>Follow‐up:</p> <p>(a) 11 days to 52 weeks</p> <p>(b) 11 days to 52 weeks</p> <p>(c) 8 &amp; 12 weeks</p> <p>(d) 8 weeks to 52 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>(a) The mean weight loss ranged across placebo groups from −4.9 kg to 0.3 kg</p> <p>(b) The mean weight loss ranged across placebo groups from −4.9 kg to 0.3 kg<br/>(c) The mean weight loss ranged across placebo groups from −1.7 kg to −0.5 kg<br/>(d) The mean weight loss ranged across placebo groups from −3.1 kg to −0.5 kg </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>(a) The mean weight loss in the fluoxetine groups was <b>2.7 kg</b> higher (4 kg higher to 1.4 kg higher) </p> <p>(b) The mean weight loss in the fluoxetine groups was <b>2.5 kg</b> higher (3.8 kg higher to 1.2 kg higher)<br/>(c) The mean weight loss in the fluoxetine groups was <b>4 kg</b> higher (8.8 kg higher to 0.8 kg lower) </p> <p>(d) The mean weight loss in the fluoxetine groups was <b>1.5 kg</b> higher (3.5 kg higher to 0.5 kg lower) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(a) 956 (10)</p> <p>(b) 819 (7)<br/>(c) 182 (2)<br/>(d) 279 (3) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(a) &amp; (b)</p> <p>⊕⊝⊝⊝<br/><b>low</b><sup>a</sup> </p> <p>(c) &amp; (d)<br/>⊝⊝⊝⊝<br/><b>very</b> <b>low</b><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(a) The 95% prediction interval ranged between −7.1 kg and 1.7 kg</p> <p>(b) The 95% prediction interval ranged between −6.4 kg and 1.4 kg</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p><b>Health‐related quality of life</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p><b>Not reported</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Any adverse event (N)</b> </p> <p>Follow‐up: median 3 months, maximum 12 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>562 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>664 per 1000</b> (557 to 798) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.18</b> (0.99 to 1.42) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1253 (9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>l<b>ow</b><sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Only 9/19 trials reported on the outcome 'any adverse event'</p> <p>Adverse events dizziness, drowsiness, fatigue, insomnia and nausea were observed approximately twice as often following fluoxetine treatment </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Anthropometric measurements other than weight loss in kg (BMI reduction measured in</b> <b>kg/m²)</b> </p> <p>Follow‐up: median 3 months, maximum 12 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean BMI ranged across placebo groups from −0.4 kg/m² to −1.2 kg/m²</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean BMI reduction in the fluoxetine groups was <b>1.1 kg/m²</b> higher (3.7 kg/m² higher to 1.4 kg/m² lower) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>97 (3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>very low</b><sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Morbidity: depression (N)</b> </p> <p>Follow‐up: median 9.2 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>61 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>73 per 1000</b> (35 to 154) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.20</b> (0.57 to 2.52) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>393 (3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>very low</b><sup>e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>All‐cause mortality</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p><b>Not reported</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Socioeconomic effects</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p><b>Not reported</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>BMI:</b> boy mass index; <b>CI:</b> confidence interval; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>GRADE Working Group grades of evidence<br/><b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded by 1 level because of reporting bias and by 1 level because of imprecision (small median sample size) ‒ see <a href="./appendices#CD011688-sec-0121">Appendix 1</a><br/><sup>b</sup>Downgraded by 1 level because of reporting bias and attrition bias, by 1 level because of inconsistency (point estimates varied widely) and by 1 level because of imprecision (small median sample size, small number of trials) ‒ see <a href="./appendices#CD011688-sec-0121">Appendix 1</a><br/><sup>c</sup>Downgraded by 1 level because of reporting bias and attrition bias, and by 1 level because of imprecision (small median sample) ‒ see <a href="./appendices#CD011688-sec-0121">Appendix 1</a><br/><sup>d</sup>Downgraded by 1 level because of reporting bias and performance bias and by 2 levels because of imprecision (CI consistent with benefit and harm, small median sample size, small number of trials) ‒ see <a href="./appendices#CD011688-sec-0121">Appendix 1</a><br/><sup>e</sup>Downgraded by 1 level because of reporting bias, performance bias and attrition bias, and by 2 levels because of imprecision (CI consistent with benefit and harm, small median sample size, small number of trials) ‒ see <a href="./appendices#CD011688-sec-0121">Appendix 1</a> </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD011688-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD011688-sec-0009"></div> <section id="CD011688-sec-0010"> <h3 class="title" id="CD011688-sec-0010">Description of the condition</h3> <p>Excess body weight is the sixth most important risk factor contributing to the overall burden of non‐communicable diseases (NCDs) worldwide. Over the past 30 years, the prevalence of weight gain has considerably increased in high‐, low‐ and middle‐income countries. According to the latest available estimates and projections, the World Health Organization (WHO) indicated that approximately 1.9 billion adults aged 18 years and over were overweight and 600 million were obese in 2014 (<a href="./references#CD011688-bbs2-0108" title="World Health Organization. Obesity and overweight. www.who.int/mediacentre/factsheets/fs311/en (accessed 30 April 2015).">WHO 2014</a>). In addition, the projection for the next 15 years is not promising: if current secular trends continue at the same pace, by 2030 the estimated total numbers of overweight and obese people will be 2.16 billion and 1.12 billion, respectively (<a href="./references#CD011688-bbs2-0086" title="KellyT , YangW , ChenCS , ReynoldsK , HeJ . Global burden of obesity in 2005 and projections to 2030. International Journal of Obesity (2005)2008;32(9):1431-7. [DOI: 10.1038/ijo.2008.102]">Kelly 2008</a>), with most residing in low‐ and middle‐income countries. </p> <p>It is well known that NCDs are the leading causes of death worldwide. Of the 57 million deaths that occurred in 2008, the majority (36 million) were attributed to cardiovascular diseases, diabetes, cancers and chronic respiratory diseases (<a href="./references#CD011688-bbs2-0108" title="World Health Organization. Obesity and overweight. www.who.int/mediacentre/factsheets/fs311/en (accessed 30 April 2015).">WHO 2014</a>). </p> <p>Body mass index (BMI) is useful for identifying individuals who are overweight and obese in adult populations. BMI is calculated by dividing a person's weight (in kilograms) by the square of her/his height (in metres) (kg/m²). Individuals with a BMI ranging from 25 to 29.9 are classified as being overweight, and those with a BMI of 30 or more are considered obese. Weight gain is associated with NCDs, including cardiovascular diseases, stroke, hypertension, osteoarthritis, fatty liver, several types of cancers, metabolic syndrome, respiratory disorders and type 2 diabetes mellitus (<a href="./references#CD011688-bbs2-0075" title="HaslamDW , JamesWP . Obesity. Lancet2005;366(9492):1197-209.">Haslam 2005</a>; <a href="./references#CD011688-bbs2-0108" title="World Health Organization. Obesity and overweight. www.who.int/mediacentre/factsheets/fs311/en (accessed 30 April 2015).">WHO 2014</a>). </p> <p>Obesity has become a major public health concern, and it alone represents an independent risk factor for cardiovascular disease; therefore, the global state of this condition necessitates effective preventive and therapeutic strategies to reduce its prevalence and abate the costs of complications. The adverse health consequences of obesity are manifold, potentially involving all major organ systems and the detriment of health‐related quality of life (<a href="./references#CD011688-bbs2-0095" title="National Task Force on the Prevention and Treatment of Obesity. Overweight, obesity, and health risk. Archives of Internal Medicine2000;160(7):898-904. [DOI: 10.1001/archinte.160.7.898.]">NTF 2000</a>). It has been shown, moreover, that life expectancy is reduced by seven years in obese individuals aged 40 years and older (<a href="./references#CD011688-bbs2-0096" title="PeetersA , BarendregtJJ , WillekensF , MackenbachJP , Al MamunA , BonneuxL . NEDCOM, the Netherlands epidemiology and demography compression of morbidity research group. Obesity in adulthood and its consequences for life expectancy: a life-table analysis. Annals of Internal Medicine2003;138(1):24-32.">Peeters 2003</a>). </p> </section> <section id="CD011688-sec-0011"> <h3 class="title" id="CD011688-sec-0011">Description of the intervention</h3> <p>Non‐pharmacological, pharmacological and surgical strategies to reduce weight and maintain weight loss over time should be made available to individuals with these conditions. Pharmacological therapy has been used for some people, in addition to behaviour‐changing interventions, to facilitate weight loss and prevent weight rebound for a certain period of time. </p> <p>Fluoxetine is a selective serotonin reuptake inhibitor (SSRI) with the capacity to enhance serotonin activity. Although it has not been approved for weight loss, it is being prescribed for this indication (<a href="./references#CD011688-bbs2-0055" title="AnelliM , BizziA , CacciaS , CadegoniAM , FracassoC , GarattiniS . Anorectic activity of fluoxetine and norfluoxetine in mice, rats and guinea pigs. Journal of Pharmacy and Pharmacology1992;44(8):696-8.">Anelli 1992</a>). </p> <p>Approved indications for fluoxetine are major depression, obsessive behaviours, panic disorders and bulimia (<a href="./references#CD011688-bbs2-0053" title="AignerM , TreasureJ , KayeW , KasperS , WFSBP Task Force on Eating Disorders. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of eating disorders. World Journal of Biological Psychiatry2011;12(6):400-43.">Aigner 2011</a>; <a href="./references#CD011688-bbs2-0056" title="Beasley CM Jr, BosomworthJC , WernickeJF . Fluoxetine: relationships among dose, response, adverse events, and plasma concentrations in the treatment of depression. Psychopharmacology Bulletin1990;26(1):18-24.">Beasley 1990</a>; <a href="./references#CD011688-bbs2-0074" title="HalpernA , ManciniMC . Treatment of obesity: an update on anti-obesity medications. Obesity Reviews2003;4(1):25-42.">Halpern 2003</a>; <a href="./references#CD011688-bbs2-0096" title="PeetersA , BarendregtJJ , WillekensF , MackenbachJP , Al MamunA , BonneuxL . NEDCOM, the Netherlands epidemiology and demography compression of morbidity research group. Obesity in adulthood and its consequences for life expectancy: a life-table analysis. Annals of Internal Medicine2003;138(1):24-32.">Peeters 2003</a>). However, physicians have used it off‐label to promote weight loss (<a href="./references#CD011688-bbs2-0007" title="DargaL , Carroll-MichalsL , BotsfordS , LucasC . Fluoxetine's effect on weight loss in obese subjects. American Journal of Clinical Nutrition1991;54(2):321-5. GoldsteinD , RampeyA , EnasG , PotvinJ , FludzinskiL , LevineL . Fluoxetine: a randomized clinical trial in the treatment of obesity. International Journal of Obesity and Related Metabolic Disorders1994;18(3):129-35. ">Goldstein 1994</a>; <a href="./references#CD011688-bbs2-0097" title="ReimherrF , AmsterdamJ , QuitkinF , RosenbaumJ , FavaM , ZajeckaJ , et al. Optimal length of continuation therapy in depression: a prospective assessment during long-term fluoxetine treatment. American Journal of Psychiatry1998;155(9):1247-53. [DOI: 10.1176/ajp.155.9.1247]">Reimherr 1998</a>; <a href="./references#CD011688-bbs2-0103" title="SerrettiA , MandelliL . Antidepressants and body weight: a comprehensive review and meta-analysis. Journal of Clinical Psychiatry2010;71(10):1259-72.">Serretti 2010</a>). </p> <section id="CD011688-sec-0012"> <h4 class="title">Adverse effects of the intervention</h4> <p>The adverse effects of fluoxetine with incidences of greater than 5% are headache, nausea, somnolence, asthenia, diarrhoea, insomnia, nervousness, sweating and tremor (<a href="./references#CD011688-bbs2-0109" title="WiseS . Clinical studies with fluoxetine in obesity. American Journal of Clinical Nutrition1992;55(1 Suppl):181S-4S. [PMID: 1728831]">Wise 1992</a>). Additionally sexual dysfunction has been reported, including erectile dysfunction, anorgasmia and diminished libido, which have been well documented in 30% to 70% of people and frequently result in treatment non‐compliance (<a href="./references#CD011688-bbs2-0062" title="ColmanE , GoldenJ , RobertsM , EganA , WeaverJ , RosebraughC . The FDA's assessment of two drugs for chronic weight management. New England Journal of Medicine2012;367(17):1577-9.">Colman 2012</a>; <a href="./references#CD011688-bbs2-0107" title="WenthurCJ , BennettMR , LindsleyCW . Classics in chemical neuroscience: fluoxetine (Prozac). ACS Chemical Neuroscience2014;5(1):14-23.">Wenthur 2014</a>). </p> </section> </section> <section id="CD011688-sec-0013"> <h3 class="title" id="CD011688-sec-0013">How the intervention might work</h3> <p>As endogenous serotonin levels respond to both deprivation and energy excess, and reduced caloric intake lowers central nervous system serotonin levels and turnover, this neurotransmitter appears to operate on appetite. Fluoxetine acts specifically by blocking the reuptake of serotonin (5‐hydroxytryptamine (5‐HT)), which is a neurotransmitter shown to reduce food intake by preventing the membrane uptake carrier transport of serotonin from the extracellular space to the inside of serotonin nerve terminals (<a href="./references#CD011688-bbs2-0088" title="LeibowitzSF , WeissGF , SuhJS . Medium hypothalamic nuclei mediate serotonin's inhibitory effect on feeding behaviour. Pharmacology, Biochemistry, and Behavior1990;37(4):735-42.">Leibowitz 1990</a>). Fluoxetine increases extracellular concentrations of serotonin and amplifies signals sent by serotonin neurons. Because serotonin neurons are widespread in the central nervous system, the functional consequences of blocking its uptake are diverse and include symptoms such as decreased food intake; altered food selection; endocrine changes (increases in adrenocorticotropic hormone and corticosterone concentrations, potentiating a 5‐HT‐induced rise of corticosterone and prolactin concentrations) (<a href="./references#CD011688-bbs2-0068" title="FullerRW , WongDT , RobertsonDW . Fluoxetine, a selective inhibitor of serotonin uptake. Medicinal Research Reviews1991;11(1):17-34.">Fuller 1991</a>); and normalisation of unusual eating behaviours (such as the frequency and severity of binge eating episodes) (<a href="./references#CD011688-bbs2-0073" title="HalfordJC , HarroldJA . Neuropharmacology of human appetite expression. Developmental Disabilities Research Reviews2008;14(2):158-64.">Halford 2008</a>). </p> <p>Additionally, the hypophagic effects of serotonergic drugs appear to be influenced by the anorexigenic melanocortin system. The hypothalamic serotonin satiety system is known to interact with orexigenic systems, a family of peptides that stimulate food consumption in the hypothalamus; major orexigenic representatives are orexin and neuropeptide Y (<a href="./references#CD011688-bbs2-0070" title="GutiérrezA , SaracíbarG , CasisL , EchevarríaE , RodríguezVM , MacarullaMT , et al. Effects of fluoxetine administration on neuropeptide Y and orexins in obese Zucker rat hypothalamus. Obesity Research2002;10(6):532-40.">Gutiérrez 2002</a>). In the case of serotonin, its potent anorexigenic effect can block hunger signals produced by neuropeptide Y (<a href="./references#CD011688-bbs2-0067" title="DrydenS , FrankishHM , WangQ , PickavanceL , WilliamsG . The serotonergic agent fluoxetine reduces neuropeptide Y levels and neuropeptide Y secretion in the hypothalamus of lean and obese rats. Neuroscience1996;72(2):557-66.">Dryden 1996</a>; <a href="./references#CD011688-bbs2-0084" title="Ioannides-DemosL , ProiettoJ , McNeilJJ . Pharmacotherapy for obesity. Drugs2005;65(10):1391-418.">Ioannides‐Demos 2005</a>). Furthermore, the hypophagic effects of serotonergic drugs appear to extend the effect to another anorexigenic system such as that driven by melanocortin. It has been postulated that fluoxetine can generate a reduction in body weight gain by inhibiting neuropeptide Y action in the paraventricular nucleus of the hypothalamus, a site where neuropeptide Y exerts its hyperphagic effects (<a href="./references#CD011688-bbs2-0067" title="DrydenS , FrankishHM , WangQ , PickavanceL , WilliamsG . The serotonergic agent fluoxetine reduces neuropeptide Y levels and neuropeptide Y secretion in the hypothalamus of lean and obese rats. Neuroscience1996;72(2):557-66.">Dryden 1996</a>; <a href="./references#CD011688-bbs2-0070" title="GutiérrezA , SaracíbarG , CasisL , EchevarríaE , RodríguezVM , MacarullaMT , et al. Effects of fluoxetine administration on neuropeptide Y and orexins in obese Zucker rat hypothalamus. Obesity Research2002;10(6):532-40.">Gutiérrez 2002</a>). The neurons of the hypothalamic paraventricular nucleus contain moderate to abundant levels of serotonin receptor subtypes related to hypophagia (2A and 1B). The proximity of neuropeptide Y and 5‐HT neurons in the hypothalamus suggest that these two systems may interact on hyperphagia/hypophagia regulation but serotonin may also be responsible for altered appetite and feeding behaviours. In addition, these neurons contain corticotrophin‐releasing factor too, a neuropeptide that suppresses feeding behaviours (<a href="./references#CD011688-bbs2-0058" title="BoisvertJP , BoschuetzTJ , ReschJM , MuellerCR , ChoiS . Serotonin mediated changes in corticotropin releasing factor mRNA expression and feeding behavior isolated to the hypothalamic paraventricular nuclei. Neuroscience Letters2011;498(3):213-7. [PMID: 21600959]">Boisvert 2011</a>; <a href="./references#CD011688-bbs2-0084" title="Ioannides-DemosL , ProiettoJ , McNeilJJ . Pharmacotherapy for obesity. Drugs2005;65(10):1391-418.">Ioannides‐Demos 2005</a>). </p> <p>The effects of fluoxetine in reducing caloric intake by modifying appetite have been documented in both lean and obese humans. Specifically, this drug may reduce appetite before and after the consumption of fixed caloric loads, decreasing pre‐meal appetite and caloric intake during unrestricted meals (<a href="./references#CD011688-bbs2-0072" title="HalfordJC , HarroldJA , BoylandEJ , LawtonCL , BlundellJE . Serotonergic drugs: effects on appetite expression and use for the treatment of obesity. Drugs2007;67(1):27-55.">Halford 2007</a>; <a href="./references#CD011688-bbs2-0091" title="McGuirkJ , SilverstoneT . The effect of the 5-HT re-uptake inhibitor fluoxetine on food intake and body weight in healthy male subjects. International Journal of Obesity1990;14(4):361-72. [PMID: 2361813]">McGuirk 1990</a>). There are also some speculations that fluoxetine contributes to weight loss by increasing resting energy expenditure (<a href="./references#CD011688-bbs2-0071" title="HalfordJC , HarroldJA , LawtonCL , BlundellJE . Serotonin (5-HT) drugs: effects on appetite expression and use for the treatment of obesity. Current Drug Targets2005;6(2):201-13.">Halford 2005</a>; <a href="./references#CD011688-bbs2-0106" title="SuplicyH , BoguszewskiCL , dos SantosCM , do Desterro de FigueiredoM , CunhaDR , RadominskiR . A comparative study of five centrally acting drugs on the pharmacological treatment of obesity. International Journal of Obesity2013;38(8):1097-103. [DOI: 10.1038/ijo.2013.225]">Suplicy 2013</a>). </p> </section> <section id="CD011688-sec-0014"> <h3 class="title" id="CD011688-sec-0014">Why it is important to do this review</h3> <p>Fluoxetine is an SSRI that affects weight control, and can be used either alone or in combination with other behaviour‐changing or pharmacological interventions. The benefit‐risk ratio of this drug is, however, unclear. There has been no systematic review performed to date to evaluate the effects of fluoxetine in overweight or obese adult people. Given the prevalence of being overweight and obesity, it is important to establish the possible impact of fluoxetine on people affected by these conditions. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD011688-sec-0015" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD011688-sec-0015"></div> <p>To assess the effects of fluoxetine for overweight or obese adults.</p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD011688-sec-0016" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD011688-sec-0016"></div> <section id="CD011688-sec-0017"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD011688-sec-0018"> <h4 class="title">Types of studies</h4> <p>We included randomised controlled trials (RCT) comparing the administration of fluoxetine versus another pharmacological therapy with anti‐obesity agents, no treatment or placebo for overweight or obese adults. </p> </section> <section id="CD011688-sec-0019"> <h4 class="title">Types of participants</h4> <p>We included adults (aged 18 years and older) who were overweight or obese according to WHO 2000 criteria, with or without comorbidities, of any ethnicity, who received fluoxetine as treatment for this condition. </p> <section id="CD011688-sec-0020"> <h5 class="title">Diagnostic criteria for being overweight and obese</h5> <p>We calculated BMI by dividing a person's weight by the square of her/his height (kg/m²). We calculated a range of between 25 and 29.9 as overweight, and 30 or more as indicating obesity (<a href="./references#CD011688-bbs2-0108" title="World Health Organization. Obesity and overweight. www.who.int/mediacentre/factsheets/fs311/en (accessed 30 April 2015).">WHO 2014</a>). </p> </section> </section> <section id="CD011688-sec-0021"> <h4 class="title">Types of interventions</h4> <p>We planned to investigate the following comparisons of any treatment duration of fluoxetine versus a control/comparator. </p> <section id="CD011688-sec-0022"> <h5 class="title">Intervention</h5> <p> <ul id="CD011688-list-0001"> <li> <p>Fluoxetine</p> </li> </ul> </p> </section> <section id="CD011688-sec-0023"> <h5 class="title">Comparator</h5> <p> <ul id="CD011688-list-0002"> <li> <p>Placebo</p> </li> <li> <p>Another anti‐obesity agent (e.g. orlistat, metformin)</p> </li> <li> <p>Non‐pharmacological therapy for overweight or obesity (e.g. diet, exercise)</p> </li> <li> <p>No treatment</p> </li> </ul> </p> <p>Concomitant interventions had to be identical in the intervention and comparator groups to establish fair comparisons. </p> <p>If a trial included multiple arms, we included any arm that met our review inclusion criteria. </p> </section> <section id="CD011688-sec-0024"> <h5 class="title">Minimum duration of intervention</h5> <p>Minimal duration of intervention was three days.</p> </section> <section id="CD011688-sec-0025"> <h5 class="title">Summary of specific exclusion criteria</h5> <p>We excluded trials of the following categories of participants.</p> <p> <ul id="CD011688-list-0003"> <li> <p>Children</p> </li> <li> <p>Pregnant women</p> </li> <li> <p>People with diabetes mellitus</p> </li> <li> <p>People with polycystic ovary syndrome</p> </li> <li> <p>People with schizophrenia</p> </li> <li> <p>People with eating disorders</p> </li> <li> <p>People with HIV infection</p> </li> <li> <p>People with cancer</p> </li> </ul> </p> </section> </section> <section id="CD011688-sec-0026"> <h4 class="title">Types of outcome measures</h4> <section id="CD011688-sec-0027"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD011688-list-0004"> <li> <p>Weight loss (kg)</p> </li> <li> <p>Health‐related quality of life</p> </li> <li> <p>Adverse events</p> </li> </ul> </p> </section> <section id="CD011688-sec-0028"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD011688-list-0005"> <li> <p>Anthropometric measurements other than weight loss in kg</p> </li> <li> <p>Morbidity</p> </li> <li> <p>All‐cause mortality</p> </li> <li> <p>Socioeconomic effects</p> </li> </ul> </p> </section> <section id="CD011688-sec-0029"> <h5 class="title">Method of outcome measurement</h5> <p> <ul id="CD011688-list-0006"> <li> <p>Weight loss: measured in kg.</p> </li> <li> <p>Health‐related quality of life: evaluated by a validated instrument, such as the Short‐Form Health Survey (SF‐36) or the 12‐item Short‐Form Health Survey (SF‐12). </p> </li> <li> <p>Adverse events: such as headache, nausea, somnolence, asthenia, diarrhoea, insomnia, nervousness, sweating, tremor. </p> </li> <li> <p>Anthropometric measurements other than weight loss in kg: defined as BMI.</p> </li> <li> <p>Morbidity: cardiovascular diseases and psychiatric disorders.</p> </li> <li> <p>All‐cause mortality: defined as death from any cause.</p> </li> <li> <p>Socioeconomic effects: such as costs of treatment, hospitalisation, resources lost due to illness by the participant or absence from work. </p> </li> </ul> </p> </section> <section id="CD011688-sec-0030"> <h5 class="title">Timing of outcome measurement</h5> <p> <ul id="CD011688-list-0007"> <li> <p>For weight loss, health‐related quality of life and anthropometric measurements: at 3, 6 and 12 months. </p> </li> <li> <p>For adverse events, morbidity and all‐cause mortality: at any time after the randomisation of participants to intervention/comparator groups. </p> </li> <li> <p>Socioeconomic effects: measured for up to 12 months.</p> </li> </ul> </p> </section> </section> </section> <section id="CD011688-sec-0031"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD011688-sec-0032"> <h4 class="title">Electronic searches</h4> <p>We searched the following sources from the inception of each database to the specified date and placed no restrictions on the language of publications. </p> <p> <ul id="CD011688-list-0008"> <li> <p>Cochrane Central Register of Controlled Trials (CENTRAL) via the Cochrane Register of Studies Online (CRSO) (until 20 December 2018). </p> </li> <li> <p>MEDLINE Ovid (Epub Ahead of Print, In‐Process &amp; Other Non‐Indexed Citations, Ovid MEDLINE(R) Daily and Ovid MEDLINE(R); from 1946 until 20 December 2018. </p> </li> <li> <p>Embase Ovid (from 1974 until 25 December 2018).</p> </li> <li> <p>LILACS (Latin American and Caribbean Health Science Information database; from 1982 until 28 December 2018). </p> </li> <li> <p>ClinicalTrials.gov (<a href="http://www.clinicaltrials.gov" target="_blank">www.clinicaltrials.gov</a>) (until 31 December 2018). </p> </li> <li> <p>World Health Organization International Clinical Trials Registry Platform (ICTRP) (<a href="http://apps.who.int/trialsearch/" target="_blank">www.who.int/trialsearch</a>) (until 31 December 2018). </p> </li> </ul> </p> <p>We continuously applied a MEDLINE (via Ovid SP) email alert service established by the Cochrane Metabolic and Endocrine Disorders (CMED) Group to identify newly published studies using the same search strategy as described for MEDLINE (for details on search strategies see <a href="./appendices#CD011688-sec-0122">Appendix 2</a>). After supplying the final review draft for editorial approval, the CMED Group performed a complete updated search on all databases available at the editorial office and sent the results to the review authors. In case we detected new studies for inclusion, we evaluated these and incorporated findings in our review before submission of the final review draft. </p> </section> <section id="CD011688-sec-0033"> <h4 class="title">Searching other resources</h4> <p>We planned to identify other potentially eligible trials or ancillary publications by searching the reference lists of retrieved included trials, systematic reviews, meta‐analyses and health technology assessment reports. In addition we contacted the authors of the included trials to identify any further studies we may have missed. </p> <p>We defined grey literature as records detected in ClinicalTrials.gov or WHO ICTRP.</p> <p>We did not use abstracts or conference proceedings for data extraction because this information source does not fulfil the CONSORT requirements which is "an evidence‐based, minimum set of recommendations for reporting randomized trials" (<a href="./references#CD011688-bbs2-0063" title="The CONSORT statement. www.consort-statement.org (last accessed 19 May 2016).">CONSORT</a>; <a href="./references#CD011688-bbs2-0101" title="SchererRW , LangenbergP , vonElmE . Full publication of results initially presented in abstracts. Cochrane Database of Systematic Reviews2007, Issue 2. Art. No: MR000005. [DOI: 10.1002/14651858.MR000005.pub3]">Scherer 2007</a>). However, we planned to specify trial details in the table '<a href="./references#CD011688-sec-0148" title="">Characteristics of studies awaiting classification</a>'. </p> </section> </section> <section id="CD011688-sec-0034"> <h3 class="title" id="CD011688-sec-0034">Data collection and analysis</h3> <section id="CD011688-sec-0035"> <h4 class="title">Selection of studies</h4> <p>Two review authors (AS and GM) independently scanned the title or abstract, or both, of every record retrieved, to determine which trials should be assessed further. We investigated the full text articles of all potentially relevant articles. We resolved any discrepancies through consensus or by recourse to a third review author (AGG). If we could not resolve a disagreement, we recorded the study in the '<a href="./references#CD011688-bbs1-0003" title="">Studies awaiting classification</a>' section and contacted trial authors for clarification. We present an adapted PRISMA flow diagram to show the process of trial selection (<a href="#CD011688-fig-0001">Figure 1</a>; <a href="./references#CD011688-bbs2-0089" title="LiberatiA , AltmanDG , TetzlaffJ , MulrowC , GøtzschePC , IoannidisJP , et al. The PRISMA statement for reporting systematic and meta-analyses of studies that evaluate interventions: explanation and elaboration. PLoS Medicine2009;6(7):e1000100. [DOI: 10.1371/journal.pmed.1000100]">Liberati 2009</a>). We listed all articles excluded after full‐text assessment in the '<a href="./references#CD011688-sec-0147" title="">Characteristics of excluded studies</a>' table and provided the reasons for exclusion. </p> <div class="figure" id="CD011688-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Trial flow diagram." data-id="CD011688-fig-0001" src="/cdsr/doi/10.1002/14651858.CD011688.pub2/media/CDSR/CD011688/image_n/nCD011688-FIG-01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Trial flow diagram.</p> </div> </div> </div> </section> <section id="CD011688-sec-0036"> <h4 class="title">Data extraction and management</h4> <p>For trials that fulfilled our inclusion criteria, two review authors (AS and YR) independently abstracted relevant key participant and intervention characteristics. We reported data on efficacy outcomes and adverse events using standard data extraction sheets from the CMED Group. We resolved any disagreements by discussion or, if required, by consultation with a third review author (AGG) (for details see <a href="./references#CD011688-sec-0146" title="">Characteristics of included studies</a>; <a href="#CD011688-tbl-0002">Table 1</a>; <a href="./appendices#CD011688-sec-0122">Appendix 2</a>; <a href="./appendices#CD011688-sec-0123">Appendix 3</a>; <a href="./appendices#CD011688-sec-0124">Appendix 4</a>; <a href="./appendices#CD011688-sec-0125">Appendix 5</a>; <a href="./appendices#CD011688-sec-0126">Appendix 6</a>; <a href="./appendices#CD011688-sec-0127">Appendix 7</a>; <a href="./appendices#CD011688-sec-0128">Appendix 8</a>; <a href="./appendices#CD011688-sec-0129">Appendix 9</a>; <a href="./appendices#CD011688-sec-0130">Appendix 10</a>; <a href="./appendices#CD011688-sec-0131">Appendix 11</a>; <a href="./appendices#CD011688-sec-0132">Appendix 12</a>; <a href="./appendices#CD011688-sec-0133">Appendix 13</a>; <a href="./appendices#CD011688-sec-0134">Appendix 14</a>; <a href="./appendices#CD011688-sec-0135">Appendix 15</a>; <a href="./appendices#CD011688-sec-0121">Appendix 1</a>). </p> <div class="table" id="CD011688-tbl-0002"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Overview of trial populations</span></div> <tbody> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Trial ID</b> </p> <p><b>(trial design)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Intervention(s) and comparator(s)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Description of power and sample size calculation</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Screened/eligible<br/>(N)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Randomised<br/>(N)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>ITT<br/>(N)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Analysed<br/>(N)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Finishing trial<br/>(N)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Randomised finishing trial<br/>(%)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Duration of intervention</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="5" valign="top"> <p><a href="./references#CD011688-bbs2-0001" title="Al-HelliA , Al-AbbassiM , JasimG , Al-BayatyM . Effects of fluoxetine, omega 3, or their combination on serum leptin in Iraqi obese subjects. International Journal of Pharmaceutical Sciences Review and Research2015;35(1):90-5. ">Al‐Helli 2015</a><br/>(parallel RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: fluoxetine 20 mg</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>48/48</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="5" valign="top"> <p>2 months</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I2: omega‐3 gel</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I3: fluoxetine 20 mg + omega‐3 gel</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100</p> </td> </tr> <tr> <th align="right" class="headercell" colspan="3" rowspan="1" scope="col" valign="top"> <p><b>total:</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>48</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>48</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>48</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>48</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>100</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="7" valign="top"> <p><a href="./references#CD011688-bbs2-0017" title="SuplicyH , BoguszewskiC , Dos SantosC , Do DesterroM , CunhaD , RadomiskiR . A comparative study of five centrally acting drugs on the pharmacological treatment of obesity. International Journal of Obesity2014;38(8):1097-103. ">Suplicy 2014</a><br/>(parallel RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: diethylpropion</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>"As we had calculated the day to day coefficient of variation of resting metabolic rate for this method to be less than 5% for a given subject, we calculated that it was necessary to study at least 26 subjects to have sufficient power" </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>507/180</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>76.7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="7" valign="top"> <p>52 weeks</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I2: fenproporex</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>74.2</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I3: mazindol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>82.7</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I4: fluoxetine 20 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>64.5</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I5: sibutramine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: placebo</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>51.7</p> </td> </tr> <tr> <th align="right" class="headercell" colspan="3" rowspan="1" scope="col" valign="top"> <p><b>total:</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>180</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>174</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>174</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>129</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>71.7</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="5" valign="top"> <p><a href="./references#CD011688-bbs2-0008" title="GuimarãesC , PereiraL , Lucif JúniorN , CesarinoE , AlmeidaC , CarvalhoD , et al. Tolerability and effectiveness of fluoxetine, metformin and sibutramine in reducing anthropometric and metabolic parameters in obese patients. Arquivos Brasileiros de Endocrinologia e Metabologia2006;50(6):1020-5. ">Guimaraes 2006</a><br/>(parallel RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: sibutramine</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>35/35</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="5" valign="top"> <p>90 days</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I2: metformin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I3: fluoxetine 60 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: placebo</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100</p> </td> </tr> <tr> <th align="right" class="headercell" colspan="3" rowspan="1" scope="col" valign="top"> <p><b>total:</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>35</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>35</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>35</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>35</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>100</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><a href="./references#CD011688-bbs2-0003" title="BondiM , MenozziR , BertoliniM , VenneriM , RioG . Metabolic effects of fluoxetine in obese menopausal women. Journal of Endocrinological Investigation2000;23(5):280-6. ">Bondi 2000</a><br/>(parallel RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: fluoxetine 40 mg</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>32/32</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>12 weeks</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I2: fluoxetine 60 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: placebo</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100</p> </td> </tr> <tr> <th align="right" class="headercell" colspan="3" rowspan="1" scope="col" valign="top"> <p><b>total:</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>32</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>32</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>32</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>32</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>100</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD011688-bbs2-0009" title="HuangC , ChianC , LinJ . Short-term treatment of obesity with fluoxetine as a supplement to a low calorie diet. Changgeng Yi Xue za Zhi [Chang Gung Medical Journal]1998;21(1):50-6. ">Huang 1998</a><br/>(parallel RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: fluoxetine 60 mg</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>60/60</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>93.3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>12 weeks</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: no treatment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>73.3</p> </td> </tr> <tr> <th align="right" class="headercell" colspan="3" rowspan="1" scope="col" valign="top"> <p><b>total:</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>60</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>—</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>50</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>50</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>83.3</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD011688-bbs2-0004" title="BrossR , HofferL . Fluoxetine increases resting energy expenditure and basal body temperature in humans. American Journal of Clinical Nutrition1995;61(5):1020-5. ">Bross 1995</a><br/>(parallel RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: fluoxetine 60 mg</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>20/20</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>3 weeks</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: placebo</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100</p> </td> </tr> <tr> <th align="right" class="headercell" colspan="3" rowspan="1" scope="col" valign="top"> <p><b>total:</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>20</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>20</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>20</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>20</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>100</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD011688-bbs2-0005" title="Fernández-SotoM , González-JiménezA , Barredo-AcedoF , Luna del CastilloJ , Escobar-JiménezF . Comparison of fluoxetine and placebo in the treatment of obesity. Annals of Nutrition &amp; Metabolism1995;39(3):159-63. ">Fernández‐Soto 1995</a> </p> <p>(cross‐over RCT)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: fluoxetine 60 mg</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>42 participants with full cross‐over</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>78.2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>3 months</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: placebo</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>78.9</p> </td> </tr> <tr> <th align="right" class="headercell" colspan="3" rowspan="1" scope="col" valign="top"> <p><b>total:</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>42</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>—</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>33</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>33</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>78.5</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD011688-bbs2-0011" title="LawtonC , WalesJ , HillA , BlundellJ . Serotoninergic manipulation, meal-induced satiety and eating pattern: effect of fluoxetine in obese female subjects. Obesity Research1995;3(4):345-56. ">Lawton 1995</a><br/>(cross‐over RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: fluoxetine 60 mg</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>13 participants with full cross‐over</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>92.3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>2 weeks</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: placebo</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>92.3</p> </td> </tr> <tr> <th align="right" class="headercell" colspan="3" rowspan="1" scope="col" valign="top"> <p><b>total:</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>13</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>12</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>12</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>12</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>92.3</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD011688-bbs2-0007" title="DargaL , Carroll-MichalsL , BotsfordS , LucasC . Fluoxetine's effect on weight loss in obese subjects. American Journal of Clinical Nutrition1991;54(2):321-5. GoldsteinD , RampeyA , EnasG , PotvinJ , FludzinskiL , LevineL . Fluoxetine: a randomized clinical trial in the treatment of obesity. International Journal of Obesity and Related Metabolic Disorders1994;18(3):129-35. ">Goldstein 1994</a><br/>(parallel RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: fluoxetine 60 mg</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>458/458</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>230</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>217</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>217</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>99</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>43</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>52 weeks</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: placebo</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>228</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>217</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>217</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>108</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>47.3</p> </td> </tr> <tr> <th align="right" class="headercell" colspan="3" rowspan="1" scope="col" valign="top"> <p><b>total:</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>458</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>434</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>434</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>207</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>45.1</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><a href="./references#CD011688-bbs2-0006" title="GoldsteinD , RampeyA , DornseifB , LevineL , PotvinJ , FludzinskiL . Fluoxetine: a randomized clinical trial in the maintenance of weight loss. Obesity Research1993;1(2):92-8. ">Goldstein 1993</a><br/>(parallel RCT)<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: fluoxetine 60 mg</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>458/450</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>106</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>61</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>61</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>56.6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>40 weeks</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I2: fluoxetine 20 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>104</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>72</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>72</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>67.3</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: placebo</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>107</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>72</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>72</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>72</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>67.2</p> </td> </tr> <tr> <th align="right" class="headercell" colspan="3" rowspan="1" scope="col" valign="top"> <p><b>total:</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>317</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>205</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>205</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>202</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>63.7</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD011688-bbs2-0014" title="PedrinolaF , RissoW , LimaN , MedeirosG . Fluoxetine induced weight loss in overweight subjects: a double-blind placebo-controlled trial. Arquivos Brasileiros de Endocrinologia e Metabologia1993;37:31-3. ">Pedrinola 1993</a><br/>(parallel RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: fluoxetine 40 mg</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>20/20</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>12 weeks</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: placebo</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80</p> </td> </tr> <tr> <th align="right" class="headercell" colspan="3" rowspan="1" scope="col" valign="top"> <p><b>total:</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>20</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>—</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>18</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>18</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>90</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD011688-bbs2-0018" title="VisserM , SeidellJ , KoppeschaarH , SmitsP . No specific effect of fluoxetine treatment on fasting glucose, insulin, lipid levels, and blood pressure in healthy men with abdominal obesity. Obesity Research1994;2(2):152-9. VisserM , SeidellJ , KoppeschaarH , SmitsP . The effect of fluoxetine on body weight, body composition and visceral fat accumulation. International Journal of Obesity and Related Metabolic Disorders1993;17(5):247-53. ">Visser 1993</a><br/>(parallel RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: fluoxetine 60 mg</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>"Based on earlier studies at our department 40 men in total were selected for detecting a 10% improvement in body weight, fat‐free mass and abdominal fat areas, with 80% probability" </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>132/40</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>90</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>12 weeks</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: placebo</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100</p> </td> </tr> <tr> <th align="right" class="headercell" colspan="3" rowspan="1" scope="col" valign="top"> <p><b>total:</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>40</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>—</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>38</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>38</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>95</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><a href="./references#CD011688-bbs2-0019" title="WurtmanJ , WurtmanR , BerryE , GleasonR , GoldbergH , McDermottJ , et al. Dexfenfluramine, fluoxetine, and weight loss among female carbohydrate cravers. Neuropsychopharmacology1993;9(3):201-10. ">Wurtman 1993</a><br/>(parallel RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: dexfenfluramine</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>87/87</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>75</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>12 weeks</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I2: fluoxetine 20 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: placebo</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>86.2</p> </td> </tr> <tr> <th align="right" class="headercell" colspan="3" rowspan="1" scope="col" valign="top"> <p><b>total:</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>87</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>87</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>87</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>64</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>73.5</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD011688-bbs2-0010" title="KopelmanP , ElliottM , SimondsA , CramerD , WardS , WedzichaJ . Short-term use of fluoxetine in asymptomatic obese subjects with sleep-related hypoventilation. International Journal of Obesity and Related Metabolic Disorders1992;16(10):825-30. ">Kopelman 1992</a><br/>(cross‐over RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: fluoxetine 60 mg</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>11 participants with full cross‐over</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>3 days</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: placebo</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100</p> </td> </tr> <tr> <th align="right" class="headercell" colspan="3" rowspan="1" scope="col" valign="top"> <p><b>total:</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>11</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>11</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>11</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>11</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>100</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD011688-bbs2-0016" title="StinsonJ , MurphyC , AndrewsJ , TomkinG . An assessment of the thermogenic effects of fluoxetine in obese subjects. International Journal of Obesity and Related Metabolic Disorders1992;16(5):391-5. ">Stinson 1992</a><br/>(cross‐over RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: fluoxetine 60 mg</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>"A 12‐wk placebo‐subtracted total weight loss of at least 5% was considered. It was assumed that roughly 10% of participants in the placebo group would have a weight loss of 5% at the end of the study and the magnitude of the effect (the minimum difference between treatment arms to be considered clinically relevant) was assumed to be 40%. </p> <p>"Power was set as 0.8 with an alpha level of 0.05, resulting in an estimate minimum sample size of 26 participants per group" </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>30 participants with full cross‐over</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>2 weeks</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: placebo</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100</p> </td> </tr> <tr> <th align="right" class="headercell" colspan="3" rowspan="1" scope="col" valign="top"> <p><b>total:</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>30</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>30</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>30</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>30</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>100</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="7" valign="top"> <p><a href="./references#CD011688-bbs2-0002" title="BagiellaE , CairellaM , DelB , GodiR . Changes in attitude toward food by obese patients treated with placebo and serotoninergic agents. Current Therapeutic Research, Clinical and Experimental1991;50(2):205-10. ">Bagiella 1991</a><br/>(parallel RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: fenfluramine</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>60/60</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="7" valign="top"> <p>12 weeks</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I2: 5‐hydroxy‐tryptophan</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I3: d‐fenfluramine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I4: fluoxetine 20 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I5: fluvoxamine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: placebo</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <th align="right" class="headercell" colspan="3" rowspan="1" scope="col" valign="top"> <p><b>total:</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>60</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>60</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>60</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>60</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>100</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD011688-bbs2-0015" title="PijlH , KoppeschaarH , WillekensF , Op de KampI , VeldhuisH , MeindersA . Effect of serotonin re-uptake inhibition by fluoxetine on body weight and spontaneous food choice in obesity. International Journal of Obesity1991;15(3):237-42. ">Pijl 1991</a><br/>(parallel RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: fluoxetine 60 mg</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>24/24</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>91.6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>6 weeks</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: placebo</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100</p> </td> </tr> <tr> <th align="right" class="headercell" colspan="3" rowspan="1" scope="col" valign="top"> <p><b>total:</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>24</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>—</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>23</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>23</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>95.8</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><a href="./references#CD011688-bbs2-0013" title="LevineL , EnasG , ThompsonW , ByynyR , DauerA , KirbyR , et al. Use of fluoxetine, a selective serotonin-uptake inhibitor, in the treatment of obesity: a dose-response study. International Journal of Obesity1989;13(5):635-45. ">Levine 1989</a><br/>(parallel RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: fluoxetine 10 mg</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="5" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="5" valign="top"> <p>655/655</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>131</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>131</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>131</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>61</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>8 weeks</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I2: fluoxetine 20 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>131</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>131</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>131</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>86</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>65.6</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I3: fluoxetine 40 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>131</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>131</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>131</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>68.7</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I4: fluoxetine 60 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>131</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>131</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>131</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>87</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>66.4</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: placebo</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>131</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>131</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>131</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>74</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>56.4</p> </td> </tr> <tr> <th align="right" class="headercell" colspan="3" rowspan="1" scope="col" valign="top"> <p><b>total:</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>655</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>655</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>655</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>417</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>63.6</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD011688-bbs2-0012" title="LevineL , RosenblattS , BosomworthJ . Use of a serotonin re-uptake inhibitor, fluoxetine, in the treatment of obesity. International Journal of Obesity1987;11(Suppl 3):185-90. ">Levine 1987</a><br/>(parallel RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: fluoxetine 60 mg</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>120/120</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>59</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>11 days</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: placebo</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>59</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>86.6</p> </td> </tr> <tr> <th align="right" class="headercell" colspan="3" rowspan="1" scope="col" valign="top"> <p><b>total:</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>120</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>118</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>100</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>100</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>83.3</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>Grand total<sup>b</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>All interventions</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="3" valign="top"></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>1280</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="3" valign="top"></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>842</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="3" valign="top"></td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>All comparators</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>936</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>761</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>All interventions and comparators</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>2216</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>1603</b> </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>— denotes not reported</p> <p><sup>a</sup>Obese outpatients were randomised who had lost 23.6 kg after 8 weeks of single‐blind fluoxetine 60 mg/d in the "qualification phase"<br/><sup>b</sup>Numbers do not add up correctly because <a href="./references#CD011688-bbs2-0002" title="BagiellaE , CairellaM , DelB , GodiR . Changes in attitude toward food by obese patients treated with placebo and serotoninergic agents. Current Therapeutic Research, Clinical and Experimental1991;50(2):205-10. ">Bagiella 1991</a> did not provide the numbers of randomised participants per intervention and comparator group; <a href="./references#CD011688-bbs2-0005" title="Fernández-SotoM , González-JiménezA , Barredo-AcedoF , Luna del CastilloJ , Escobar-JiménezF . Comparison of fluoxetine and placebo in the treatment of obesity. Annals of Nutrition &amp; Metabolism1995;39(3):159-63. ">Fernández‐Soto 1995</a>, <a href="./references#CD011688-bbs2-0010" title="KopelmanP , ElliottM , SimondsA , CramerD , WardS , WedzichaJ . Short-term use of fluoxetine in asymptomatic obese subjects with sleep-related hypoventilation. International Journal of Obesity and Related Metabolic Disorders1992;16(10):825-30. ">Kopelman 1992</a>, <a href="./references#CD011688-bbs2-0011" title="LawtonC , WalesJ , HillA , BlundellJ . Serotoninergic manipulation, meal-induced satiety and eating pattern: effect of fluoxetine in obese female subjects. Obesity Research1995;3(4):345-56. ">Lawton 1995</a> and <a href="./references#CD011688-bbs2-0016" title="StinsonJ , MurphyC , AndrewsJ , TomkinG . An assessment of the thermogenic effects of fluoxetine in obese subjects. International Journal of Obesity and Related Metabolic Disorders1992;16(5):391-5. ">Stinson 1992</a> were cross‐over trials and were subsumed under all interventions only </p> <p><b>C:</b> comparator; <b>I:</b> Intervention; <b>ITT:</b> intention‐to‐treat; <b>RCT:</b> randomised controlled trial; <b>wk</b>: week. </p> </div> </div> <p>We planned to provide information including the trial identifier for potentially relevant ongoing studies in the 'Characteristics of ongoing studies' table and in <a href="./appendices#CD011688-sec-0128">Appendix 8</a> 'Matrix of trial endpoints (publications and trial documents)'. We tried to find the protocol of each included trial and reported primary, secondary and other outcomes measured by the study personnel (objectively) in comparison with the data from the publications in <a href="./appendices#CD011688-sec-0128">Appendix 8</a>. </p> <p>We planned to analyse clinical study reports from manufacturers, provided they were willing to share the information. We also planned to collect these clinical study reports from the regulatory agencies. We sent an email request to the authors of the included trials to enquire whether they were willing to answer questions regarding their trials: <a href="./appendices#CD011688-sec-0134">Appendix 14</a> shows the results of this survey. Thereafter, we sought relevant missing information on the trial from the primary author(s) of the article, if required. </p> <section id="CD011688-sec-0037"> <h5 class="title">Dealing with duplicate and companion publications</h5> <p>In the event of duplicate publications, companion documents or multiple reports of a primary trial, we planned to maximise the information yield by collating all available data and use the most complete data set aggregated across all known publications. We listed duplicate publications, companion documents, multiple reports of a primary trial and trial documents of included trials (such as trial registry information) as secondary references under the study identifier (ID) of the included trial. Furthermore, we listed duplicate publications, companion documents, multiple reports of a trial and trial documents of excluded trials (such as trial registry information) as secondary references under the study ID of the excluded trial. </p> </section> <section id="CD011688-sec-0038"> <h5 class="title">Data from clinical trial registers</h5> <p>If data from included trials were available as study results in clinical trial registries such as <a href="http://ClinicalTrials.gov" target="_blank">ClinicalTrials.gov</a> or similar sources, we planned to make full use of this information and to extract the data. If there was also a full publication of the trial, we collected and critically appraised all available data. If an included trial was marked as a completed study in a clinical trials registry but no additional information (study results, publication or both) was available, we planned to add this trial to the table '<a href="./references#CD011688-sec-0148" title="">Characteristics of studies awaiting classification</a>'. </p> </section> </section> <section id="CD011688-sec-0039"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two review authors (AS and YR) independently assessed the 'Risk of bias' of each included trial. We resolved disagreements by consensus or by consulting a third review author (AGG). In case of disagreement, we consulted the rest of the review author team and we made a judgement based on consensus. If adequate information was unavailable from the trials or trial protocols, we contacted the trial authors to recover missing data on 'Risk of bias' items. </p> <p>We used the Cochrane 'Risk of bias' assessment tool (<a href="./references#CD011688-bbs2-0079" title="HigginsJP , AltmanDG , GøtzschePC , JüniP , MoherD , OxmanAD , et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ2011;343:d5928.">Higgins 2011a</a>; <a href="./references#CD011688-bbs2-0081" title="HigginsJP , AltmanDG , Sterne JA (editors). Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Churchill R, Chandler J, Cumpston MS (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.2.0 (updated June 2017). Cochrane, 2017. Available from www.training.cochrane.org/handbook.">Higgins 2017</a>), assigning assessments of low, high, or unclear risk of bias (for details, see <a href="./appendices#CD011688-sec-0123">Appendix 3</a>; <a href="./appendices#CD011688-sec-0124">Appendix 4</a>). We evaluated individual bias items as described in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> according to the criteria and associated categorisations contained therein <i>(</i><a href="./references#CD011688-bbs2-0081" title="HigginsJP , AltmanDG , Sterne JA (editors). Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Churchill R, Chandler J, Cumpston MS (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.2.0 (updated June 2017). Cochrane, 2017. Available from www.training.cochrane.org/handbook.">Higgins 2017</a>). </p> <section id="CD011688-sec-0040"> <h5 class="title">Summary assessment of risk of bias</h5> <p>We present a 'Risk of bias' graph (<a href="#CD011688-fig-0002">Figure 2</a>) and a 'Risk of bias' summary figure (<a href="#CD011688-fig-0003">Figure 3</a>). </p> <div class="figure" id="CD011688-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included trials (blank cells indicate that the particular outcome was not measured in some trials)." data-id="CD011688-fig-0002" src="/cdsr/doi/10.1002/14651858.CD011688.pub2/media/CDSR/CD011688/image_n/nCD011688-FIG-02.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included trials (blank cells indicate that the particular outcome was not measured in some trials). </p> </div> </div> </div> <div class="figure" id="CD011688-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included trial ((blank cells indicate that the particular outcome was not measured in some trials)." data-id="CD011688-fig-0003" src="/cdsr/doi/10.1002/14651858.CD011688.pub2/media/CDSR/CD011688/image_n/nCD011688-FIG-03.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included trial ((blank cells indicate that the particular outcome was not measured in some trials). </p> </div> </div> </div> <p>We distinguished between self‐reported, investigator‐assessed and adjudicated outcome measures. </p> <p>We accepted the following outcomes as self‐reported.</p> <p> <ul id="CD011688-list-0009"> <li> <p>Health‐related quality of life.</p> </li> <li> <p>Adverse events, if measured by participants.</p> </li> <li> <p>Weight loss and other anthropometric measures, if measured by participants.</p> </li> </ul> </p> <p>We required the following outcomes to be investigator‐assessed.</p> <p> <ul id="CD011688-list-0010"> <li> <p>Weight loss and other anthropometric measures, if measured by study personnel.</p> </li> <li> <p>Adverse events, if measured by study personnel.</p> </li> <li> <p>All‐cause mortality.</p> </li> <li> <p>Morbidity.</p> </li> <li> <p>Socioeconomic effects.</p> </li> </ul> </p> <section id="CD011688-sec-0041"> <h6 class="title">Risk of bias for a trial across outcomes</h6> <p>Some 'Risk of bias' domains, such as selection bias (sequence generation and allocation sequence concealment), affect the risk of bias across all outcome measures in a trial. In case of high risk of selection bias, all endpoints investigated in the associated trial were marked as high risk. Otherwise, we did not perform a summary assessment of the risk of bias across all outcomes for a trial. </p> </section> <section id="CD011688-sec-0042"> <h6 class="title">Risk of bias for an outcome within a trial and across domains</h6> <p>We assessed the risk of bias for an outcome measure by including all entries relevant to that outcome (i.e. both trial‐level entries and outcome‐specific entries). We considered low risk of bias to denote a low risk of bias for all key domains; unclear risk to denote an unclear risk of bias for one or more key domains; and high risk to denote a high risk of bias for one or more key domains. </p> </section> <section id="CD011688-sec-0043"> <h6 class="title">Risk of bias for an outcome across trials and across domains</h6> <p>These are the main summary assessments that we incorporated into our judgements about the quality of the certainty of the 'Summary of findings' tables. We defined outcomes as at low risk of bias when most information came from trials at low risk of bias; unclear risk when most information came from trials at low or unclear risk of bias; and high risk when a sufficient proportion of information came from trials at high risk of bias. </p> </section> </section> </section> <section id="CD011688-sec-0044"> <h4 class="title">Measures of treatment effect</h4> <p>When at least two included trials were available for a comparison of a given outcome, we planned to express dichotomous data as a risk ratio (RR) or an odds ratio (OR) with 95% confidence intervals (CIs). For continuous outcomes measured on the same scale (e.g. weight loss in kg) we planned to estimate the intervention effect using the mean difference (MD) with 95% CIs. For continuous outcomes that measured the same underlying concept (e.g. health‐related quality of life) but used different measurement scales, we planned to calculate the standardised mean difference (SMD). We wanted to express time‐to‐event data as a hazard ratio (HR) with 95% CIs. </p> </section> <section id="CD011688-sec-0045"> <h4 class="title">Unit of analysis issues</h4> <p>We took into account the level at which randomisation occurred, such as cross‐over trials, cluster‐randomised trials and multiple observations for the same outcome. If more than one comparison from the same trial was eligible for inclusion in the same meta‐analysis, we either combined groups to create a single pair‐wise comparison or appropriately reduced the sample size so that the same participants did not contribute more than once (splitting the 'shared' group into two or more groups). While the latter approach offers some solution to adjusting the precision of the comparison, it does not account for correlation arising from inclusion of the same set of participants in multiple comparisons (<a href="./references#CD011688-bbs2-0080" title="HigginsJP , DeeksJJ , Altman DG (editors), on behalf of the Cochrane Statistical Methods Group. Chapter 16: Special topics in statistics. In: Higgins JP, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.">Higgins 2011b</a>). </p> <p>We planned to re‐analyse cluster‐RCTs that had not appropriately adjusted for potential clustering of participants within clusters in their analyses. Variance of the intervention effects would have been inflated by a design effect. Calculation of a design effect involves estimation of an intra‐cluster correlation (ICC). We planned to obtain estimates of ICCs through contact with the trial authors, or by imputing ICC values using either estimates from other included trials that reported ICCs, or external estimates from empirical research (e.g. <a href="./references#CD011688-bbs2-0057" title="BellML , McKenzieJE . Designing psycho-oncology randomised trials and cluster randomised trials: variance components and intra-cluster correlation of commonly used psychosocial measures. Psychooncology2013;22:1738-47.">Bell 2013</a>). We planned to examine the impact of clustering by performing sensitivity analyses. </p> </section> <section id="CD011688-sec-0046"> <h4 class="title">Dealing with missing data</h4> <p>If possible, we obtained missing data from the authors of included trials. We carefully evaluated important numerical data such as screened, randomly assigned participants, as well as intention‐to‐treat and as‐treated and per‐protocol populations. We investigated attrition rates (e.g. dropouts, losses to follow‐up, withdrawals), and we critically appraised issues concerning missing data and use of imputation methods (e.g. last observation carried forward). </p> <p>For trials in which the standard deviation (SD) of the outcome was not available at follow‐up or could not be re‐created, we planned to standardise by the average of the pooled baseline SD from those trials that reported this information. </p> <p>When included trials did not report means and SDs for outcomes, and we did not receive requested information from trial authors, we planned to impute these values by estimating the mean and the variance from the median, the range, and the size of the sample (<a href="./references#CD011688-bbs2-0082" title="HozoSP , DjulbegovicB , HozoI . Estimating the mean and variance from the median, range, and the size of a sample. BMC Medical Research Methodology2005;5:13. [DOI: 10.1186/1471-2288-5-13]">Hozo 2005</a>). </p> <p>We planned to investigate the impact of imputation on meta‐analyses by performing sensitivity analyses and we reported per outcome which trials were included with imputed SDs. </p> </section> <section id="CD011688-sec-0047"> <h4 class="title">Assessment of heterogeneity</h4> <p>In the event of substantial clinical or methodological heterogeneity, we did not report trial results as the pooled effect estimate in a meta‐analysis. </p> <p>We identified heterogeneity (inconsistency) by visually inspecting the forest plots and by using a standard Chi² test with a significance level of α = 0.1 (<a href="./references#CD011688-bbs2-0065" title="DeeksJJ , HigginsJP , Altman DG (editors), on behalf of the Cochrane Statistical Methods Group. Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JP, Churchill R, Chandler J, Cumpston MS (editors). Cochrane Handbook for Systematic Reviews of Interventions version 5.2.0 (updated June 2017), Cochrane, 2017. Available from www.training.cochrane.org/handbook.">Deeks 2017</a>). In view of the low power of this test, we also considered the I² statistic, which quantifies inconsistency across trials to assess the impact of heterogeneity on the meta‐analysis (<a href="./references#CD011688-bbs2-0076" title="HigginsJP , ThompsonSG . Quantifying heterogeneity in a meta-analysis. Statistics in Medicine2002;21(11):1539-58.">Higgins 2002</a>; <a href="./references#CD011688-bbs2-0077" title="HigginsJP , ThompsonSG , DeeksJJ , AltmanDG . Measuring inconsistency in meta-analysis. BMJ2003;327(7414):557-60.">Higgins 2003</a>). </p> <p>When we found heterogeneity, we attempted to determine possible reasons for this by examining individual trial and subgroup characteristics. </p> </section> <section id="CD011688-sec-0048"> <h4 class="title">Assessment of reporting biases</h4> <p>If we included 10 or more studies in a meta‐analysis investigating a particular outcome, we used funnel plots to assess small‐study effects. Several explanations might account for funnel plot asymmetry, including true heterogeneity of effect with respect to trial size, poor methodological design (and hence bias of small trials), and publication bias (<a href="./references#CD011688-bbs2-0105" title="SterneJA , EggerM , MoherD , Boutron I (editors). Chapter 10: Addressing reporting biases. In: Higgins JP, Churchill R, Chandler J, Cumpston MS (editors), Cochrane Handbook for Systematic Reviews of Interventions version 5.2.0 (updated June 2017), Cochrane, 2017. Available from www.training.cochrane.org/handbook.">Sterne 2017</a>). Therefore we interpreted results carefully (<a href="./references#CD011688-bbs2-0104" title="SterneJA , SuttonAJ , IoannidisJP , TerrinN , JonesDR , LauJ , et al. Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials. BMJ2011;343:d4002.">Sterne 2011</a>). </p> </section> <section id="CD011688-sec-0049"> <h4 class="title">Data synthesis</h4> <p>We planned to undertake (or display) a meta‐analysis only if we judged participants, interventions, comparisons, and outcomes to be sufficiently similar to ensure an answer that was clinically meaningful. Unless good evidence showed homogeneous effects across trials of different methodological quality, we primarily summarised low risk of bias data using a random‐effects model (<a href="./references#CD011688-bbs2-0110" title="WoodL , EggerM , GluudLL , SchulzKF , JüniP , AltmanDG , et al. Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study. BMJ2008;336(7644):601-5.">Wood 2008</a>). We interpreted random‐effects meta‐analyses with due consideration for the whole distribution of effects and presented a prediction interval (<a href="./references#CD011688-bbs2-0059" title="BorensteinM , HigginsJP , HedgesLV , RothsteinHR . Basics of meta-analysis: I² is not an absolute measure of heterogeneity. Research Synthesis Methods2017;8(1):5-18.">Borenstein 2017a</a>; <a href="./references#CD011688-bbs2-0060" title="BorensteinM . Prediction intervals. www.meta-analysis.com/prediction (accessed 3 July 2017).">Borenstein 2017b</a>; <a href="./references#CD011688-bbs2-0078" title="HigginsJP , ThompsonSG , SpiegelhalterDJ . A re-evaluation of random-effects meta-analysis. Journal of the Royal Statistical Society: Series A (Statistics in Society)2009;172(1):137-59.">Higgins 2009</a>). A prediction interval needs at least three trials to be calculated and specifies a predicted range for the true treatment effect in an individual trial (<a href="./references#CD011688-bbs2-0099" title="RileyRD , HigginsJP , DeeksJJ . Interpretation of random effects meta-analyses. BMJ2011;342:d549.">Riley 2011</a>; <a href="./references#CD011688-bbs2-0100" title="RileyRD , KauserI , BlandM , ThijsL , StaessenJA , WangJ , et al. Meta-analysis of randomised trials with a continuous outcome according to baseline imbalance and availability of individual participant data. Statistics in Medicine2013;32(16):2747-66.">Riley 2013</a>). For rare events such as event rates below 1%, we planned to use the Peto's odds ratio method, provided that there was no substantial imbalance between intervention and comparator group sizes, and intervention effects were not exceptionally large. In addition, we performed statistical analyses according to the statistical guidelines presented in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD011688-bbs2-0065" title="DeeksJJ , HigginsJP , Altman DG (editors), on behalf of the Cochrane Statistical Methods Group. Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JP, Churchill R, Chandler J, Cumpston MS (editors). Cochrane Handbook for Systematic Reviews of Interventions version 5.2.0 (updated June 2017), Cochrane, 2017. Available from www.training.cochrane.org/handbook.">Deeks 2017</a>). </p> </section> <section id="CD011688-sec-0050"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We expected the following characteristics to introduce clinical heterogeneity, and we planned to carry out the following subgroup analyses including investigation of interactions (<a href="./references#CD011688-bbs2-0054" title="AltmanDG , BlandJM . Interaction revisited: the difference between two estimates. BMJ2003;326(7382):219. [PMID: 12543843]">Altman 2003</a>). </p> <p> <ul id="CD011688-list-0011"> <li> <p>Magnitude of obesity</p> </li> <li> <p>Overweight versus obesity</p> </li> <li> <p>Gender</p> </li> <li> <p>Ethnicity</p> </li> <li> <p>Age</p> </li> <li> <p>Different comparison interventions</p> </li> <li> <p>Fluoxetine dosage</p> </li> <li> <p>Duration of intervention</p> </li> <li> <p>Treatment compliance</p> </li> <li> <p>Socioeconomic status</p> </li> </ul> </p> </section> <section id="CD011688-sec-0051"> <h4 class="title">Sensitivity analysis</h4> <p>We planned to perform sensitivity analyses to explore the influence of the following factors (when applicable) on effect sizes by restricting analysis to the following. </p> <p> <ul id="CD011688-list-0012"> <li> <p>Published trials</p> </li> <li> <p>The effect of risk of bias, as specified in the <a href="#CD011688-sec-0039">Assessment of risk of bias in included studies</a> section </p> </li> <li> <p>Very long or large trials to establish the extent to which they dominated the results</p> </li> <li> <p>Use of the following filters: diagnostic criteria, imputation, language of publication, source of funding (industry versus other), or country </p> </li> </ul> </p> <p>We also tested the robustness of the results by repeating the analysis using different measures of effect size (RR, OR, etc.) and different statistical models (fixed‐effect and random‐effects models). </p> </section> <section id="CD011688-sec-0052"> <h4 class="title">Summary of findings and assessment of the certainty of the evidence</h4> <section id="CD011688-sec-0053"> <h5 class="title">Certainty of the evidence</h5> <p>We present the overall certainty of the evidence for each outcome specified below according to the GRADE approach, which takes into account issues related not only to internal validity (risk of bias, inconsistency, imprecision, publication bias) but also to external validity, such as directness of results<i>.</i> Two review authors (AS and YR) independently rated the certainty of the evidence for each outcome. We resolved disagreements by consensus or by consulting a third review author (AGG). In case of disagreement, we consulted the rest of the review author team and we made a judgement based on consensus. </p> <p>We include an appendix entitled 'Checklist to aid consistency and reproducibility of GRADE assessments' (<a href="./appendices#CD011688-sec-0121">Appendix 1</a>), to help with standardisation of the 'Summary of findings' tables (<a href="./references#CD011688-bbs2-0092" title="MeaderN , KingK , LlewellynA , NormanG , BrownJ , RodgersM , et al. A checklist designed to aid consistency and reproducibility of GRADE assessments: development and pilot validation. Systematic Reviews2014;3(82):1-9. [DOI: 10.1186/2046-4053-3-82]">Meader 2014</a>). Alternatively, we planned to use the GRADEpro Guideline Development Tool (GDT) software and planned to present evidence profile tables as an appendix (<a href="./references#CD011688-bbs2-0069" title="GRADEproGDT. Version accessed 24 October 2017. Hamilton (ON): McMaster University (developed by Evidence Prime), 2015. Available at gradepro.org.">GRADEproGDT 2015</a>). We present results for outcomes as described in the <a href="#CD011688-sec-0026">Types of outcome measures</a> section. If meta‐analysis was not possible, we planned to present the results in a narrative format in the '<a href="./full#CD011688-tbl-0001">summary of findings Table 1</a>'. We justify all decisions to downgrade the quality of trials by using footnotes, and add comments to aid the reader's understanding of this Cochrane Review when necessary. </p> </section> <section id="CD011688-sec-0054"> <h5 class="title">'Summary of findings' table</h5> <p>We present a summary of the evidence in the <a href="./full#CD011688-tbl-0001">summary of findings Table 1</a>. This provides key information about the best estimate of the magnitude of effect, in relative terms and as absolute differences, for each relevant comparison of alternative management strategies, numbers of participants and trials addressing each important outcome and a rating of overall confidence in effect estimates for each outcome. We created the 'Summary of findings table' using the methods described in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD011688-bbs2-0102" title="SchünemannHJ , OxmanAD , HigginsJP , VistGE , GlasziouP , AklE , et al, on behalf of the Cochrane GRADEing Methods Group and the Cochrane Statistical Methods Group. Chapter 11: Completing ‘Summary of findings’ tables and grading the confidence in or quality of the evidence. In: Higgins JP, Churchill R, Chandler J, Cumpston MS (editors), Cochrane Handbook for Systematic Reviews of Interventions version 5.2.0 (updated June 2017). Cochrane, 2017. Available from www.training.cochrane.org/handbook.">Schünemann 2017</a>), along with Review Manager 5 table editor (<a href="./references#CD011688-bbs2-0098" title="Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014.">Review Manager 2014</a>). Intervention presented in the 'Summary of findings' table was fluoxetine and comparator was placebo. </p> <p>We reported the following outcomes, listed according to priority.<br/>  </p> <p> <ul id="CD011688-list-0013"> <li> <p>Weight loss (kg)</p> </li> <li> <p>Health‐related quality of life</p> </li> <li> <p>Any adverse event</p> </li> <li> <p>Anthropometric measurements other than weight loss in kg</p> </li> <li> <p>Morbidity</p> </li> <li> <p>All‐cause mortality</p> </li> <li> <p>Socioeconomic effects</p> </li> </ul> </p> </section> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD011688-sec-0055" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD011688-sec-0055"></div> <section id="CD011688-sec-0056"> <h3 class="title">Description of studies</h3> <p>For a detailed description of trials, see <a href="#CD011688-tbl-0002">Table 1</a>, '<a href="./references#CD011688-sec-0146" title="">Characteristics of included studies</a>' and '<a href="./references#CD011688-sec-0147" title="">Characteristics of excluded studies</a>' sections. </p> <section id="CD011688-sec-0057"> <h4 class="title">Results of the search</h4> <p>From the last updated search performed in December 2018, we screened 1036 bibliographic records after removing duplicates. Of these we excluded 984 records on the basis of their abstracts because they were not relevant for this review. We retrieved 52 full‐text publications and conference abstracts for detailed examination. Of the 52 articles examined in detail, we excluded 34; one trial is awaiting classification. Nineteen trials met our inclusion criteria. There were 15 parallel clinical trials (<a href="./references#CD011688-bbs2-0001" title="Al-HelliA , Al-AbbassiM , JasimG , Al-BayatyM . Effects of fluoxetine, omega 3, or their combination on serum leptin in Iraqi obese subjects. International Journal of Pharmaceutical Sciences Review and Research2015;35(1):90-5. ">Al‐Helli 2015</a>; <a href="./references#CD011688-bbs2-0002" title="BagiellaE , CairellaM , DelB , GodiR . Changes in attitude toward food by obese patients treated with placebo and serotoninergic agents. Current Therapeutic Research, Clinical and Experimental1991;50(2):205-10. ">Bagiella 1991</a>; <a href="./references#CD011688-bbs2-0003" title="BondiM , MenozziR , BertoliniM , VenneriM , RioG . Metabolic effects of fluoxetine in obese menopausal women. Journal of Endocrinological Investigation2000;23(5):280-6. ">Bondi 2000</a>; <a href="./references#CD011688-bbs2-0004" title="BrossR , HofferL . Fluoxetine increases resting energy expenditure and basal body temperature in humans. American Journal of Clinical Nutrition1995;61(5):1020-5. ">Bross 1995</a>; <a href="./references#CD011688-bbs2-0006" title="GoldsteinD , RampeyA , DornseifB , LevineL , PotvinJ , FludzinskiL . Fluoxetine: a randomized clinical trial in the maintenance of weight loss. Obesity Research1993;1(2):92-8. ">Goldstein 1993</a>; <a href="./references#CD011688-bbs2-0007" title="DargaL , Carroll-MichalsL , BotsfordS , LucasC . Fluoxetine's effect on weight loss in obese subjects. American Journal of Clinical Nutrition1991;54(2):321-5. GoldsteinD , RampeyA , EnasG , PotvinJ , FludzinskiL , LevineL . Fluoxetine: a randomized clinical trial in the treatment of obesity. International Journal of Obesity and Related Metabolic Disorders1994;18(3):129-35. ">Goldstein 1994</a>; <a href="./references#CD011688-bbs2-0008" title="GuimarãesC , PereiraL , Lucif JúniorN , CesarinoE , AlmeidaC , CarvalhoD , et al. Tolerability and effectiveness of fluoxetine, metformin and sibutramine in reducing anthropometric and metabolic parameters in obese patients. Arquivos Brasileiros de Endocrinologia e Metabologia2006;50(6):1020-5. ">Guimaraes 2006</a>; <a href="./references#CD011688-bbs2-0009" title="HuangC , ChianC , LinJ . Short-term treatment of obesity with fluoxetine as a supplement to a low calorie diet. Changgeng Yi Xue za Zhi [Chang Gung Medical Journal]1998;21(1):50-6. ">Huang 1998</a>; <a href="./references#CD011688-bbs2-0012" title="LevineL , RosenblattS , BosomworthJ . Use of a serotonin re-uptake inhibitor, fluoxetine, in the treatment of obesity. International Journal of Obesity1987;11(Suppl 3):185-90. ">Levine 1987</a>; <a href="./references#CD011688-bbs2-0013" title="LevineL , EnasG , ThompsonW , ByynyR , DauerA , KirbyR , et al. Use of fluoxetine, a selective serotonin-uptake inhibitor, in the treatment of obesity: a dose-response study. International Journal of Obesity1989;13(5):635-45. ">Levine 1989</a>; <a href="./references#CD011688-bbs2-0014" title="PedrinolaF , RissoW , LimaN , MedeirosG . Fluoxetine induced weight loss in overweight subjects: a double-blind placebo-controlled trial. Arquivos Brasileiros de Endocrinologia e Metabologia1993;37:31-3. ">Pedrinola 1993</a>; <a href="./references#CD011688-bbs2-0015" title="PijlH , KoppeschaarH , WillekensF , Op de KampI , VeldhuisH , MeindersA . Effect of serotonin re-uptake inhibition by fluoxetine on body weight and spontaneous food choice in obesity. International Journal of Obesity1991;15(3):237-42. ">Pijl 1991</a>; <a href="./references#CD011688-bbs2-0017" title="SuplicyH , BoguszewskiC , Dos SantosC , Do DesterroM , CunhaD , RadomiskiR . A comparative study of five centrally acting drugs on the pharmacological treatment of obesity. International Journal of Obesity2014;38(8):1097-103. ">Suplicy 2014</a>; <a href="./references#CD011688-bbs2-0018" title="VisserM , SeidellJ , KoppeschaarH , SmitsP . No specific effect of fluoxetine treatment on fasting glucose, insulin, lipid levels, and blood pressure in healthy men with abdominal obesity. Obesity Research1994;2(2):152-9. VisserM , SeidellJ , KoppeschaarH , SmitsP . The effect of fluoxetine on body weight, body composition and visceral fat accumulation. International Journal of Obesity and Related Metabolic Disorders1993;17(5):247-53. ">Visser 1993</a>; <a href="./references#CD011688-bbs2-0019" title="WurtmanJ , WurtmanR , BerryE , GleasonR , GoldbergH , McDermottJ , et al. Dexfenfluramine, fluoxetine, and weight loss among female carbohydrate cravers. Neuropsychopharmacology1993;9(3):201-10. ">Wurtman 1993</a>); and four cross‐over clinical trials (<a href="./references#CD011688-bbs2-0005" title="Fernández-SotoM , González-JiménezA , Barredo-AcedoF , Luna del CastilloJ , Escobar-JiménezF . Comparison of fluoxetine and placebo in the treatment of obesity. Annals of Nutrition &amp; Metabolism1995;39(3):159-63. ">Fernández‐Soto 1995</a>; <a href="./references#CD011688-bbs2-0010" title="KopelmanP , ElliottM , SimondsA , CramerD , WardS , WedzichaJ . Short-term use of fluoxetine in asymptomatic obese subjects with sleep-related hypoventilation. International Journal of Obesity and Related Metabolic Disorders1992;16(10):825-30. ">Kopelman 1992</a>; <a href="./references#CD011688-bbs2-0011" title="LawtonC , WalesJ , HillA , BlundellJ . Serotoninergic manipulation, meal-induced satiety and eating pattern: effect of fluoxetine in obese female subjects. Obesity Research1995;3(4):345-56. ">Lawton 1995</a>; <a href="./references#CD011688-bbs2-0016" title="StinsonJ , MurphyC , AndrewsJ , TomkinG . An assessment of the thermogenic effects of fluoxetine in obese subjects. International Journal of Obesity and Related Metabolic Disorders1992;16(5):391-5. ">Stinson 1992</a>) (see <a href="#CD011688-fig-0001">Figure 1</a>). </p> </section> <section id="CD011688-sec-0058"> <h4 class="title">Included studies</h4> <p>Details of the characteristics of included trials are presented in the <a href="./references#CD011688-sec-0146" title="">Characteristics of included studies</a> table and the following appendices: <a href="./appendices#CD011688-sec-0125">Appendix 5</a>; <a href="./appendices#CD011688-sec-0126">Appendix 6</a>; <a href="./appendices#CD011688-sec-0127">Appendix 7</a>; <a href="./appendices#CD011688-sec-0128">Appendix 8</a>; <a href="./appendices#CD011688-sec-0129">Appendix 9</a>; <a href="./appendices#CD011688-sec-0130">Appendix 10</a>; <a href="./appendices#CD011688-sec-0131">Appendix 11</a>; <a href="./appendices#CD011688-sec-0132">Appendix 12</a>; <a href="./appendices#CD011688-sec-0133">Appendix 13</a>; <a href="./appendices#CD011688-sec-0134">Appendix 14</a>; <a href="./appendices#CD011688-sec-0135">Appendix 15</a>. The following is a brief overview. </p> <section id="CD011688-sec-0059"> <h5 class="title">Source of data</h5> <p>We obtained data from published literature. We did not find data from trial registries, web‐based data repositories or correspondence with authors (<a href="./appendices#CD011688-sec-0134">Appendix 14</a>). </p> </section> <section id="CD011688-sec-0060"> <h5 class="title">Comparisons</h5> <p>We identified a great variety of interventions in our 19 included trials, which we grouped into five main comparisons with overall 56 trial arms. </p> <p>A) Eighteen trials compared fluoxetine with placebo (<a href="./references#CD011688-bbs2-0001" title="Al-HelliA , Al-AbbassiM , JasimG , Al-BayatyM . Effects of fluoxetine, omega 3, or their combination on serum leptin in Iraqi obese subjects. International Journal of Pharmaceutical Sciences Review and Research2015;35(1):90-5. ">Al‐Helli 2015</a>; <a href="./references#CD011688-bbs2-0002" title="BagiellaE , CairellaM , DelB , GodiR . Changes in attitude toward food by obese patients treated with placebo and serotoninergic agents. Current Therapeutic Research, Clinical and Experimental1991;50(2):205-10. ">Bagiella 1991</a>; <a href="./references#CD011688-bbs2-0003" title="BondiM , MenozziR , BertoliniM , VenneriM , RioG . Metabolic effects of fluoxetine in obese menopausal women. Journal of Endocrinological Investigation2000;23(5):280-6. ">Bondi 2000</a>; <a href="./references#CD011688-bbs2-0004" title="BrossR , HofferL . Fluoxetine increases resting energy expenditure and basal body temperature in humans. American Journal of Clinical Nutrition1995;61(5):1020-5. ">Bross 1995</a>; <a href="./references#CD011688-bbs2-0005" title="Fernández-SotoM , González-JiménezA , Barredo-AcedoF , Luna del CastilloJ , Escobar-JiménezF . Comparison of fluoxetine and placebo in the treatment of obesity. Annals of Nutrition &amp; Metabolism1995;39(3):159-63. ">Fernández‐Soto 1995</a>; <a href="./references#CD011688-bbs2-0006" title="GoldsteinD , RampeyA , DornseifB , LevineL , PotvinJ , FludzinskiL . Fluoxetine: a randomized clinical trial in the maintenance of weight loss. Obesity Research1993;1(2):92-8. ">Goldstein 1993</a>; <a href="./references#CD011688-bbs2-0007" title="DargaL , Carroll-MichalsL , BotsfordS , LucasC . Fluoxetine's effect on weight loss in obese subjects. American Journal of Clinical Nutrition1991;54(2):321-5. GoldsteinD , RampeyA , EnasG , PotvinJ , FludzinskiL , LevineL . Fluoxetine: a randomized clinical trial in the treatment of obesity. International Journal of Obesity and Related Metabolic Disorders1994;18(3):129-35. ">Goldstein 1994</a>; <a href="./references#CD011688-bbs2-0008" title="GuimarãesC , PereiraL , Lucif JúniorN , CesarinoE , AlmeidaC , CarvalhoD , et al. Tolerability and effectiveness of fluoxetine, metformin and sibutramine in reducing anthropometric and metabolic parameters in obese patients. Arquivos Brasileiros de Endocrinologia e Metabologia2006;50(6):1020-5. ">Guimaraes 2006</a>; <a href="./references#CD011688-bbs2-0010" title="KopelmanP , ElliottM , SimondsA , CramerD , WardS , WedzichaJ . Short-term use of fluoxetine in asymptomatic obese subjects with sleep-related hypoventilation. International Journal of Obesity and Related Metabolic Disorders1992;16(10):825-30. ">Kopelman 1992</a>; <a href="./references#CD011688-bbs2-0011" title="LawtonC , WalesJ , HillA , BlundellJ . Serotoninergic manipulation, meal-induced satiety and eating pattern: effect of fluoxetine in obese female subjects. Obesity Research1995;3(4):345-56. ">Lawton 1995</a>; <a href="./references#CD011688-bbs2-0012" title="LevineL , RosenblattS , BosomworthJ . Use of a serotonin re-uptake inhibitor, fluoxetine, in the treatment of obesity. International Journal of Obesity1987;11(Suppl 3):185-90. ">Levine 1987</a>; <a href="./references#CD011688-bbs2-0013" title="LevineL , EnasG , ThompsonW , ByynyR , DauerA , KirbyR , et al. Use of fluoxetine, a selective serotonin-uptake inhibitor, in the treatment of obesity: a dose-response study. International Journal of Obesity1989;13(5):635-45. ">Levine 1989</a>; <a href="./references#CD011688-bbs2-0014" title="PedrinolaF , RissoW , LimaN , MedeirosG . Fluoxetine induced weight loss in overweight subjects: a double-blind placebo-controlled trial. Arquivos Brasileiros de Endocrinologia e Metabologia1993;37:31-3. ">Pedrinola 1993</a>; <a href="./references#CD011688-bbs2-0015" title="PijlH , KoppeschaarH , WillekensF , Op de KampI , VeldhuisH , MeindersA . Effect of serotonin re-uptake inhibition by fluoxetine on body weight and spontaneous food choice in obesity. International Journal of Obesity1991;15(3):237-42. ">Pijl 1991</a>; <a href="./references#CD011688-bbs2-0016" title="StinsonJ , MurphyC , AndrewsJ , TomkinG . An assessment of the thermogenic effects of fluoxetine in obese subjects. International Journal of Obesity and Related Metabolic Disorders1992;16(5):391-5. ">Stinson 1992</a>; <a href="./references#CD011688-bbs2-0017" title="SuplicyH , BoguszewskiC , Dos SantosC , Do DesterroM , CunhaD , RadomiskiR . A comparative study of five centrally acting drugs on the pharmacological treatment of obesity. International Journal of Obesity2014;38(8):1097-103. ">Suplicy 2014</a>; <a href="./references#CD011688-bbs2-0018" title="VisserM , SeidellJ , KoppeschaarH , SmitsP . No specific effect of fluoxetine treatment on fasting glucose, insulin, lipid levels, and blood pressure in healthy men with abdominal obesity. Obesity Research1994;2(2):152-9. VisserM , SeidellJ , KoppeschaarH , SmitsP . The effect of fluoxetine on body weight, body composition and visceral fat accumulation. International Journal of Obesity and Related Metabolic Disorders1993;17(5):247-53. ">Visser 1993</a>; <a href="./references#CD011688-bbs2-0019" title="WurtmanJ , WurtmanR , BerryE , GleasonR , GoldbergH , McDermottJ , et al. Dexfenfluramine, fluoxetine, and weight loss among female carbohydrate cravers. Neuropsychopharmacology1993;9(3):201-10. ">Wurtman 1993</a>). </p> <p>B) Four trials compared fluoxetine with another anti‐obesity agent (<a href="./references#CD011688-bbs2-0002" title="BagiellaE , CairellaM , DelB , GodiR . Changes in attitude toward food by obese patients treated with placebo and serotoninergic agents. Current Therapeutic Research, Clinical and Experimental1991;50(2):205-10. ">Bagiella 1991</a>; <a href="./references#CD011688-bbs2-0008" title="GuimarãesC , PereiraL , Lucif JúniorN , CesarinoE , AlmeidaC , CarvalhoD , et al. Tolerability and effectiveness of fluoxetine, metformin and sibutramine in reducing anthropometric and metabolic parameters in obese patients. Arquivos Brasileiros de Endocrinologia e Metabologia2006;50(6):1020-5. ">Guimaraes 2006</a>; <a href="./references#CD011688-bbs2-0017" title="SuplicyH , BoguszewskiC , Dos SantosC , Do DesterroM , CunhaD , RadomiskiR . A comparative study of five centrally acting drugs on the pharmacological treatment of obesity. International Journal of Obesity2014;38(8):1097-103. ">Suplicy 2014</a>; <a href="./references#CD011688-bbs2-0019" title="WurtmanJ , WurtmanR , BerryE , GleasonR , GoldbergH , McDermottJ , et al. Dexfenfluramine, fluoxetine, and weight loss among female carbohydrate cravers. Neuropsychopharmacology1993;9(3):201-10. ">Wurtman 1993</a>). </p> <p>C) One trial compared fluoxetine with no treatment (<a href="./references#CD011688-bbs2-0009" title="HuangC , ChianC , LinJ . Short-term treatment of obesity with fluoxetine as a supplement to a low calorie diet. Changgeng Yi Xue za Zhi [Chang Gung Medical Journal]1998;21(1):50-6. ">Huang 1998</a>). </p> <p>D) One trial compared fluoxetine with a non‐pharmacological treatment (<a href="./references#CD011688-bbs2-0001" title="Al-HelliA , Al-AbbassiM , JasimG , Al-BayatyM . Effects of fluoxetine, omega 3, or their combination on serum leptin in Iraqi obese subjects. International Journal of Pharmaceutical Sciences Review and Research2015;35(1):90-5. ">Al‐Helli 2015</a>). </p> <p>E) Three trials compared fluoxetine 60 mg/d with fluoxetine at smaller doses (10, 20 and 40 mg/d) (<a href="./references#CD011688-bbs2-0003" title="BondiM , MenozziR , BertoliniM , VenneriM , RioG . Metabolic effects of fluoxetine in obese menopausal women. Journal of Endocrinological Investigation2000;23(5):280-6. ">Bondi 2000</a>; <a href="./references#CD011688-bbs2-0006" title="GoldsteinD , RampeyA , DornseifB , LevineL , PotvinJ , FludzinskiL . Fluoxetine: a randomized clinical trial in the maintenance of weight loss. Obesity Research1993;1(2):92-8. ">Goldstein 1993</a>; <a href="./references#CD011688-bbs2-0013" title="LevineL , EnasG , ThompsonW , ByynyR , DauerA , KirbyR , et al. Use of fluoxetine, a selective serotonin-uptake inhibitor, in the treatment of obesity: a dose-response study. International Journal of Obesity1989;13(5):635-45. ">Levine 1989</a>). </p> </section> <section id="CD011688-sec-0061"> <h5 class="title">Overview of trial populations</h5> <p>There were a total of 2216 participants in 19 trials, including one trial with 60 participants which did not specify how many participants constituted each arm of the study (<a href="./references#CD011688-bbs2-0002" title="BagiellaE , CairellaM , DelB , GodiR . Changes in attitude toward food by obese patients treated with placebo and serotoninergic agents. Current Therapeutic Research, Clinical and Experimental1991;50(2):205-10. ">Bagiella 1991</a>). A total of 1280 participants without depression, mental illness or abnormal eating patterns were randomly assigned to the fluoxetine groups (680 participants received 60 mg/d, 149 received 40 mg/d, 320 received 20 mg/d and 131 received 10 mg/d). The comparator groups of interest for this review had 936 participants with 730 on placebo, 164 using other anti‐obesity agents, 12 being treated non‐pharmacologically and 30 who received no treatment. </p> <p>The proportion of participants in the intervention groups who finished the trials was lowest in <a href="./references#CD011688-bbs2-0006" title="GoldsteinD , RampeyA , DornseifB , LevineL , PotvinJ , FludzinskiL . Fluoxetine: a randomized clinical trial in the maintenance of weight loss. Obesity Research1993;1(2):92-8. ">Goldstein 1993</a> with 43% at 52 weeks of follow‐up, and ranged from 56.6% to 82.7% in five other trials (<a href="./references#CD011688-bbs2-0005" title="Fernández-SotoM , González-JiménezA , Barredo-AcedoF , Luna del CastilloJ , Escobar-JiménezF . Comparison of fluoxetine and placebo in the treatment of obesity. Annals of Nutrition &amp; Metabolism1995;39(3):159-63. ">Fernández‐Soto 1995</a>; <a href="./references#CD011688-bbs2-0007" title="DargaL , Carroll-MichalsL , BotsfordS , LucasC . Fluoxetine's effect on weight loss in obese subjects. American Journal of Clinical Nutrition1991;54(2):321-5. GoldsteinD , RampeyA , EnasG , PotvinJ , FludzinskiL , LevineL . Fluoxetine: a randomized clinical trial in the treatment of obesity. International Journal of Obesity and Related Metabolic Disorders1994;18(3):129-35. ">Goldstein 1994</a>; <a href="./references#CD011688-bbs2-0013" title="LevineL , EnasG , ThompsonW , ByynyR , DauerA , KirbyR , et al. Use of fluoxetine, a selective serotonin-uptake inhibitor, in the treatment of obesity: a dose-response study. International Journal of Obesity1989;13(5):635-45. ">Levine 1989</a>; <a href="./references#CD011688-bbs2-0017" title="SuplicyH , BoguszewskiC , Dos SantosC , Do DesterroM , CunhaD , RadomiskiR . A comparative study of five centrally acting drugs on the pharmacological treatment of obesity. International Journal of Obesity2014;38(8):1097-103. ">Suplicy 2014</a>; <a href="./references#CD011688-bbs2-0019" title="WurtmanJ , WurtmanR , BerryE , GleasonR , GoldbergH , McDermottJ , et al. Dexfenfluramine, fluoxetine, and weight loss among female carbohydrate cravers. Neuropsychopharmacology1993;9(3):201-10. ">Wurtman 1993</a>). The 12 trials with highest proportion of participants in the intervention groups who finished the trials were <a href="./references#CD011688-bbs2-0001" title="Al-HelliA , Al-AbbassiM , JasimG , Al-BayatyM . Effects of fluoxetine, omega 3, or their combination on serum leptin in Iraqi obese subjects. International Journal of Pharmaceutical Sciences Review and Research2015;35(1):90-5. ">Al‐Helli 2015</a>, <a href="./references#CD011688-bbs2-0003" title="BondiM , MenozziR , BertoliniM , VenneriM , RioG . Metabolic effects of fluoxetine in obese menopausal women. Journal of Endocrinological Investigation2000;23(5):280-6. ">Bondi 2000</a>, <a href="./references#CD011688-bbs2-0004" title="BrossR , HofferL . Fluoxetine increases resting energy expenditure and basal body temperature in humans. American Journal of Clinical Nutrition1995;61(5):1020-5. ">Bross 1995</a>, <a href="./references#CD011688-bbs2-0008" title="GuimarãesC , PereiraL , Lucif JúniorN , CesarinoE , AlmeidaC , CarvalhoD , et al. Tolerability and effectiveness of fluoxetine, metformin and sibutramine in reducing anthropometric and metabolic parameters in obese patients. Arquivos Brasileiros de Endocrinologia e Metabologia2006;50(6):1020-5. ">Guimaraes 2006</a>, <a href="./references#CD011688-bbs2-0009" title="HuangC , ChianC , LinJ . Short-term treatment of obesity with fluoxetine as a supplement to a low calorie diet. Changgeng Yi Xue za Zhi [Chang Gung Medical Journal]1998;21(1):50-6. ">Huang 1998</a>, <a href="./references#CD011688-bbs2-0010" title="KopelmanP , ElliottM , SimondsA , CramerD , WardS , WedzichaJ . Short-term use of fluoxetine in asymptomatic obese subjects with sleep-related hypoventilation. International Journal of Obesity and Related Metabolic Disorders1992;16(10):825-30. ">Kopelman 1992</a>, <a href="./references#CD011688-bbs2-0011" title="LawtonC , WalesJ , HillA , BlundellJ . Serotoninergic manipulation, meal-induced satiety and eating pattern: effect of fluoxetine in obese female subjects. Obesity Research1995;3(4):345-56. ">Lawton 1995</a>, <a href="./references#CD011688-bbs2-0012" title="LevineL , RosenblattS , BosomworthJ . Use of a serotonin re-uptake inhibitor, fluoxetine, in the treatment of obesity. International Journal of Obesity1987;11(Suppl 3):185-90. ">Levine 1987</a>, <a href="./references#CD011688-bbs2-0014" title="PedrinolaF , RissoW , LimaN , MedeirosG . Fluoxetine induced weight loss in overweight subjects: a double-blind placebo-controlled trial. Arquivos Brasileiros de Endocrinologia e Metabologia1993;37:31-3. ">Pedrinola 1993</a>, <a href="./references#CD011688-bbs2-0015" title="PijlH , KoppeschaarH , WillekensF , Op de KampI , VeldhuisH , MeindersA . Effect of serotonin re-uptake inhibition by fluoxetine on body weight and spontaneous food choice in obesity. International Journal of Obesity1991;15(3):237-42. ">Pijl 1991</a>, <a href="./references#CD011688-bbs2-0016" title="StinsonJ , MurphyC , AndrewsJ , TomkinG . An assessment of the thermogenic effects of fluoxetine in obese subjects. International Journal of Obesity and Related Metabolic Disorders1992;16(5):391-5. ">Stinson 1992</a>and <a href="./references#CD011688-bbs2-0018" title="VisserM , SeidellJ , KoppeschaarH , SmitsP . No specific effect of fluoxetine treatment on fasting glucose, insulin, lipid levels, and blood pressure in healthy men with abdominal obesity. Obesity Research1994;2(2):152-9. VisserM , SeidellJ , KoppeschaarH , SmitsP . The effect of fluoxetine on body weight, body composition and visceral fat accumulation. International Journal of Obesity and Related Metabolic Disorders1993;17(5):247-53. ">Visser 1993</a>, with proportions of 80% to 100%. In the comparator groups, the proportion of participants who finished the trials was lowest in <a href="./references#CD011688-bbs2-0007" title="DargaL , Carroll-MichalsL , BotsfordS , LucasC . Fluoxetine's effect on weight loss in obese subjects. American Journal of Clinical Nutrition1991;54(2):321-5. GoldsteinD , RampeyA , EnasG , PotvinJ , FludzinskiL , LevineL . Fluoxetine: a randomized clinical trial in the treatment of obesity. International Journal of Obesity and Related Metabolic Disorders1994;18(3):129-35. ">Goldstein 1994</a>, <a href="./references#CD011688-bbs2-0013" title="LevineL , EnasG , ThompsonW , ByynyR , DauerA , KirbyR , et al. Use of fluoxetine, a selective serotonin-uptake inhibitor, in the treatment of obesity: a dose-response study. International Journal of Obesity1989;13(5):635-45. ">Levine 1989</a> and <a href="./references#CD011688-bbs2-0017" title="SuplicyH , BoguszewskiC , Dos SantosC , Do DesterroM , CunhaD , RadomiskiR . A comparative study of five centrally acting drugs on the pharmacological treatment of obesity. International Journal of Obesity2014;38(8):1097-103. ">Suplicy 2014</a> with 47.3% to 56.4% of participants. In four other trials, the proportion who finished ranged from 67.3% to 80% (<a href="./references#CD011688-bbs2-0005" title="Fernández-SotoM , González-JiménezA , Barredo-AcedoF , Luna del CastilloJ , Escobar-JiménezF . Comparison of fluoxetine and placebo in the treatment of obesity. Annals of Nutrition &amp; Metabolism1995;39(3):159-63. ">Fernández‐Soto 1995</a>; <a href="./references#CD011688-bbs2-0006" title="GoldsteinD , RampeyA , DornseifB , LevineL , PotvinJ , FludzinskiL . Fluoxetine: a randomized clinical trial in the maintenance of weight loss. Obesity Research1993;1(2):92-8. ">Goldstein 1993</a>; <a href="./references#CD011688-bbs2-0009" title="HuangC , ChianC , LinJ . Short-term treatment of obesity with fluoxetine as a supplement to a low calorie diet. Changgeng Yi Xue za Zhi [Chang Gung Medical Journal]1998;21(1):50-6. ">Huang 1998</a>; <a href="./references#CD011688-bbs2-0014" title="PedrinolaF , RissoW , LimaN , MedeirosG . Fluoxetine induced weight loss in overweight subjects: a double-blind placebo-controlled trial. Arquivos Brasileiros de Endocrinologia e Metabologia1993;37:31-3. ">Pedrinola 1993</a>). The 11 trials with the highest proportion of participants in the comparator groups who finished the trial were <a href="./references#CD011688-bbs2-0001" title="Al-HelliA , Al-AbbassiM , JasimG , Al-BayatyM . Effects of fluoxetine, omega 3, or their combination on serum leptin in Iraqi obese subjects. International Journal of Pharmaceutical Sciences Review and Research2015;35(1):90-5. ">Al‐Helli 2015</a>, <a href="./references#CD011688-bbs2-0003" title="BondiM , MenozziR , BertoliniM , VenneriM , RioG . Metabolic effects of fluoxetine in obese menopausal women. Journal of Endocrinological Investigation2000;23(5):280-6. ">Bondi 2000</a>, <a href="./references#CD011688-bbs2-0004" title="BrossR , HofferL . Fluoxetine increases resting energy expenditure and basal body temperature in humans. American Journal of Clinical Nutrition1995;61(5):1020-5. ">Bross 1995</a>, <a href="./references#CD011688-bbs2-0008" title="GuimarãesC , PereiraL , Lucif JúniorN , CesarinoE , AlmeidaC , CarvalhoD , et al. Tolerability and effectiveness of fluoxetine, metformin and sibutramine in reducing anthropometric and metabolic parameters in obese patients. Arquivos Brasileiros de Endocrinologia e Metabologia2006;50(6):1020-5. ">Guimaraes 2006</a>, <a href="./references#CD011688-bbs2-0010" title="KopelmanP , ElliottM , SimondsA , CramerD , WardS , WedzichaJ . Short-term use of fluoxetine in asymptomatic obese subjects with sleep-related hypoventilation. International Journal of Obesity and Related Metabolic Disorders1992;16(10):825-30. ">Kopelman 1992</a>, <a href="./references#CD011688-bbs2-0011" title="LawtonC , WalesJ , HillA , BlundellJ . Serotoninergic manipulation, meal-induced satiety and eating pattern: effect of fluoxetine in obese female subjects. Obesity Research1995;3(4):345-56. ">Lawton 1995</a>, <a href="./references#CD011688-bbs2-0012" title="LevineL , RosenblattS , BosomworthJ . Use of a serotonin re-uptake inhibitor, fluoxetine, in the treatment of obesity. International Journal of Obesity1987;11(Suppl 3):185-90. ">Levine 1987</a>, <a href="./references#CD011688-bbs2-0015" title="PijlH , KoppeschaarH , WillekensF , Op de KampI , VeldhuisH , MeindersA . Effect of serotonin re-uptake inhibition by fluoxetine on body weight and spontaneous food choice in obesity. International Journal of Obesity1991;15(3):237-42. ">Pijl 1991</a>, <a href="./references#CD011688-bbs2-0016" title="StinsonJ , MurphyC , AndrewsJ , TomkinG . An assessment of the thermogenic effects of fluoxetine in obese subjects. International Journal of Obesity and Related Metabolic Disorders1992;16(5):391-5. ">Stinson 1992</a>, <a href="./references#CD011688-bbs2-0018" title="VisserM , SeidellJ , KoppeschaarH , SmitsP . No specific effect of fluoxetine treatment on fasting glucose, insulin, lipid levels, and blood pressure in healthy men with abdominal obesity. Obesity Research1994;2(2):152-9. VisserM , SeidellJ , KoppeschaarH , SmitsP . The effect of fluoxetine on body weight, body composition and visceral fat accumulation. International Journal of Obesity and Related Metabolic Disorders1993;17(5):247-53. ">Visser 1993</a> and <a href="./references#CD011688-bbs2-0019" title="WurtmanJ , WurtmanR , BerryE , GleasonR , GoldbergH , McDermottJ , et al. Dexfenfluramine, fluoxetine, and weight loss among female carbohydrate cravers. Neuropsychopharmacology1993;9(3):201-10. ">Wurtman 1993</a>, with proportions ranging from 86.2% to 100%. The sample size ranged from 20 in <a href="./references#CD011688-bbs2-0004" title="BrossR , HofferL . Fluoxetine increases resting energy expenditure and basal body temperature in humans. American Journal of Clinical Nutrition1995;61(5):1020-5. ">Bross 1995</a> and <a href="./references#CD011688-bbs2-0014" title="PedrinolaF , RissoW , LimaN , MedeirosG . Fluoxetine induced weight loss in overweight subjects: a double-blind placebo-controlled trial. Arquivos Brasileiros de Endocrinologia e Metabologia1993;37:31-3. ">Pedrinola 1993</a> to 655 in <a href="./references#CD011688-bbs2-0013" title="LevineL , EnasG , ThompsonW , ByynyR , DauerA , KirbyR , et al. Use of fluoxetine, a selective serotonin-uptake inhibitor, in the treatment of obesity: a dose-response study. International Journal of Obesity1989;13(5):635-45. ">Levine 1989</a>. See <a href="#CD011688-tbl-0002">Table 1</a> for details. </p> </section> <section id="CD011688-sec-0062"> <h5 class="title">Trial design</h5> <p>Of the 19 trials included in this review, 15 were parallel comparisons with individual randomisation (<a href="./references#CD011688-bbs2-0001" title="Al-HelliA , Al-AbbassiM , JasimG , Al-BayatyM . Effects of fluoxetine, omega 3, or their combination on serum leptin in Iraqi obese subjects. International Journal of Pharmaceutical Sciences Review and Research2015;35(1):90-5. ">Al‐Helli 2015</a>; <a href="./references#CD011688-bbs2-0002" title="BagiellaE , CairellaM , DelB , GodiR . Changes in attitude toward food by obese patients treated with placebo and serotoninergic agents. Current Therapeutic Research, Clinical and Experimental1991;50(2):205-10. ">Bagiella 1991</a>; <a href="./references#CD011688-bbs2-0003" title="BondiM , MenozziR , BertoliniM , VenneriM , RioG . Metabolic effects of fluoxetine in obese menopausal women. Journal of Endocrinological Investigation2000;23(5):280-6. ">Bondi 2000</a>; <a href="./references#CD011688-bbs2-0004" title="BrossR , HofferL . Fluoxetine increases resting energy expenditure and basal body temperature in humans. American Journal of Clinical Nutrition1995;61(5):1020-5. ">Bross 1995</a>; <a href="./references#CD011688-bbs2-0006" title="GoldsteinD , RampeyA , DornseifB , LevineL , PotvinJ , FludzinskiL . Fluoxetine: a randomized clinical trial in the maintenance of weight loss. Obesity Research1993;1(2):92-8. ">Goldstein 1993</a>; <a href="./references#CD011688-bbs2-0007" title="DargaL , Carroll-MichalsL , BotsfordS , LucasC . Fluoxetine's effect on weight loss in obese subjects. American Journal of Clinical Nutrition1991;54(2):321-5. GoldsteinD , RampeyA , EnasG , PotvinJ , FludzinskiL , LevineL . Fluoxetine: a randomized clinical trial in the treatment of obesity. International Journal of Obesity and Related Metabolic Disorders1994;18(3):129-35. ">Goldstein 1994</a>; <a href="./references#CD011688-bbs2-0008" title="GuimarãesC , PereiraL , Lucif JúniorN , CesarinoE , AlmeidaC , CarvalhoD , et al. Tolerability and effectiveness of fluoxetine, metformin and sibutramine in reducing anthropometric and metabolic parameters in obese patients. Arquivos Brasileiros de Endocrinologia e Metabologia2006;50(6):1020-5. ">Guimaraes 2006</a>; <a href="./references#CD011688-bbs2-0009" title="HuangC , ChianC , LinJ . Short-term treatment of obesity with fluoxetine as a supplement to a low calorie diet. Changgeng Yi Xue za Zhi [Chang Gung Medical Journal]1998;21(1):50-6. ">Huang 1998</a>; <a href="./references#CD011688-bbs2-0012" title="LevineL , RosenblattS , BosomworthJ . Use of a serotonin re-uptake inhibitor, fluoxetine, in the treatment of obesity. International Journal of Obesity1987;11(Suppl 3):185-90. ">Levine 1987</a>; <a href="./references#CD011688-bbs2-0013" title="LevineL , EnasG , ThompsonW , ByynyR , DauerA , KirbyR , et al. Use of fluoxetine, a selective serotonin-uptake inhibitor, in the treatment of obesity: a dose-response study. International Journal of Obesity1989;13(5):635-45. ">Levine 1989</a>; <a href="./references#CD011688-bbs2-0014" title="PedrinolaF , RissoW , LimaN , MedeirosG . Fluoxetine induced weight loss in overweight subjects: a double-blind placebo-controlled trial. Arquivos Brasileiros de Endocrinologia e Metabologia1993;37:31-3. ">Pedrinola 1993</a>; <a href="./references#CD011688-bbs2-0015" title="PijlH , KoppeschaarH , WillekensF , Op de KampI , VeldhuisH , MeindersA . Effect of serotonin re-uptake inhibition by fluoxetine on body weight and spontaneous food choice in obesity. International Journal of Obesity1991;15(3):237-42. ">Pijl 1991</a>; <a href="./references#CD011688-bbs2-0017" title="SuplicyH , BoguszewskiC , Dos SantosC , Do DesterroM , CunhaD , RadomiskiR . A comparative study of five centrally acting drugs on the pharmacological treatment of obesity. International Journal of Obesity2014;38(8):1097-103. ">Suplicy 2014</a>; <a href="./references#CD011688-bbs2-0018" title="VisserM , SeidellJ , KoppeschaarH , SmitsP . No specific effect of fluoxetine treatment on fasting glucose, insulin, lipid levels, and blood pressure in healthy men with abdominal obesity. Obesity Research1994;2(2):152-9. VisserM , SeidellJ , KoppeschaarH , SmitsP . The effect of fluoxetine on body weight, body composition and visceral fat accumulation. International Journal of Obesity and Related Metabolic Disorders1993;17(5):247-53. ">Visser 1993</a>; <a href="./references#CD011688-bbs2-0019" title="WurtmanJ , WurtmanR , BerryE , GleasonR , GoldbergH , McDermottJ , et al. Dexfenfluramine, fluoxetine, and weight loss among female carbohydrate cravers. Neuropsychopharmacology1993;9(3):201-10. ">Wurtman 1993</a>); and four trials were cross‐over comparisons (<a href="./references#CD011688-bbs2-0005" title="Fernández-SotoM , González-JiménezA , Barredo-AcedoF , Luna del CastilloJ , Escobar-JiménezF . Comparison of fluoxetine and placebo in the treatment of obesity. Annals of Nutrition &amp; Metabolism1995;39(3):159-63. ">Fernández‐Soto 1995</a>; <a href="./references#CD011688-bbs2-0010" title="KopelmanP , ElliottM , SimondsA , CramerD , WardS , WedzichaJ . Short-term use of fluoxetine in asymptomatic obese subjects with sleep-related hypoventilation. International Journal of Obesity and Related Metabolic Disorders1992;16(10):825-30. ">Kopelman 1992</a>; <a href="./references#CD011688-bbs2-0011" title="LawtonC , WalesJ , HillA , BlundellJ . Serotoninergic manipulation, meal-induced satiety and eating pattern: effect of fluoxetine in obese female subjects. Obesity Research1995;3(4):345-56. ">Lawton 1995</a>; <a href="./references#CD011688-bbs2-0016" title="StinsonJ , MurphyC , AndrewsJ , TomkinG . An assessment of the thermogenic effects of fluoxetine in obese subjects. International Journal of Obesity and Related Metabolic Disorders1992;16(5):391-5. ">Stinson 1992</a>). </p> <p>Fifteen trials were performed with a parallel group superiority design and used a placebo as comparator (<a href="./references#CD011688-bbs2-0001" title="Al-HelliA , Al-AbbassiM , JasimG , Al-BayatyM . Effects of fluoxetine, omega 3, or their combination on serum leptin in Iraqi obese subjects. International Journal of Pharmaceutical Sciences Review and Research2015;35(1):90-5. ">Al‐Helli 2015</a>; <a href="./references#CD011688-bbs2-0002" title="BagiellaE , CairellaM , DelB , GodiR . Changes in attitude toward food by obese patients treated with placebo and serotoninergic agents. Current Therapeutic Research, Clinical and Experimental1991;50(2):205-10. ">Bagiella 1991</a>; <a href="./references#CD011688-bbs2-0004" title="BrossR , HofferL . Fluoxetine increases resting energy expenditure and basal body temperature in humans. American Journal of Clinical Nutrition1995;61(5):1020-5. ">Bross 1995</a>; <a href="./references#CD011688-bbs2-0005" title="Fernández-SotoM , González-JiménezA , Barredo-AcedoF , Luna del CastilloJ , Escobar-JiménezF . Comparison of fluoxetine and placebo in the treatment of obesity. Annals of Nutrition &amp; Metabolism1995;39(3):159-63. ">Fernández‐Soto 1995</a>; <a href="./references#CD011688-bbs2-0007" title="DargaL , Carroll-MichalsL , BotsfordS , LucasC . Fluoxetine's effect on weight loss in obese subjects. American Journal of Clinical Nutrition1991;54(2):321-5. GoldsteinD , RampeyA , EnasG , PotvinJ , FludzinskiL , LevineL . Fluoxetine: a randomized clinical trial in the treatment of obesity. International Journal of Obesity and Related Metabolic Disorders1994;18(3):129-35. ">Goldstein 1994</a>; <a href="./references#CD011688-bbs2-0008" title="GuimarãesC , PereiraL , Lucif JúniorN , CesarinoE , AlmeidaC , CarvalhoD , et al. Tolerability and effectiveness of fluoxetine, metformin and sibutramine in reducing anthropometric and metabolic parameters in obese patients. Arquivos Brasileiros de Endocrinologia e Metabologia2006;50(6):1020-5. ">Guimaraes 2006</a>; <a href="./references#CD011688-bbs2-0010" title="KopelmanP , ElliottM , SimondsA , CramerD , WardS , WedzichaJ . Short-term use of fluoxetine in asymptomatic obese subjects with sleep-related hypoventilation. International Journal of Obesity and Related Metabolic Disorders1992;16(10):825-30. ">Kopelman 1992</a>; <a href="./references#CD011688-bbs2-0011" title="LawtonC , WalesJ , HillA , BlundellJ . Serotoninergic manipulation, meal-induced satiety and eating pattern: effect of fluoxetine in obese female subjects. Obesity Research1995;3(4):345-56. ">Lawton 1995</a>; <a href="./references#CD011688-bbs2-0012" title="LevineL , RosenblattS , BosomworthJ . Use of a serotonin re-uptake inhibitor, fluoxetine, in the treatment of obesity. International Journal of Obesity1987;11(Suppl 3):185-90. ">Levine 1987</a>; <a href="./references#CD011688-bbs2-0014" title="PedrinolaF , RissoW , LimaN , MedeirosG . Fluoxetine induced weight loss in overweight subjects: a double-blind placebo-controlled trial. Arquivos Brasileiros de Endocrinologia e Metabologia1993;37:31-3. ">Pedrinola 1993</a>; <a href="./references#CD011688-bbs2-0015" title="PijlH , KoppeschaarH , WillekensF , Op de KampI , VeldhuisH , MeindersA . Effect of serotonin re-uptake inhibition by fluoxetine on body weight and spontaneous food choice in obesity. International Journal of Obesity1991;15(3):237-42. ">Pijl 1991</a>; <a href="./references#CD011688-bbs2-0016" title="StinsonJ , MurphyC , AndrewsJ , TomkinG . An assessment of the thermogenic effects of fluoxetine in obese subjects. International Journal of Obesity and Related Metabolic Disorders1992;16(5):391-5. ">Stinson 1992</a>; <a href="./references#CD011688-bbs2-0017" title="SuplicyH , BoguszewskiC , Dos SantosC , Do DesterroM , CunhaD , RadomiskiR . A comparative study of five centrally acting drugs on the pharmacological treatment of obesity. International Journal of Obesity2014;38(8):1097-103. ">Suplicy 2014</a>; <a href="./references#CD011688-bbs2-0018" title="VisserM , SeidellJ , KoppeschaarH , SmitsP . No specific effect of fluoxetine treatment on fasting glucose, insulin, lipid levels, and blood pressure in healthy men with abdominal obesity. Obesity Research1994;2(2):152-9. VisserM , SeidellJ , KoppeschaarH , SmitsP . The effect of fluoxetine on body weight, body composition and visceral fat accumulation. International Journal of Obesity and Related Metabolic Disorders1993;17(5):247-53. ">Visser 1993</a>; <a href="./references#CD011688-bbs2-0019" title="WurtmanJ , WurtmanR , BerryE , GleasonR , GoldbergH , McDermottJ , et al. Dexfenfluramine, fluoxetine, and weight loss among female carbohydrate cravers. Neuropsychopharmacology1993;9(3):201-10. ">Wurtman 1993</a>), and only one trial used no treatment as the comparator (<a href="./references#CD011688-bbs2-0009" title="HuangC , ChianC , LinJ . Short-term treatment of obesity with fluoxetine as a supplement to a low calorie diet. Changgeng Yi Xue za Zhi [Chang Gung Medical Journal]1998;21(1):50-6. ">Huang 1998</a>). Three trials used an equivalence design (<a href="./references#CD011688-bbs2-0003" title="BondiM , MenozziR , BertoliniM , VenneriM , RioG . Metabolic effects of fluoxetine in obese menopausal women. Journal of Endocrinological Investigation2000;23(5):280-6. ">Bondi 2000</a>; <a href="./references#CD011688-bbs2-0006" title="GoldsteinD , RampeyA , DornseifB , LevineL , PotvinJ , FludzinskiL . Fluoxetine: a randomized clinical trial in the maintenance of weight loss. Obesity Research1993;1(2):92-8. ">Goldstein 1993</a>; <a href="./references#CD011688-bbs2-0013" title="LevineL , EnasG , ThompsonW , ByynyR , DauerA , KirbyR , et al. Use of fluoxetine, a selective serotonin-uptake inhibitor, in the treatment of obesity: a dose-response study. International Journal of Obesity1989;13(5):635-45. ">Levine 1989</a>). </p> <p>Of the 19 trials, one trial had six comparisons (five intervention groups and one placebo group) (<a href="./references#CD011688-bbs2-0017" title="SuplicyH , BoguszewskiC , Dos SantosC , Do DesterroM , CunhaD , RadomiskiR . A comparative study of five centrally acting drugs on the pharmacological treatment of obesity. International Journal of Obesity2014;38(8):1097-103. ">Suplicy 2014</a>); one trial had five arms (four fluoxetine groups and one placebo group) (<a href="./references#CD011688-bbs2-0013" title="LevineL , EnasG , ThompsonW , ByynyR , DauerA , KirbyR , et al. Use of fluoxetine, a selective serotonin-uptake inhibitor, in the treatment of obesity: a dose-response study. International Journal of Obesity1989;13(5):635-45. ">Levine 1989</a>); two trials had four arms (three intervention groups and one placebo arm) (<a href="./references#CD011688-bbs2-0001" title="Al-HelliA , Al-AbbassiM , JasimG , Al-BayatyM . Effects of fluoxetine, omega 3, or their combination on serum leptin in Iraqi obese subjects. International Journal of Pharmaceutical Sciences Review and Research2015;35(1):90-5. ">Al‐Helli 2015</a>; <a href="./references#CD011688-bbs2-0008" title="GuimarãesC , PereiraL , Lucif JúniorN , CesarinoE , AlmeidaC , CarvalhoD , et al. Tolerability and effectiveness of fluoxetine, metformin and sibutramine in reducing anthropometric and metabolic parameters in obese patients. Arquivos Brasileiros de Endocrinologia e Metabologia2006;50(6):1020-5. ">Guimaraes 2006</a>); three trials had three arms (two intervention groups and one placebo group) (<a href="./references#CD011688-bbs2-0003" title="BondiM , MenozziR , BertoliniM , VenneriM , RioG . Metabolic effects of fluoxetine in obese menopausal women. Journal of Endocrinological Investigation2000;23(5):280-6. ">Bondi 2000</a>; <a href="./references#CD011688-bbs2-0006" title="GoldsteinD , RampeyA , DornseifB , LevineL , PotvinJ , FludzinskiL . Fluoxetine: a randomized clinical trial in the maintenance of weight loss. Obesity Research1993;1(2):92-8. ">Goldstein 1993</a>; <a href="./references#CD011688-bbs2-0019" title="WurtmanJ , WurtmanR , BerryE , GleasonR , GoldbergH , McDermottJ , et al. Dexfenfluramine, fluoxetine, and weight loss among female carbohydrate cravers. Neuropsychopharmacology1993;9(3):201-10. ">Wurtman 1993</a>); 11 trials had two arms (one intervention group and one placebo group) (<a href="./references#CD011688-bbs2-0002" title="BagiellaE , CairellaM , DelB , GodiR . Changes in attitude toward food by obese patients treated with placebo and serotoninergic agents. Current Therapeutic Research, Clinical and Experimental1991;50(2):205-10. ">Bagiella 1991</a>; <a href="./references#CD011688-bbs2-0004" title="BrossR , HofferL . Fluoxetine increases resting energy expenditure and basal body temperature in humans. American Journal of Clinical Nutrition1995;61(5):1020-5. ">Bross 1995</a>; <a href="./references#CD011688-bbs2-0005" title="Fernández-SotoM , González-JiménezA , Barredo-AcedoF , Luna del CastilloJ , Escobar-JiménezF . Comparison of fluoxetine and placebo in the treatment of obesity. Annals of Nutrition &amp; Metabolism1995;39(3):159-63. ">Fernández‐Soto 1995</a>; <a href="./references#CD011688-bbs2-0007" title="DargaL , Carroll-MichalsL , BotsfordS , LucasC . Fluoxetine's effect on weight loss in obese subjects. American Journal of Clinical Nutrition1991;54(2):321-5. GoldsteinD , RampeyA , EnasG , PotvinJ , FludzinskiL , LevineL . Fluoxetine: a randomized clinical trial in the treatment of obesity. International Journal of Obesity and Related Metabolic Disorders1994;18(3):129-35. ">Goldstein 1994</a>; <a href="./references#CD011688-bbs2-0010" title="KopelmanP , ElliottM , SimondsA , CramerD , WardS , WedzichaJ . Short-term use of fluoxetine in asymptomatic obese subjects with sleep-related hypoventilation. International Journal of Obesity and Related Metabolic Disorders1992;16(10):825-30. ">Kopelman 1992</a>; <a href="./references#CD011688-bbs2-0011" title="LawtonC , WalesJ , HillA , BlundellJ . Serotoninergic manipulation, meal-induced satiety and eating pattern: effect of fluoxetine in obese female subjects. Obesity Research1995;3(4):345-56. ">Lawton 1995</a>; <a href="./references#CD011688-bbs2-0012" title="LevineL , RosenblattS , BosomworthJ . Use of a serotonin re-uptake inhibitor, fluoxetine, in the treatment of obesity. International Journal of Obesity1987;11(Suppl 3):185-90. ">Levine 1987</a>; <a href="./references#CD011688-bbs2-0014" title="PedrinolaF , RissoW , LimaN , MedeirosG . Fluoxetine induced weight loss in overweight subjects: a double-blind placebo-controlled trial. Arquivos Brasileiros de Endocrinologia e Metabologia1993;37:31-3. ">Pedrinola 1993</a>; <a href="./references#CD011688-bbs2-0015" title="PijlH , KoppeschaarH , WillekensF , Op de KampI , VeldhuisH , MeindersA . Effect of serotonin re-uptake inhibition by fluoxetine on body weight and spontaneous food choice in obesity. International Journal of Obesity1991;15(3):237-42. ">Pijl 1991</a>; <a href="./references#CD011688-bbs2-0016" title="StinsonJ , MurphyC , AndrewsJ , TomkinG . An assessment of the thermogenic effects of fluoxetine in obese subjects. International Journal of Obesity and Related Metabolic Disorders1992;16(5):391-5. ">Stinson 1992</a>; <a href="./references#CD011688-bbs2-0018" title="VisserM , SeidellJ , KoppeschaarH , SmitsP . No specific effect of fluoxetine treatment on fasting glucose, insulin, lipid levels, and blood pressure in healthy men with abdominal obesity. Obesity Research1994;2(2):152-9. VisserM , SeidellJ , KoppeschaarH , SmitsP . The effect of fluoxetine on body weight, body composition and visceral fat accumulation. International Journal of Obesity and Related Metabolic Disorders1993;17(5):247-53. ">Visser 1993</a>); and one trial had two arms with a no‐treatment group used as the comparator group (<a href="./references#CD011688-bbs2-0009" title="HuangC , ChianC , LinJ . Short-term treatment of obesity with fluoxetine as a supplement to a low calorie diet. Changgeng Yi Xue za Zhi [Chang Gung Medical Journal]1998;21(1):50-6. ">Huang 1998</a>). </p> <p>Sixteen trials were performed in a single centre (<a href="./references#CD011688-bbs2-0001" title="Al-HelliA , Al-AbbassiM , JasimG , Al-BayatyM . Effects of fluoxetine, omega 3, or their combination on serum leptin in Iraqi obese subjects. International Journal of Pharmaceutical Sciences Review and Research2015;35(1):90-5. ">Al‐Helli 2015</a>; <a href="./references#CD011688-bbs2-0002" title="BagiellaE , CairellaM , DelB , GodiR . Changes in attitude toward food by obese patients treated with placebo and serotoninergic agents. Current Therapeutic Research, Clinical and Experimental1991;50(2):205-10. ">Bagiella 1991</a>; <a href="./references#CD011688-bbs2-0003" title="BondiM , MenozziR , BertoliniM , VenneriM , RioG . Metabolic effects of fluoxetine in obese menopausal women. Journal of Endocrinological Investigation2000;23(5):280-6. ">Bondi 2000</a>; <a href="./references#CD011688-bbs2-0004" title="BrossR , HofferL . Fluoxetine increases resting energy expenditure and basal body temperature in humans. American Journal of Clinical Nutrition1995;61(5):1020-5. ">Bross 1995</a>; <a href="./references#CD011688-bbs2-0005" title="Fernández-SotoM , González-JiménezA , Barredo-AcedoF , Luna del CastilloJ , Escobar-JiménezF . Comparison of fluoxetine and placebo in the treatment of obesity. Annals of Nutrition &amp; Metabolism1995;39(3):159-63. ">Fernández‐Soto 1995</a>; <a href="./references#CD011688-bbs2-0008" title="GuimarãesC , PereiraL , Lucif JúniorN , CesarinoE , AlmeidaC , CarvalhoD , et al. Tolerability and effectiveness of fluoxetine, metformin and sibutramine in reducing anthropometric and metabolic parameters in obese patients. Arquivos Brasileiros de Endocrinologia e Metabologia2006;50(6):1020-5. ">Guimaraes 2006</a>; <a href="./references#CD011688-bbs2-0009" title="HuangC , ChianC , LinJ . Short-term treatment of obesity with fluoxetine as a supplement to a low calorie diet. Changgeng Yi Xue za Zhi [Chang Gung Medical Journal]1998;21(1):50-6. ">Huang 1998</a>; <a href="./references#CD011688-bbs2-0010" title="KopelmanP , ElliottM , SimondsA , CramerD , WardS , WedzichaJ . Short-term use of fluoxetine in asymptomatic obese subjects with sleep-related hypoventilation. International Journal of Obesity and Related Metabolic Disorders1992;16(10):825-30. ">Kopelman 1992</a>; <a href="./references#CD011688-bbs2-0011" title="LawtonC , WalesJ , HillA , BlundellJ . Serotoninergic manipulation, meal-induced satiety and eating pattern: effect of fluoxetine in obese female subjects. Obesity Research1995;3(4):345-56. ">Lawton 1995</a>; <a href="./references#CD011688-bbs2-0012" title="LevineL , RosenblattS , BosomworthJ . Use of a serotonin re-uptake inhibitor, fluoxetine, in the treatment of obesity. International Journal of Obesity1987;11(Suppl 3):185-90. ">Levine 1987</a>; <a href="./references#CD011688-bbs2-0014" title="PedrinolaF , RissoW , LimaN , MedeirosG . Fluoxetine induced weight loss in overweight subjects: a double-blind placebo-controlled trial. Arquivos Brasileiros de Endocrinologia e Metabologia1993;37:31-3. ">Pedrinola 1993</a>; <a href="./references#CD011688-bbs2-0015" title="PijlH , KoppeschaarH , WillekensF , Op de KampI , VeldhuisH , MeindersA . Effect of serotonin re-uptake inhibition by fluoxetine on body weight and spontaneous food choice in obesity. International Journal of Obesity1991;15(3):237-42. ">Pijl 1991</a>; <a href="./references#CD011688-bbs2-0016" title="StinsonJ , MurphyC , AndrewsJ , TomkinG . An assessment of the thermogenic effects of fluoxetine in obese subjects. International Journal of Obesity and Related Metabolic Disorders1992;16(5):391-5. ">Stinson 1992</a>; <a href="./references#CD011688-bbs2-0017" title="SuplicyH , BoguszewskiC , Dos SantosC , Do DesterroM , CunhaD , RadomiskiR . A comparative study of five centrally acting drugs on the pharmacological treatment of obesity. International Journal of Obesity2014;38(8):1097-103. ">Suplicy 2014</a>; <a href="./references#CD011688-bbs2-0018" title="VisserM , SeidellJ , KoppeschaarH , SmitsP . No specific effect of fluoxetine treatment on fasting glucose, insulin, lipid levels, and blood pressure in healthy men with abdominal obesity. Obesity Research1994;2(2):152-9. VisserM , SeidellJ , KoppeschaarH , SmitsP . The effect of fluoxetine on body weight, body composition and visceral fat accumulation. International Journal of Obesity and Related Metabolic Disorders1993;17(5):247-53. ">Visser 1993</a>; <a href="./references#CD011688-bbs2-0019" title="WurtmanJ , WurtmanR , BerryE , GleasonR , GoldbergH , McDermottJ , et al. Dexfenfluramine, fluoxetine, and weight loss among female carbohydrate cravers. Neuropsychopharmacology1993;9(3):201-10. ">Wurtman 1993</a>); and three trials were performed in multiple centres ranging from 6 to 10 centres (<a href="./references#CD011688-bbs2-0006" title="GoldsteinD , RampeyA , DornseifB , LevineL , PotvinJ , FludzinskiL . Fluoxetine: a randomized clinical trial in the maintenance of weight loss. Obesity Research1993;1(2):92-8. ">Goldstein 1993</a>; <a href="./references#CD011688-bbs2-0007" title="DargaL , Carroll-MichalsL , BotsfordS , LucasC . Fluoxetine's effect on weight loss in obese subjects. American Journal of Clinical Nutrition1991;54(2):321-5. GoldsteinD , RampeyA , EnasG , PotvinJ , FludzinskiL , LevineL . Fluoxetine: a randomized clinical trial in the treatment of obesity. International Journal of Obesity and Related Metabolic Disorders1994;18(3):129-35. ">Goldstein 1994</a>; <a href="./references#CD011688-bbs2-0013" title="LevineL , EnasG , ThompsonW , ByynyR , DauerA , KirbyR , et al. Use of fluoxetine, a selective serotonin-uptake inhibitor, in the treatment of obesity: a dose-response study. International Journal of Obesity1989;13(5):635-45. ">Levine 1989</a>). </p> <p>Twelve trials were reported as double‐blinded for participants and personnel (<a href="./references#CD011688-bbs2-0003" title="BondiM , MenozziR , BertoliniM , VenneriM , RioG . Metabolic effects of fluoxetine in obese menopausal women. Journal of Endocrinological Investigation2000;23(5):280-6. ">Bondi 2000</a>; <a href="./references#CD011688-bbs2-0004" title="BrossR , HofferL . Fluoxetine increases resting energy expenditure and basal body temperature in humans. American Journal of Clinical Nutrition1995;61(5):1020-5. ">Bross 1995</a>; <a href="./references#CD011688-bbs2-0005" title="Fernández-SotoM , González-JiménezA , Barredo-AcedoF , Luna del CastilloJ , Escobar-JiménezF . Comparison of fluoxetine and placebo in the treatment of obesity. Annals of Nutrition &amp; Metabolism1995;39(3):159-63. ">Fernández‐Soto 1995</a>; <a href="./references#CD011688-bbs2-0006" title="GoldsteinD , RampeyA , DornseifB , LevineL , PotvinJ , FludzinskiL . Fluoxetine: a randomized clinical trial in the maintenance of weight loss. Obesity Research1993;1(2):92-8. ">Goldstein 1993</a>; <a href="./references#CD011688-bbs2-0010" title="KopelmanP , ElliottM , SimondsA , CramerD , WardS , WedzichaJ . Short-term use of fluoxetine in asymptomatic obese subjects with sleep-related hypoventilation. International Journal of Obesity and Related Metabolic Disorders1992;16(10):825-30. ">Kopelman 1992</a>; <a href="./references#CD011688-bbs2-0011" title="LawtonC , WalesJ , HillA , BlundellJ . Serotoninergic manipulation, meal-induced satiety and eating pattern: effect of fluoxetine in obese female subjects. Obesity Research1995;3(4):345-56. ">Lawton 1995</a>; <a href="./references#CD011688-bbs2-0013" title="LevineL , EnasG , ThompsonW , ByynyR , DauerA , KirbyR , et al. Use of fluoxetine, a selective serotonin-uptake inhibitor, in the treatment of obesity: a dose-response study. International Journal of Obesity1989;13(5):635-45. ">Levine 1989</a>; <a href="./references#CD011688-bbs2-0014" title="PedrinolaF , RissoW , LimaN , MedeirosG . Fluoxetine induced weight loss in overweight subjects: a double-blind placebo-controlled trial. Arquivos Brasileiros de Endocrinologia e Metabologia1993;37:31-3. ">Pedrinola 1993</a>; <a href="./references#CD011688-bbs2-0015" title="PijlH , KoppeschaarH , WillekensF , Op de KampI , VeldhuisH , MeindersA . Effect of serotonin re-uptake inhibition by fluoxetine on body weight and spontaneous food choice in obesity. International Journal of Obesity1991;15(3):237-42. ">Pijl 1991</a>; <a href="./references#CD011688-bbs2-0016" title="StinsonJ , MurphyC , AndrewsJ , TomkinG . An assessment of the thermogenic effects of fluoxetine in obese subjects. International Journal of Obesity and Related Metabolic Disorders1992;16(5):391-5. ">Stinson 1992</a>; <a href="./references#CD011688-bbs2-0018" title="VisserM , SeidellJ , KoppeschaarH , SmitsP . No specific effect of fluoxetine treatment on fasting glucose, insulin, lipid levels, and blood pressure in healthy men with abdominal obesity. Obesity Research1994;2(2):152-9. VisserM , SeidellJ , KoppeschaarH , SmitsP . The effect of fluoxetine on body weight, body composition and visceral fat accumulation. International Journal of Obesity and Related Metabolic Disorders1993;17(5):247-53. ">Visser 1993</a>; <a href="./references#CD011688-bbs2-0019" title="WurtmanJ , WurtmanR , BerryE , GleasonR , GoldbergH , McDermottJ , et al. Dexfenfluramine, fluoxetine, and weight loss among female carbohydrate cravers. Neuropsychopharmacology1993;9(3):201-10. ">Wurtman 1993</a>). Two trials were reported as single‐blinded for participants (<a href="./references#CD011688-bbs2-0016" title="StinsonJ , MurphyC , AndrewsJ , TomkinG . An assessment of the thermogenic effects of fluoxetine in obese subjects. International Journal of Obesity and Related Metabolic Disorders1992;16(5):391-5. ">Stinson 1992</a>; <a href="./references#CD011688-bbs2-0018" title="VisserM , SeidellJ , KoppeschaarH , SmitsP . No specific effect of fluoxetine treatment on fasting glucose, insulin, lipid levels, and blood pressure in healthy men with abdominal obesity. Obesity Research1994;2(2):152-9. VisserM , SeidellJ , KoppeschaarH , SmitsP . The effect of fluoxetine on body weight, body composition and visceral fat accumulation. International Journal of Obesity and Related Metabolic Disorders1993;17(5):247-53. ">Visser 1993</a>); and two trials did not state whether they were blinded as to participants, personnel or assessors (<a href="./references#CD011688-bbs2-0001" title="Al-HelliA , Al-AbbassiM , JasimG , Al-BayatyM . Effects of fluoxetine, omega 3, or their combination on serum leptin in Iraqi obese subjects. International Journal of Pharmaceutical Sciences Review and Research2015;35(1):90-5. ">Al‐Helli 2015</a>; <a href="./references#CD011688-bbs2-0002" title="BagiellaE , CairellaM , DelB , GodiR . Changes in attitude toward food by obese patients treated with placebo and serotoninergic agents. Current Therapeutic Research, Clinical and Experimental1991;50(2):205-10. ">Bagiella 1991</a>). </p> <p>The trials were performed between 1987 and 2015. The duration of the interventions ranged from three days (<a href="./references#CD011688-bbs2-0010" title="KopelmanP , ElliottM , SimondsA , CramerD , WardS , WedzichaJ . Short-term use of fluoxetine in asymptomatic obese subjects with sleep-related hypoventilation. International Journal of Obesity and Related Metabolic Disorders1992;16(10):825-30. ">Kopelman 1992</a>) to 52 weeks (<a href="./references#CD011688-bbs2-0007" title="DargaL , Carroll-MichalsL , BotsfordS , LucasC . Fluoxetine's effect on weight loss in obese subjects. American Journal of Clinical Nutrition1991;54(2):321-5. GoldsteinD , RampeyA , EnasG , PotvinJ , FludzinskiL , LevineL . Fluoxetine: a randomized clinical trial in the treatment of obesity. International Journal of Obesity and Related Metabolic Disorders1994;18(3):129-35. ">Goldstein 1994</a>; <a href="./references#CD011688-bbs2-0017" title="SuplicyH , BoguszewskiC , Dos SantosC , Do DesterroM , CunhaD , RadomiskiR . A comparative study of five centrally acting drugs on the pharmacological treatment of obesity. International Journal of Obesity2014;38(8):1097-103. ">Suplicy 2014</a>), with a median of duration of 12 weeks. The duration of follow‐up ranged from three weeks (<a href="./references#CD011688-bbs2-0004" title="BrossR , HofferL . Fluoxetine increases resting energy expenditure and basal body temperature in humans. American Journal of Clinical Nutrition1995;61(5):1020-5. ">Bross 1995</a>) to 52 weeks (<a href="./references#CD011688-bbs2-0017" title="SuplicyH , BoguszewskiC , Dos SantosC , Do DesterroM , CunhaD , RadomiskiR . A comparative study of five centrally acting drugs on the pharmacological treatment of obesity. International Journal of Obesity2014;38(8):1097-103. ">Suplicy 2014</a>; <a href="./references#CD011688-bbs2-0007" title="DargaL , Carroll-MichalsL , BotsfordS , LucasC . Fluoxetine's effect on weight loss in obese subjects. American Journal of Clinical Nutrition1991;54(2):321-5. GoldsteinD , RampeyA , EnasG , PotvinJ , FludzinskiL , LevineL . Fluoxetine: a randomized clinical trial in the treatment of obesity. International Journal of Obesity and Related Metabolic Disorders1994;18(3):129-35. ">Goldstein 1994</a>), with a median duration of 12 weeks. Eight trials reported a run‐in period of between four days and nine weeks (<a href="./references#CD011688-bbs2-0004" title="BrossR , HofferL . Fluoxetine increases resting energy expenditure and basal body temperature in humans. American Journal of Clinical Nutrition1995;61(5):1020-5. ">Bross 1995</a>; <a href="./references#CD011688-bbs2-0006" title="GoldsteinD , RampeyA , DornseifB , LevineL , PotvinJ , FludzinskiL . Fluoxetine: a randomized clinical trial in the maintenance of weight loss. Obesity Research1993;1(2):92-8. ">Goldstein 1993</a>). No trials were terminated before their prespecified end. </p> </section> <section id="CD011688-sec-0063"> <h5 class="title">Settings</h5> <p>The interventions were performed in an outpatient setting in eight trials (<a href="./references#CD011688-bbs2-0002" title="BagiellaE , CairellaM , DelB , GodiR . Changes in attitude toward food by obese patients treated with placebo and serotoninergic agents. Current Therapeutic Research, Clinical and Experimental1991;50(2):205-10. ">Bagiella 1991</a>; <a href="./references#CD011688-bbs2-0005" title="Fernández-SotoM , González-JiménezA , Barredo-AcedoF , Luna del CastilloJ , Escobar-JiménezF . Comparison of fluoxetine and placebo in the treatment of obesity. Annals of Nutrition &amp; Metabolism1995;39(3):159-63. ">Fernández‐Soto 1995</a>; <a href="./references#CD011688-bbs2-0006" title="GoldsteinD , RampeyA , DornseifB , LevineL , PotvinJ , FludzinskiL . Fluoxetine: a randomized clinical trial in the maintenance of weight loss. Obesity Research1993;1(2):92-8. ">Goldstein 1993</a>; <a href="./references#CD011688-bbs2-0007" title="DargaL , Carroll-MichalsL , BotsfordS , LucasC . Fluoxetine's effect on weight loss in obese subjects. American Journal of Clinical Nutrition1991;54(2):321-5. GoldsteinD , RampeyA , EnasG , PotvinJ , FludzinskiL , LevineL . Fluoxetine: a randomized clinical trial in the treatment of obesity. International Journal of Obesity and Related Metabolic Disorders1994;18(3):129-35. ">Goldstein 1994</a>; <a href="./references#CD011688-bbs2-0008" title="GuimarãesC , PereiraL , Lucif JúniorN , CesarinoE , AlmeidaC , CarvalhoD , et al. Tolerability and effectiveness of fluoxetine, metformin and sibutramine in reducing anthropometric and metabolic parameters in obese patients. Arquivos Brasileiros de Endocrinologia e Metabologia2006;50(6):1020-5. ">Guimaraes 2006</a>; <a href="./references#CD011688-bbs2-0012" title="LevineL , RosenblattS , BosomworthJ . Use of a serotonin re-uptake inhibitor, fluoxetine, in the treatment of obesity. International Journal of Obesity1987;11(Suppl 3):185-90. ">Levine 1987</a>; <a href="./references#CD011688-bbs2-0013" title="LevineL , EnasG , ThompsonW , ByynyR , DauerA , KirbyR , et al. Use of fluoxetine, a selective serotonin-uptake inhibitor, in the treatment of obesity: a dose-response study. International Journal of Obesity1989;13(5):635-45. ">Levine 1989</a>; <a href="./references#CD011688-bbs2-0018" title="VisserM , SeidellJ , KoppeschaarH , SmitsP . No specific effect of fluoxetine treatment on fasting glucose, insulin, lipid levels, and blood pressure in healthy men with abdominal obesity. Obesity Research1994;2(2):152-9. VisserM , SeidellJ , KoppeschaarH , SmitsP . The effect of fluoxetine on body weight, body composition and visceral fat accumulation. International Journal of Obesity and Related Metabolic Disorders1993;17(5):247-53. ">Visser 1993</a>); in an outpatient obesity or research clinic in nine trials (<a href="./references#CD011688-bbs2-0001" title="Al-HelliA , Al-AbbassiM , JasimG , Al-BayatyM . Effects of fluoxetine, omega 3, or their combination on serum leptin in Iraqi obese subjects. International Journal of Pharmaceutical Sciences Review and Research2015;35(1):90-5. ">Al‐Helli 2015</a>; <a href="./references#CD011688-bbs2-0003" title="BondiM , MenozziR , BertoliniM , VenneriM , RioG . Metabolic effects of fluoxetine in obese menopausal women. Journal of Endocrinological Investigation2000;23(5):280-6. ">Bondi 2000</a>; <a href="./references#CD011688-bbs2-0009" title="HuangC , ChianC , LinJ . Short-term treatment of obesity with fluoxetine as a supplement to a low calorie diet. Changgeng Yi Xue za Zhi [Chang Gung Medical Journal]1998;21(1):50-6. ">Huang 1998</a>; <a href="./references#CD011688-bbs2-0011" title="LawtonC , WalesJ , HillA , BlundellJ . Serotoninergic manipulation, meal-induced satiety and eating pattern: effect of fluoxetine in obese female subjects. Obesity Research1995;3(4):345-56. ">Lawton 1995</a>; <a href="./references#CD011688-bbs2-0014" title="PedrinolaF , RissoW , LimaN , MedeirosG . Fluoxetine induced weight loss in overweight subjects: a double-blind placebo-controlled trial. Arquivos Brasileiros de Endocrinologia e Metabologia1993;37:31-3. ">Pedrinola 1993</a>; <a href="./references#CD011688-bbs2-0015" title="PijlH , KoppeschaarH , WillekensF , Op de KampI , VeldhuisH , MeindersA . Effect of serotonin re-uptake inhibition by fluoxetine on body weight and spontaneous food choice in obesity. International Journal of Obesity1991;15(3):237-42. ">Pijl 1991</a>; <a href="./references#CD011688-bbs2-0016" title="StinsonJ , MurphyC , AndrewsJ , TomkinG . An assessment of the thermogenic effects of fluoxetine in obese subjects. International Journal of Obesity and Related Metabolic Disorders1992;16(5):391-5. ">Stinson 1992</a>; <a href="./references#CD011688-bbs2-0017" title="SuplicyH , BoguszewskiC , Dos SantosC , Do DesterroM , CunhaD , RadomiskiR . A comparative study of five centrally acting drugs on the pharmacological treatment of obesity. International Journal of Obesity2014;38(8):1097-103. ">Suplicy 2014</a>; <a href="./references#CD011688-bbs2-0019" title="WurtmanJ , WurtmanR , BerryE , GleasonR , GoldbergH , McDermottJ , et al. Dexfenfluramine, fluoxetine, and weight loss among female carbohydrate cravers. Neuropsychopharmacology1993;9(3):201-10. ">Wurtman 1993</a>); and on hospitalised participants during intervention or outcomes assessment in two trials (<a href="./references#CD011688-bbs2-0004" title="BrossR , HofferL . Fluoxetine increases resting energy expenditure and basal body temperature in humans. American Journal of Clinical Nutrition1995;61(5):1020-5. ">Bross 1995</a>; <a href="./references#CD011688-bbs2-0010" title="KopelmanP , ElliottM , SimondsA , CramerD , WardS , WedzichaJ . Short-term use of fluoxetine in asymptomatic obese subjects with sleep-related hypoventilation. International Journal of Obesity and Related Metabolic Disorders1992;16(10):825-30. ">Kopelman 1992</a>). Five trials were performed in the USA (<a href="./references#CD011688-bbs2-0007" title="DargaL , Carroll-MichalsL , BotsfordS , LucasC . Fluoxetine's effect on weight loss in obese subjects. American Journal of Clinical Nutrition1991;54(2):321-5. GoldsteinD , RampeyA , EnasG , PotvinJ , FludzinskiL , LevineL . Fluoxetine: a randomized clinical trial in the treatment of obesity. International Journal of Obesity and Related Metabolic Disorders1994;18(3):129-35. ">Goldstein 1994</a>; <a href="./references#CD011688-bbs2-0006" title="GoldsteinD , RampeyA , DornseifB , LevineL , PotvinJ , FludzinskiL . Fluoxetine: a randomized clinical trial in the maintenance of weight loss. Obesity Research1993;1(2):92-8. ">Goldstein 1993</a>; <a href="./references#CD011688-bbs2-0019" title="WurtmanJ , WurtmanR , BerryE , GleasonR , GoldbergH , McDermottJ , et al. Dexfenfluramine, fluoxetine, and weight loss among female carbohydrate cravers. Neuropsychopharmacology1993;9(3):201-10. ">Wurtman 1993</a>; <a href="./references#CD011688-bbs2-0013" title="LevineL , EnasG , ThompsonW , ByynyR , DauerA , KirbyR , et al. Use of fluoxetine, a selective serotonin-uptake inhibitor, in the treatment of obesity: a dose-response study. International Journal of Obesity1989;13(5):635-45. ">Levine 1989</a>; <a href="./references#CD011688-bbs2-0012" title="LevineL , RosenblattS , BosomworthJ . Use of a serotonin re-uptake inhibitor, fluoxetine, in the treatment of obesity. International Journal of Obesity1987;11(Suppl 3):185-90. ">Levine 1987</a>); three in Brazil (<a href="./references#CD011688-bbs2-0008" title="GuimarãesC , PereiraL , Lucif JúniorN , CesarinoE , AlmeidaC , CarvalhoD , et al. Tolerability and effectiveness of fluoxetine, metformin and sibutramine in reducing anthropometric and metabolic parameters in obese patients. Arquivos Brasileiros de Endocrinologia e Metabologia2006;50(6):1020-5. ">Guimaraes 2006</a>; <a href="./references#CD011688-bbs2-0014" title="PedrinolaF , RissoW , LimaN , MedeirosG . Fluoxetine induced weight loss in overweight subjects: a double-blind placebo-controlled trial. Arquivos Brasileiros de Endocrinologia e Metabologia1993;37:31-3. ">Pedrinola 1993</a>; <a href="./references#CD011688-bbs2-0017" title="SuplicyH , BoguszewskiC , Dos SantosC , Do DesterroM , CunhaD , RadomiskiR . A comparative study of five centrally acting drugs on the pharmacological treatment of obesity. International Journal of Obesity2014;38(8):1097-103. ">Suplicy 2014</a>); two in the UK (<a href="./references#CD011688-bbs2-0010" title="KopelmanP , ElliottM , SimondsA , CramerD , WardS , WedzichaJ . Short-term use of fluoxetine in asymptomatic obese subjects with sleep-related hypoventilation. International Journal of Obesity and Related Metabolic Disorders1992;16(10):825-30. ">Kopelman 1992</a>; <a href="./references#CD011688-bbs2-0011" title="LawtonC , WalesJ , HillA , BlundellJ . Serotoninergic manipulation, meal-induced satiety and eating pattern: effect of fluoxetine in obese female subjects. Obesity Research1995;3(4):345-56. ">Lawton 1995</a>); two in Italy (<a href="./references#CD011688-bbs2-0002" title="BagiellaE , CairellaM , DelB , GodiR . Changes in attitude toward food by obese patients treated with placebo and serotoninergic agents. Current Therapeutic Research, Clinical and Experimental1991;50(2):205-10. ">Bagiella 1991</a>; <a href="./references#CD011688-bbs2-0003" title="BondiM , MenozziR , BertoliniM , VenneriM , RioG . Metabolic effects of fluoxetine in obese menopausal women. Journal of Endocrinological Investigation2000;23(5):280-6. ">Bondi 2000</a>); two in the Netherlands (<a href="./references#CD011688-bbs2-0015" title="PijlH , KoppeschaarH , WillekensF , Op de KampI , VeldhuisH , MeindersA . Effect of serotonin re-uptake inhibition by fluoxetine on body weight and spontaneous food choice in obesity. International Journal of Obesity1991;15(3):237-42. ">Pijl 1991</a>; <a href="./references#CD011688-bbs2-0018" title="VisserM , SeidellJ , KoppeschaarH , SmitsP . No specific effect of fluoxetine treatment on fasting glucose, insulin, lipid levels, and blood pressure in healthy men with abdominal obesity. Obesity Research1994;2(2):152-9. VisserM , SeidellJ , KoppeschaarH , SmitsP . The effect of fluoxetine on body weight, body composition and visceral fat accumulation. International Journal of Obesity and Related Metabolic Disorders1993;17(5):247-53. ">Visser 1993</a>); and one each in Canada (<a href="./references#CD011688-bbs2-0004" title="BrossR , HofferL . Fluoxetine increases resting energy expenditure and basal body temperature in humans. American Journal of Clinical Nutrition1995;61(5):1020-5. ">Bross 1995</a>), Spain (<a href="./references#CD011688-bbs2-0005" title="Fernández-SotoM , González-JiménezA , Barredo-AcedoF , Luna del CastilloJ , Escobar-JiménezF . Comparison of fluoxetine and placebo in the treatment of obesity. Annals of Nutrition &amp; Metabolism1995;39(3):159-63. ">Fernández‐Soto 1995</a>), Ireland (<a href="./references#CD011688-bbs2-0016" title="StinsonJ , MurphyC , AndrewsJ , TomkinG . An assessment of the thermogenic effects of fluoxetine in obese subjects. International Journal of Obesity and Related Metabolic Disorders1992;16(5):391-5. ">Stinson 1992</a>), Iraq (<a href="./references#CD011688-bbs2-0001" title="Al-HelliA , Al-AbbassiM , JasimG , Al-BayatyM . Effects of fluoxetine, omega 3, or their combination on serum leptin in Iraqi obese subjects. International Journal of Pharmaceutical Sciences Review and Research2015;35(1):90-5. ">Al‐Helli 2015</a>) and the Republic of China (<a href="./references#CD011688-bbs2-0009" title="HuangC , ChianC , LinJ . Short-term treatment of obesity with fluoxetine as a supplement to a low calorie diet. Changgeng Yi Xue za Zhi [Chang Gung Medical Journal]1998;21(1):50-6. ">Huang 1998</a>). </p> </section> <section id="CD011688-sec-0064"> <h5 class="title">Participants</h5> <p>Three trials were performed on participants from low‐ to middle‐income countries (Brazil, Iraq and the Republic of China), and the remaining 16 trials were performed on participants from high‐income countries (Ireland, Italy, Canada, Spain, the UK, the USA and the Netherlands), according to definitions from the <a href="http://www.worldbank.org" target="_blank">World Bank</a>. </p> <p>Only four trials reported ethnicities, being white participants in all four trials (<a href="./references#CD011688-bbs2-0006" title="GoldsteinD , RampeyA , DornseifB , LevineL , PotvinJ , FludzinskiL . Fluoxetine: a randomized clinical trial in the maintenance of weight loss. Obesity Research1993;1(2):92-8. ">Goldstein 1993</a>; <a href="./references#CD011688-bbs2-0007" title="DargaL , Carroll-MichalsL , BotsfordS , LucasC . Fluoxetine's effect on weight loss in obese subjects. American Journal of Clinical Nutrition1991;54(2):321-5. GoldsteinD , RampeyA , EnasG , PotvinJ , FludzinskiL , LevineL . Fluoxetine: a randomized clinical trial in the treatment of obesity. International Journal of Obesity and Related Metabolic Disorders1994;18(3):129-35. ">Goldstein 1994</a>; <a href="./references#CD011688-bbs2-0012" title="LevineL , RosenblattS , BosomworthJ . Use of a serotonin re-uptake inhibitor, fluoxetine, in the treatment of obesity. International Journal of Obesity1987;11(Suppl 3):185-90. ">Levine 1987</a>; <a href="./references#CD011688-bbs2-0013" title="LevineL , EnasG , ThompsonW , ByynyR , DauerA , KirbyR , et al. Use of fluoxetine, a selective serotonin-uptake inhibitor, in the treatment of obesity: a dose-response study. International Journal of Obesity1989;13(5):635-45. ">Levine 1989</a>). No trial reported the duration of overweight or obesity. </p> <p>Of the all trials reporting gender in our review, which involved 2216 participants, the majority of participants (from 80% to 100%) were female (see <a href="./appendices#CD011688-sec-0127">Appendix 7</a>). In three trials, however, women constituted less than 62% of participants (<a href="./references#CD011688-bbs2-0009" title="HuangC , ChianC , LinJ . Short-term treatment of obesity with fluoxetine as a supplement to a low calorie diet. Changgeng Yi Xue za Zhi [Chang Gung Medical Journal]1998;21(1):50-6. ">Huang 1998</a>, 46%; <a href="./references#CD011688-bbs2-0010" title="KopelmanP , ElliottM , SimondsA , CramerD , WardS , WedzichaJ . Short-term use of fluoxetine in asymptomatic obese subjects with sleep-related hypoventilation. International Journal of Obesity and Related Metabolic Disorders1992;16(10):825-30. ">Kopelman 1992</a>, 9%; and <a href="./references#CD011688-bbs2-0016" title="StinsonJ , MurphyC , AndrewsJ , TomkinG . An assessment of the thermogenic effects of fluoxetine in obese subjects. International Journal of Obesity and Related Metabolic Disorders1992;16(5):391-5. ">Stinson 1992</a>, 61%), one trial included exclusively men (<a href="./references#CD011688-bbs2-0018" title="VisserM , SeidellJ , KoppeschaarH , SmitsP . No specific effect of fluoxetine treatment on fasting glucose, insulin, lipid levels, and blood pressure in healthy men with abdominal obesity. Obesity Research1994;2(2):152-9. VisserM , SeidellJ , KoppeschaarH , SmitsP . The effect of fluoxetine on body weight, body composition and visceral fat accumulation. International Journal of Obesity and Related Metabolic Disorders1993;17(5):247-53. ">Visser 1993</a>) and three trials did not report the sex of the participants (<a href="./references#CD011688-bbs2-0001" title="Al-HelliA , Al-AbbassiM , JasimG , Al-BayatyM . Effects of fluoxetine, omega 3, or their combination on serum leptin in Iraqi obese subjects. International Journal of Pharmaceutical Sciences Review and Research2015;35(1):90-5. ">Al‐Helli 2015</a>; <a href="./references#CD011688-bbs2-0002" title="BagiellaE , CairellaM , DelB , GodiR . Changes in attitude toward food by obese patients treated with placebo and serotoninergic agents. Current Therapeutic Research, Clinical and Experimental1991;50(2):205-10. ">Bagiella 1991</a>; <a href="./references#CD011688-bbs2-0014" title="PedrinolaF , RissoW , LimaN , MedeirosG . Fluoxetine induced weight loss in overweight subjects: a double-blind placebo-controlled trial. Arquivos Brasileiros de Endocrinologia e Metabologia1993;37:31-3. ">Pedrinola 1993</a>). The mean age of the participants ranged from 30 years in <a href="./references#CD011688-bbs2-0008" title="GuimarãesC , PereiraL , Lucif JúniorN , CesarinoE , AlmeidaC , CarvalhoD , et al. Tolerability and effectiveness of fluoxetine, metformin and sibutramine in reducing anthropometric and metabolic parameters in obese patients. Arquivos Brasileiros de Endocrinologia e Metabologia2006;50(6):1020-5. ">Guimaraes 2006</a> to 51 years in <a href="./references#CD011688-bbs2-0003" title="BondiM , MenozziR , BertoliniM , VenneriM , RioG . Metabolic effects of fluoxetine in obese menopausal women. Journal of Endocrinological Investigation2000;23(5):280-6. ">Bondi 2000</a>. </p> <p>Baseline characteristics were similar between treatment groups in most of the trials. In one trial there was a difference in weight between the groups (84.9 kg in the fluoxetine group versus 89.2 kg in the placebo group) (<a href="./references#CD011688-bbs2-0006" title="GoldsteinD , RampeyA , DornseifB , LevineL , PotvinJ , FludzinskiL . Fluoxetine: a randomized clinical trial in the maintenance of weight loss. Obesity Research1993;1(2):92-8. ">Goldstein 1993</a>). Mean BMI at baseline in 15 trials ranged from 27.9 kg/m² (<a href="./references#CD011688-bbs2-0018" title="VisserM , SeidellJ , KoppeschaarH , SmitsP . No specific effect of fluoxetine treatment on fasting glucose, insulin, lipid levels, and blood pressure in healthy men with abdominal obesity. Obesity Research1994;2(2):152-9. VisserM , SeidellJ , KoppeschaarH , SmitsP . The effect of fluoxetine on body weight, body composition and visceral fat accumulation. International Journal of Obesity and Related Metabolic Disorders1993;17(5):247-53. ">Visser 1993</a>) to 44 kg/m² (<a href="./references#CD011688-bbs2-0010" title="KopelmanP , ElliottM , SimondsA , CramerD , WardS , WedzichaJ . Short-term use of fluoxetine in asymptomatic obese subjects with sleep-related hypoventilation. International Journal of Obesity and Related Metabolic Disorders1992;16(10):825-30. ">Kopelman 1992</a>). However, two trials reported a mean BMI of 25 kg/m² or more (<a href="./references#CD011688-bbs2-0012" title="LevineL , RosenblattS , BosomworthJ . Use of a serotonin re-uptake inhibitor, fluoxetine, in the treatment of obesity. International Journal of Obesity1987;11(Suppl 3):185-90. ">Levine 1987</a>; <a href="./references#CD011688-bbs2-0013" title="LevineL , EnasG , ThompsonW , ByynyR , DauerA , KirbyR , et al. Use of fluoxetine, a selective serotonin-uptake inhibitor, in the treatment of obesity: a dose-response study. International Journal of Obesity1989;13(5):635-45. ">Levine 1989</a>), one trial reported a mean BMI of 30 kg/m² or more (<a href="./references#CD011688-bbs2-0001" title="Al-HelliA , Al-AbbassiM , JasimG , Al-BayatyM . Effects of fluoxetine, omega 3, or their combination on serum leptin in Iraqi obese subjects. International Journal of Pharmaceutical Sciences Review and Research2015;35(1):90-5. ">Al‐Helli 2015</a>), and one trial reported a mean BMI ranging from 30 kg/m² to 40 kg/m² (<a href="./references#CD011688-bbs2-0002" title="BagiellaE , CairellaM , DelB , GodiR . Changes in attitude toward food by obese patients treated with placebo and serotoninergic agents. Current Therapeutic Research, Clinical and Experimental1991;50(2):205-10. ">Bagiella 1991</a>). Except for this last trial, all the trials reported the mean body weight of the participants at baseline, which ranged from 84.9 kg (<a href="./references#CD011688-bbs2-0006" title="GoldsteinD , RampeyA , DornseifB , LevineL , PotvinJ , FludzinskiL . Fluoxetine: a randomized clinical trial in the maintenance of weight loss. Obesity Research1993;1(2):92-8. ">Goldstein 1993</a>) to 129 Kg (<a href="./references#CD011688-bbs2-0010" title="KopelmanP , ElliottM , SimondsA , CramerD , WardS , WedzichaJ . Short-term use of fluoxetine in asymptomatic obese subjects with sleep-related hypoventilation. International Journal of Obesity and Related Metabolic Disorders1992;16(10):825-30. ">Kopelman 1992</a>). No trial reported glycosylated haemoglobin A1c (HbA1c) values. </p> <p>Of the 19 trials, only <a href="./references#CD011688-bbs2-0019" title="WurtmanJ , WurtmanR , BerryE , GleasonR , GoldbergH , McDermottJ , et al. Dexfenfluramine, fluoxetine, and weight loss among female carbohydrate cravers. Neuropsychopharmacology1993;9(3):201-10. ">Wurtman 1993</a> reported comorbidities in the participants. No trials reported that participants used co‐medications. </p> <p>The main inclusion criteria in the trials were adult participants (16 years or older) who were overweight (BMI 25 kg/m² to 29.9 kg/m²) or obese (BMI ≥ 30 kg/m²), with stable body weight before trial entry. The main exclusion criteria were pregnant or lactating women, previous bariatric surgery, use of appetite suppressants, antidepressants or medicines that could affect body weight, alcohol or drug abuse and serious medical conditions (e.g. hypertension, diabetes, viral infections). </p> </section> <section id="CD011688-sec-0065"> <h5 class="title">Diagnosis</h5> <p>The diagnostic criteria for overweight and obese participants differed between the trials. Fifteen trials used BMI greater than 25 kg/m² (overweight) or greater than 30 kg/m² (obesity) as criteria (<a href="./references#CD011688-bbs2-0002" title="BagiellaE , CairellaM , DelB , GodiR . Changes in attitude toward food by obese patients treated with placebo and serotoninergic agents. Current Therapeutic Research, Clinical and Experimental1991;50(2):205-10. ">Bagiella 1991</a>; <a href="./references#CD011688-bbs2-0003" title="BondiM , MenozziR , BertoliniM , VenneriM , RioG . Metabolic effects of fluoxetine in obese menopausal women. Journal of Endocrinological Investigation2000;23(5):280-6. ">Bondi 2000</a>; <a href="./references#CD011688-bbs2-0004" title="BrossR , HofferL . Fluoxetine increases resting energy expenditure and basal body temperature in humans. American Journal of Clinical Nutrition1995;61(5):1020-5. ">Bross 1995</a>; <a href="./references#CD011688-bbs2-0005" title="Fernández-SotoM , González-JiménezA , Barredo-AcedoF , Luna del CastilloJ , Escobar-JiménezF . Comparison of fluoxetine and placebo in the treatment of obesity. Annals of Nutrition &amp; Metabolism1995;39(3):159-63. ">Fernández‐Soto 1995</a>; <a href="./references#CD011688-bbs2-0006" title="GoldsteinD , RampeyA , DornseifB , LevineL , PotvinJ , FludzinskiL . Fluoxetine: a randomized clinical trial in the maintenance of weight loss. Obesity Research1993;1(2):92-8. ">Goldstein 1993</a>; <a href="./references#CD011688-bbs2-0007" title="DargaL , Carroll-MichalsL , BotsfordS , LucasC . Fluoxetine's effect on weight loss in obese subjects. American Journal of Clinical Nutrition1991;54(2):321-5. GoldsteinD , RampeyA , EnasG , PotvinJ , FludzinskiL , LevineL . Fluoxetine: a randomized clinical trial in the treatment of obesity. International Journal of Obesity and Related Metabolic Disorders1994;18(3):129-35. ">Goldstein 1994</a>; <a href="./references#CD011688-bbs2-0008" title="GuimarãesC , PereiraL , Lucif JúniorN , CesarinoE , AlmeidaC , CarvalhoD , et al. Tolerability and effectiveness of fluoxetine, metformin and sibutramine in reducing anthropometric and metabolic parameters in obese patients. Arquivos Brasileiros de Endocrinologia e Metabologia2006;50(6):1020-5. ">Guimaraes 2006</a>; <a href="./references#CD011688-bbs2-0010" title="KopelmanP , ElliottM , SimondsA , CramerD , WardS , WedzichaJ . Short-term use of fluoxetine in asymptomatic obese subjects with sleep-related hypoventilation. International Journal of Obesity and Related Metabolic Disorders1992;16(10):825-30. ">Kopelman 1992</a>; <a href="./references#CD011688-bbs2-0011" title="LawtonC , WalesJ , HillA , BlundellJ . Serotoninergic manipulation, meal-induced satiety and eating pattern: effect of fluoxetine in obese female subjects. Obesity Research1995;3(4):345-56. ">Lawton 1995</a>; <a href="./references#CD011688-bbs2-0012" title="LevineL , RosenblattS , BosomworthJ . Use of a serotonin re-uptake inhibitor, fluoxetine, in the treatment of obesity. International Journal of Obesity1987;11(Suppl 3):185-90. ">Levine 1987</a>; <a href="./references#CD011688-bbs2-0014" title="PedrinolaF , RissoW , LimaN , MedeirosG . Fluoxetine induced weight loss in overweight subjects: a double-blind placebo-controlled trial. Arquivos Brasileiros de Endocrinologia e Metabologia1993;37:31-3. ">Pedrinola 1993</a>; <a href="./references#CD011688-bbs2-0015" title="PijlH , KoppeschaarH , WillekensF , Op de KampI , VeldhuisH , MeindersA . Effect of serotonin re-uptake inhibition by fluoxetine on body weight and spontaneous food choice in obesity. International Journal of Obesity1991;15(3):237-42. ">Pijl 1991</a>; <a href="./references#CD011688-bbs2-0016" title="StinsonJ , MurphyC , AndrewsJ , TomkinG . An assessment of the thermogenic effects of fluoxetine in obese subjects. International Journal of Obesity and Related Metabolic Disorders1992;16(5):391-5. ">Stinson 1992</a>; <a href="./references#CD011688-bbs2-0017" title="SuplicyH , BoguszewskiC , Dos SantosC , Do DesterroM , CunhaD , RadomiskiR . A comparative study of five centrally acting drugs on the pharmacological treatment of obesity. International Journal of Obesity2014;38(8):1097-103. ">Suplicy 2014</a>; <a href="./references#CD011688-bbs2-0018" title="VisserM , SeidellJ , KoppeschaarH , SmitsP . No specific effect of fluoxetine treatment on fasting glucose, insulin, lipid levels, and blood pressure in healthy men with abdominal obesity. Obesity Research1994;2(2):152-9. VisserM , SeidellJ , KoppeschaarH , SmitsP . The effect of fluoxetine on body weight, body composition and visceral fat accumulation. International Journal of Obesity and Related Metabolic Disorders1993;17(5):247-53. ">Visser 1993</a>). One trial used more than 30% of ideal body weight according to Huang's formula (<a href="./references#CD011688-bbs2-0009" title="HuangC , ChianC , LinJ . Short-term treatment of obesity with fluoxetine as a supplement to a low calorie diet. Changgeng Yi Xue za Zhi [Chang Gung Medical Journal]1998;21(1):50-6. ">Huang 1998</a>), another trial used more than 20% to 100% of ideal body weight (<a href="./references#CD011688-bbs2-0013" title="LevineL , EnasG , ThompsonW , ByynyR , DauerA , KirbyR , et al. Use of fluoxetine, a selective serotonin-uptake inhibitor, in the treatment of obesity: a dose-response study. International Journal of Obesity1989;13(5):635-45. ">Levine 1989</a>), and another trial used 40 lb to 60 lb above ideal body weight according to the Metropolitan Life Insurance Height and Weight Table (<a href="./references#CD011688-bbs2-0019" title="WurtmanJ , WurtmanR , BerryE , GleasonR , GoldbergH , McDermottJ , et al. Dexfenfluramine, fluoxetine, and weight loss among female carbohydrate cravers. Neuropsychopharmacology1993;9(3):201-10. ">Wurtman 1993</a>). </p> </section> <section id="CD011688-sec-0066"> <h5 class="title">Interventions</h5> <p>Some of the included trials were performed with several arms. Of 19 trials, two had six arms (<a href="./references#CD011688-bbs2-0017" title="SuplicyH , BoguszewskiC , Dos SantosC , Do DesterroM , CunhaD , RadomiskiR . A comparative study of five centrally acting drugs on the pharmacological treatment of obesity. International Journal of Obesity2014;38(8):1097-103. ">Suplicy 2014</a>; <a href="./references#CD011688-bbs2-0002" title="BagiellaE , CairellaM , DelB , GodiR . Changes in attitude toward food by obese patients treated with placebo and serotoninergic agents. Current Therapeutic Research, Clinical and Experimental1991;50(2):205-10. ">Bagiella 1991</a>), one had five arms (<a href="./references#CD011688-bbs2-0013" title="LevineL , EnasG , ThompsonW , ByynyR , DauerA , KirbyR , et al. Use of fluoxetine, a selective serotonin-uptake inhibitor, in the treatment of obesity: a dose-response study. International Journal of Obesity1989;13(5):635-45. ">Levine 1989</a>), two had four arms (<a href="./references#CD011688-bbs2-0001" title="Al-HelliA , Al-AbbassiM , JasimG , Al-BayatyM . Effects of fluoxetine, omega 3, or their combination on serum leptin in Iraqi obese subjects. International Journal of Pharmaceutical Sciences Review and Research2015;35(1):90-5. ">Al‐Helli 2015</a>; <a href="./references#CD011688-bbs2-0008" title="GuimarãesC , PereiraL , Lucif JúniorN , CesarinoE , AlmeidaC , CarvalhoD , et al. Tolerability and effectiveness of fluoxetine, metformin and sibutramine in reducing anthropometric and metabolic parameters in obese patients. Arquivos Brasileiros de Endocrinologia e Metabologia2006;50(6):1020-5. ">Guimaraes 2006</a>), three had three arms (<a href="./references#CD011688-bbs2-0003" title="BondiM , MenozziR , BertoliniM , VenneriM , RioG . Metabolic effects of fluoxetine in obese menopausal women. Journal of Endocrinological Investigation2000;23(5):280-6. ">Bondi 2000</a>; <a href="./references#CD011688-bbs2-0006" title="GoldsteinD , RampeyA , DornseifB , LevineL , PotvinJ , FludzinskiL . Fluoxetine: a randomized clinical trial in the maintenance of weight loss. Obesity Research1993;1(2):92-8. ">Goldstein 1993</a>; <a href="./references#CD011688-bbs2-0019" title="WurtmanJ , WurtmanR , BerryE , GleasonR , GoldbergH , McDermottJ , et al. Dexfenfluramine, fluoxetine, and weight loss among female carbohydrate cravers. Neuropsychopharmacology1993;9(3):201-10. ">Wurtman 1993</a>), and 11 had two arms (<a href="./references#CD011688-bbs2-0004" title="BrossR , HofferL . Fluoxetine increases resting energy expenditure and basal body temperature in humans. American Journal of Clinical Nutrition1995;61(5):1020-5. ">Bross 1995</a>; <a href="./references#CD011688-bbs2-0005" title="Fernández-SotoM , González-JiménezA , Barredo-AcedoF , Luna del CastilloJ , Escobar-JiménezF . Comparison of fluoxetine and placebo in the treatment of obesity. Annals of Nutrition &amp; Metabolism1995;39(3):159-63. ">Fernández‐Soto 1995</a>; <a href="./references#CD011688-bbs2-0007" title="DargaL , Carroll-MichalsL , BotsfordS , LucasC . Fluoxetine's effect on weight loss in obese subjects. American Journal of Clinical Nutrition1991;54(2):321-5. GoldsteinD , RampeyA , EnasG , PotvinJ , FludzinskiL , LevineL . Fluoxetine: a randomized clinical trial in the treatment of obesity. International Journal of Obesity and Related Metabolic Disorders1994;18(3):129-35. ">Goldstein 1994</a>; <a href="./references#CD011688-bbs2-0009" title="HuangC , ChianC , LinJ . Short-term treatment of obesity with fluoxetine as a supplement to a low calorie diet. Changgeng Yi Xue za Zhi [Chang Gung Medical Journal]1998;21(1):50-6. ">Huang 1998</a>; <a href="./references#CD011688-bbs2-0010" title="KopelmanP , ElliottM , SimondsA , CramerD , WardS , WedzichaJ . Short-term use of fluoxetine in asymptomatic obese subjects with sleep-related hypoventilation. International Journal of Obesity and Related Metabolic Disorders1992;16(10):825-30. ">Kopelman 1992</a>; <a href="./references#CD011688-bbs2-0011" title="LawtonC , WalesJ , HillA , BlundellJ . Serotoninergic manipulation, meal-induced satiety and eating pattern: effect of fluoxetine in obese female subjects. Obesity Research1995;3(4):345-56. ">Lawton 1995</a>; <a href="./references#CD011688-bbs2-0012" title="LevineL , RosenblattS , BosomworthJ . Use of a serotonin re-uptake inhibitor, fluoxetine, in the treatment of obesity. International Journal of Obesity1987;11(Suppl 3):185-90. ">Levine 1987</a>; <a href="./references#CD011688-bbs2-0014" title="PedrinolaF , RissoW , LimaN , MedeirosG . Fluoxetine induced weight loss in overweight subjects: a double-blind placebo-controlled trial. Arquivos Brasileiros de Endocrinologia e Metabologia1993;37:31-3. ">Pedrinola 1993</a>; <a href="./references#CD011688-bbs2-0015" title="PijlH , KoppeschaarH , WillekensF , Op de KampI , VeldhuisH , MeindersA . Effect of serotonin re-uptake inhibition by fluoxetine on body weight and spontaneous food choice in obesity. International Journal of Obesity1991;15(3):237-42. ">Pijl 1991</a>; <a href="./references#CD011688-bbs2-0016" title="StinsonJ , MurphyC , AndrewsJ , TomkinG . An assessment of the thermogenic effects of fluoxetine in obese subjects. International Journal of Obesity and Related Metabolic Disorders1992;16(5):391-5. ">Stinson 1992</a>; <a href="./references#CD011688-bbs2-0018" title="VisserM , SeidellJ , KoppeschaarH , SmitsP . No specific effect of fluoxetine treatment on fasting glucose, insulin, lipid levels, and blood pressure in healthy men with abdominal obesity. Obesity Research1994;2(2):152-9. VisserM , SeidellJ , KoppeschaarH , SmitsP . The effect of fluoxetine on body weight, body composition and visceral fat accumulation. International Journal of Obesity and Related Metabolic Disorders1993;17(5):247-53. ">Visser 1993</a>). </p> <p>Two trials reported that participants received treatment before starting the trial. In <a href="./references#CD011688-bbs2-0006" title="GoldsteinD , RampeyA , DornseifB , LevineL , PotvinJ , FludzinskiL . Fluoxetine: a randomized clinical trial in the maintenance of weight loss. Obesity Research1993;1(2):92-8. ">Goldstein 1993</a>, the participants received fluoxetine 60 mg/d for eight weeks during qualification phase; in <a href="./references#CD011688-bbs2-0008" title="GuimarãesC , PereiraL , Lucif JúniorN , CesarinoE , AlmeidaC , CarvalhoD , et al. Tolerability and effectiveness of fluoxetine, metformin and sibutramine in reducing anthropometric and metabolic parameters in obese patients. Arquivos Brasileiros de Endocrinologia e Metabologia2006;50(6):1020-5. ">Guimaraes 2006</a>, the participants received dietary re‐education for six months. </p> <p>In all trials, the intervention was administered by the oral route. The doses differed between trials. In 14 trials, at least one group received 60 mg of fluoxetine once daily (<a href="./references#CD011688-bbs2-0003" title="BondiM , MenozziR , BertoliniM , VenneriM , RioG . Metabolic effects of fluoxetine in obese menopausal women. Journal of Endocrinological Investigation2000;23(5):280-6. ">Bondi 2000</a>; <a href="./references#CD011688-bbs2-0004" title="BrossR , HofferL . Fluoxetine increases resting energy expenditure and basal body temperature in humans. American Journal of Clinical Nutrition1995;61(5):1020-5. ">Bross 1995</a>; <a href="./references#CD011688-bbs2-0005" title="Fernández-SotoM , González-JiménezA , Barredo-AcedoF , Luna del CastilloJ , Escobar-JiménezF . Comparison of fluoxetine and placebo in the treatment of obesity. Annals of Nutrition &amp; Metabolism1995;39(3):159-63. ">Fernández‐Soto 1995</a>; <a href="./references#CD011688-bbs2-0006" title="GoldsteinD , RampeyA , DornseifB , LevineL , PotvinJ , FludzinskiL . Fluoxetine: a randomized clinical trial in the maintenance of weight loss. Obesity Research1993;1(2):92-8. ">Goldstein 1993</a>; <a href="./references#CD011688-bbs2-0007" title="DargaL , Carroll-MichalsL , BotsfordS , LucasC . Fluoxetine's effect on weight loss in obese subjects. American Journal of Clinical Nutrition1991;54(2):321-5. GoldsteinD , RampeyA , EnasG , PotvinJ , FludzinskiL , LevineL . Fluoxetine: a randomized clinical trial in the treatment of obesity. International Journal of Obesity and Related Metabolic Disorders1994;18(3):129-35. ">Goldstein 1994</a>; <a href="./references#CD011688-bbs2-0008" title="GuimarãesC , PereiraL , Lucif JúniorN , CesarinoE , AlmeidaC , CarvalhoD , et al. Tolerability and effectiveness of fluoxetine, metformin and sibutramine in reducing anthropometric and metabolic parameters in obese patients. Arquivos Brasileiros de Endocrinologia e Metabologia2006;50(6):1020-5. ">Guimaraes 2006</a>; <a href="./references#CD011688-bbs2-0009" title="HuangC , ChianC , LinJ . Short-term treatment of obesity with fluoxetine as a supplement to a low calorie diet. Changgeng Yi Xue za Zhi [Chang Gung Medical Journal]1998;21(1):50-6. ">Huang 1998</a>; <a href="./references#CD011688-bbs2-0010" title="KopelmanP , ElliottM , SimondsA , CramerD , WardS , WedzichaJ . Short-term use of fluoxetine in asymptomatic obese subjects with sleep-related hypoventilation. International Journal of Obesity and Related Metabolic Disorders1992;16(10):825-30. ">Kopelman 1992</a>; <a href="./references#CD011688-bbs2-0011" title="LawtonC , WalesJ , HillA , BlundellJ . Serotoninergic manipulation, meal-induced satiety and eating pattern: effect of fluoxetine in obese female subjects. Obesity Research1995;3(4):345-56. ">Lawton 1995</a>; <a href="./references#CD011688-bbs2-0012" title="LevineL , RosenblattS , BosomworthJ . Use of a serotonin re-uptake inhibitor, fluoxetine, in the treatment of obesity. International Journal of Obesity1987;11(Suppl 3):185-90. ">Levine 1987</a>; <a href="./references#CD011688-bbs2-0013" title="LevineL , EnasG , ThompsonW , ByynyR , DauerA , KirbyR , et al. Use of fluoxetine, a selective serotonin-uptake inhibitor, in the treatment of obesity: a dose-response study. International Journal of Obesity1989;13(5):635-45. ">Levine 1989</a>; <a href="./references#CD011688-bbs2-0015" title="PijlH , KoppeschaarH , WillekensF , Op de KampI , VeldhuisH , MeindersA . Effect of serotonin re-uptake inhibition by fluoxetine on body weight and spontaneous food choice in obesity. International Journal of Obesity1991;15(3):237-42. ">Pijl 1991</a>; <a href="./references#CD011688-bbs2-0016" title="StinsonJ , MurphyC , AndrewsJ , TomkinG . An assessment of the thermogenic effects of fluoxetine in obese subjects. International Journal of Obesity and Related Metabolic Disorders1992;16(5):391-5. ">Stinson 1992</a>; <a href="./references#CD011688-bbs2-0018" title="VisserM , SeidellJ , KoppeschaarH , SmitsP . No specific effect of fluoxetine treatment on fasting glucose, insulin, lipid levels, and blood pressure in healthy men with abdominal obesity. Obesity Research1994;2(2):152-9. VisserM , SeidellJ , KoppeschaarH , SmitsP . The effect of fluoxetine on body weight, body composition and visceral fat accumulation. International Journal of Obesity and Related Metabolic Disorders1993;17(5):247-53. ">Visser 1993</a>); in two trials, at least one group received 40 mg of fluoxetine once daily (<a href="./references#CD011688-bbs2-0014" title="PedrinolaF , RissoW , LimaN , MedeirosG . Fluoxetine induced weight loss in overweight subjects: a double-blind placebo-controlled trial. Arquivos Brasileiros de Endocrinologia e Metabologia1993;37:31-3. ">Pedrinola 1993</a>; <a href="./references#CD011688-bbs2-0013" title="LevineL , EnasG , ThompsonW , ByynyR , DauerA , KirbyR , et al. Use of fluoxetine, a selective serotonin-uptake inhibitor, in the treatment of obesity: a dose-response study. International Journal of Obesity1989;13(5):635-45. ">Levine 1989</a>); in five trials, at least one group received 20 mg of fluoxetine once daily (<a href="./references#CD011688-bbs2-0002" title="BagiellaE , CairellaM , DelB , GodiR . Changes in attitude toward food by obese patients treated with placebo and serotoninergic agents. Current Therapeutic Research, Clinical and Experimental1991;50(2):205-10. ">Bagiella 1991</a>; <a href="./references#CD011688-bbs2-0006" title="GoldsteinD , RampeyA , DornseifB , LevineL , PotvinJ , FludzinskiL . Fluoxetine: a randomized clinical trial in the maintenance of weight loss. Obesity Research1993;1(2):92-8. ">Goldstein 1993</a>; <a href="./references#CD011688-bbs2-0013" title="LevineL , EnasG , ThompsonW , ByynyR , DauerA , KirbyR , et al. Use of fluoxetine, a selective serotonin-uptake inhibitor, in the treatment of obesity: a dose-response study. International Journal of Obesity1989;13(5):635-45. ">Levine 1989</a>; <a href="./references#CD011688-bbs2-0017" title="SuplicyH , BoguszewskiC , Dos SantosC , Do DesterroM , CunhaD , RadomiskiR . A comparative study of five centrally acting drugs on the pharmacological treatment of obesity. International Journal of Obesity2014;38(8):1097-103. ">Suplicy 2014</a>; <a href="./references#CD011688-bbs2-0019" title="WurtmanJ , WurtmanR , BerryE , GleasonR , GoldbergH , McDermottJ , et al. Dexfenfluramine, fluoxetine, and weight loss among female carbohydrate cravers. Neuropsychopharmacology1993;9(3):201-10. ">Wurtman 1993</a>); and in one trial, one group received 10 mg of fluoxetine once daily (<a href="./references#CD011688-bbs2-0012" title="LevineL , RosenblattS , BosomworthJ . Use of a serotonin re-uptake inhibitor, fluoxetine, in the treatment of obesity. International Journal of Obesity1987;11(Suppl 3):185-90. ">Levine 1987</a>). The average daily dose of fluoxetine was 55 mg. </p> <p>A wide variety of interventions was performed. Eleven trials compared fluoxetine with placebo (<a href="./references#CD011688-bbs2-0003" title="BondiM , MenozziR , BertoliniM , VenneriM , RioG . Metabolic effects of fluoxetine in obese menopausal women. Journal of Endocrinological Investigation2000;23(5):280-6. ">Bondi 2000</a>; <a href="./references#CD011688-bbs2-0004" title="BrossR , HofferL . Fluoxetine increases resting energy expenditure and basal body temperature in humans. American Journal of Clinical Nutrition1995;61(5):1020-5. ">Bross 1995</a>; <a href="./references#CD011688-bbs2-0005" title="Fernández-SotoM , González-JiménezA , Barredo-AcedoF , Luna del CastilloJ , Escobar-JiménezF . Comparison of fluoxetine and placebo in the treatment of obesity. Annals of Nutrition &amp; Metabolism1995;39(3):159-63. ">Fernández‐Soto 1995</a>; <a href="./references#CD011688-bbs2-0007" title="DargaL , Carroll-MichalsL , BotsfordS , LucasC . Fluoxetine's effect on weight loss in obese subjects. American Journal of Clinical Nutrition1991;54(2):321-5. GoldsteinD , RampeyA , EnasG , PotvinJ , FludzinskiL , LevineL . Fluoxetine: a randomized clinical trial in the treatment of obesity. International Journal of Obesity and Related Metabolic Disorders1994;18(3):129-35. ">Goldstein 1994</a>; <a href="./references#CD011688-bbs2-0010" title="KopelmanP , ElliottM , SimondsA , CramerD , WardS , WedzichaJ . Short-term use of fluoxetine in asymptomatic obese subjects with sleep-related hypoventilation. International Journal of Obesity and Related Metabolic Disorders1992;16(10):825-30. ">Kopelman 1992</a>; <a href="./references#CD011688-bbs2-0011" title="LawtonC , WalesJ , HillA , BlundellJ . Serotoninergic manipulation, meal-induced satiety and eating pattern: effect of fluoxetine in obese female subjects. Obesity Research1995;3(4):345-56. ">Lawton 1995</a>; <a href="./references#CD011688-bbs2-0012" title="LevineL , RosenblattS , BosomworthJ . Use of a serotonin re-uptake inhibitor, fluoxetine, in the treatment of obesity. International Journal of Obesity1987;11(Suppl 3):185-90. ">Levine 1987</a>; <a href="./references#CD011688-bbs2-0014" title="PedrinolaF , RissoW , LimaN , MedeirosG . Fluoxetine induced weight loss in overweight subjects: a double-blind placebo-controlled trial. Arquivos Brasileiros de Endocrinologia e Metabologia1993;37:31-3. ">Pedrinola 1993</a>; <a href="./references#CD011688-bbs2-0015" title="PijlH , KoppeschaarH , WillekensF , Op de KampI , VeldhuisH , MeindersA . Effect of serotonin re-uptake inhibition by fluoxetine on body weight and spontaneous food choice in obesity. International Journal of Obesity1991;15(3):237-42. ">Pijl 1991</a>; <a href="./references#CD011688-bbs2-0016" title="StinsonJ , MurphyC , AndrewsJ , TomkinG . An assessment of the thermogenic effects of fluoxetine in obese subjects. International Journal of Obesity and Related Metabolic Disorders1992;16(5):391-5. ">Stinson 1992</a>; <a href="./references#CD011688-bbs2-0018" title="VisserM , SeidellJ , KoppeschaarH , SmitsP . No specific effect of fluoxetine treatment on fasting glucose, insulin, lipid levels, and blood pressure in healthy men with abdominal obesity. Obesity Research1994;2(2):152-9. VisserM , SeidellJ , KoppeschaarH , SmitsP . The effect of fluoxetine on body weight, body composition and visceral fat accumulation. International Journal of Obesity and Related Metabolic Disorders1993;17(5):247-53. ">Visser 1993</a>). Four trials compared fluoxetine with at least one anti‐obesity agent (diethylpropion, fenproporex, mazindol, sibutramine, metformin, fenfluramine, dexfenfluramine, fluvoxamine or 5‐hydroxy‐tryptophan) (<a href="./references#CD011688-bbs2-0002" title="BagiellaE , CairellaM , DelB , GodiR . Changes in attitude toward food by obese patients treated with placebo and serotoninergic agents. Current Therapeutic Research, Clinical and Experimental1991;50(2):205-10. ">Bagiella 1991</a>; <a href="./references#CD011688-bbs2-0008" title="GuimarãesC , PereiraL , Lucif JúniorN , CesarinoE , AlmeidaC , CarvalhoD , et al. Tolerability and effectiveness of fluoxetine, metformin and sibutramine in reducing anthropometric and metabolic parameters in obese patients. Arquivos Brasileiros de Endocrinologia e Metabologia2006;50(6):1020-5. ">Guimaraes 2006</a>; <a href="./references#CD011688-bbs2-0017" title="SuplicyH , BoguszewskiC , Dos SantosC , Do DesterroM , CunhaD , RadomiskiR . A comparative study of five centrally acting drugs on the pharmacological treatment of obesity. International Journal of Obesity2014;38(8):1097-103. ">Suplicy 2014</a>; <a href="./references#CD011688-bbs2-0019" title="WurtmanJ , WurtmanR , BerryE , GleasonR , GoldbergH , McDermottJ , et al. Dexfenfluramine, fluoxetine, and weight loss among female carbohydrate cravers. Neuropsychopharmacology1993;9(3):201-10. ">Wurtman 1993</a>) (see <a href="./appendices#CD011688-sec-0125">Appendix 5</a>). One trial compared fluoxetine with omega‐3 gel intake (<a href="./references#CD011688-bbs2-0001" title="Al-HelliA , Al-AbbassiM , JasimG , Al-BayatyM . Effects of fluoxetine, omega 3, or their combination on serum leptin in Iraqi obese subjects. International Journal of Pharmaceutical Sciences Review and Research2015;35(1):90-5. ">Al‐Helli 2015</a>). One trial compared fluoxetine with no treatment (<a href="./references#CD011688-bbs2-0009" title="HuangC , ChianC , LinJ . Short-term treatment of obesity with fluoxetine as a supplement to a low calorie diet. Changgeng Yi Xue za Zhi [Chang Gung Medical Journal]1998;21(1):50-6. ">Huang 1998</a>); and two trials compared 60 mg fluoxetine with smaller doses of fluoxetine (10, 20 and 40 mg/d) (<a href="./references#CD011688-bbs2-0006" title="GoldsteinD , RampeyA , DornseifB , LevineL , PotvinJ , FludzinskiL . Fluoxetine: a randomized clinical trial in the maintenance of weight loss. Obesity Research1993;1(2):92-8. ">Goldstein 1993</a>; <a href="./references#CD011688-bbs2-0013" title="LevineL , EnasG , ThompsonW , ByynyR , DauerA , KirbyR , et al. Use of fluoxetine, a selective serotonin-uptake inhibitor, in the treatment of obesity: a dose-response study. International Journal of Obesity1989;13(5):635-45. ">Levine 1989</a>). </p> <p>Of 19 trials included in our review, 15 used adequate interventions and comparators. However, four trials included at least one intervention (sibutramine and dexfenfluramine) with harmful effects on the cardiovascular system according to the Food and Drug Administration (FDA) (<a href="./references#CD011688-bbs2-0002" title="BagiellaE , CairellaM , DelB , GodiR . Changes in attitude toward food by obese patients treated with placebo and serotoninergic agents. Current Therapeutic Research, Clinical and Experimental1991;50(2):205-10. ">Bagiella 1991</a>; <a href="./references#CD011688-bbs2-0008" title="GuimarãesC , PereiraL , Lucif JúniorN , CesarinoE , AlmeidaC , CarvalhoD , et al. Tolerability and effectiveness of fluoxetine, metformin and sibutramine in reducing anthropometric and metabolic parameters in obese patients. Arquivos Brasileiros de Endocrinologia e Metabologia2006;50(6):1020-5. ">Guimaraes 2006</a>; <a href="./references#CD011688-bbs2-0017" title="SuplicyH , BoguszewskiC , Dos SantosC , Do DesterroM , CunhaD , RadomiskiR . A comparative study of five centrally acting drugs on the pharmacological treatment of obesity. International Journal of Obesity2014;38(8):1097-103. ">Suplicy 2014</a>; <a href="./references#CD011688-bbs2-0019" title="WurtmanJ , WurtmanR , BerryE , GleasonR , GoldbergH , McDermottJ , et al. Dexfenfluramine, fluoxetine, and weight loss among female carbohydrate cravers. Neuropsychopharmacology1993;9(3):201-10. ">Wurtman 1993</a>). </p> </section> <section id="CD011688-sec-0067"> <h5 class="title">Outcomes</h5> <p>Twelve of nineteen included trials explicitly stated primary or secondary outcomes (<a href="./references#CD011688-bbs2-0017" title="SuplicyH , BoguszewskiC , Dos SantosC , Do DesterroM , CunhaD , RadomiskiR . A comparative study of five centrally acting drugs on the pharmacological treatment of obesity. International Journal of Obesity2014;38(8):1097-103. ">Suplicy 2014</a>; <a href="./references#CD011688-bbs2-0008" title="GuimarãesC , PereiraL , Lucif JúniorN , CesarinoE , AlmeidaC , CarvalhoD , et al. Tolerability and effectiveness of fluoxetine, metformin and sibutramine in reducing anthropometric and metabolic parameters in obese patients. Arquivos Brasileiros de Endocrinologia e Metabologia2006;50(6):1020-5. ">Guimaraes 2006</a>; <a href="./references#CD011688-bbs2-0003" title="BondiM , MenozziR , BertoliniM , VenneriM , RioG . Metabolic effects of fluoxetine in obese menopausal women. Journal of Endocrinological Investigation2000;23(5):280-6. ">Bondi 2000</a>; <a href="./references#CD011688-bbs2-0011" title="LawtonC , WalesJ , HillA , BlundellJ . Serotoninergic manipulation, meal-induced satiety and eating pattern: effect of fluoxetine in obese female subjects. Obesity Research1995;3(4):345-56. ">Lawton 1995</a>; <a href="./references#CD011688-bbs2-0006" title="GoldsteinD , RampeyA , DornseifB , LevineL , PotvinJ , FludzinskiL . Fluoxetine: a randomized clinical trial in the maintenance of weight loss. Obesity Research1993;1(2):92-8. ">Goldstein 1993</a>; <a href="./references#CD011688-bbs2-0018" title="VisserM , SeidellJ , KoppeschaarH , SmitsP . No specific effect of fluoxetine treatment on fasting glucose, insulin, lipid levels, and blood pressure in healthy men with abdominal obesity. Obesity Research1994;2(2):152-9. VisserM , SeidellJ , KoppeschaarH , SmitsP . The effect of fluoxetine on body weight, body composition and visceral fat accumulation. International Journal of Obesity and Related Metabolic Disorders1993;17(5):247-53. ">Visser 1993</a>; <a href="./references#CD011688-bbs2-0019" title="WurtmanJ , WurtmanR , BerryE , GleasonR , GoldbergH , McDermottJ , et al. Dexfenfluramine, fluoxetine, and weight loss among female carbohydrate cravers. Neuropsychopharmacology1993;9(3):201-10. ">Wurtman 1993</a>; <a href="./references#CD011688-bbs2-0010" title="KopelmanP , ElliottM , SimondsA , CramerD , WardS , WedzichaJ . Short-term use of fluoxetine in asymptomatic obese subjects with sleep-related hypoventilation. International Journal of Obesity and Related Metabolic Disorders1992;16(10):825-30. ">Kopelman 1992</a>; <a href="./references#CD011688-bbs2-0016" title="StinsonJ , MurphyC , AndrewsJ , TomkinG . An assessment of the thermogenic effects of fluoxetine in obese subjects. International Journal of Obesity and Related Metabolic Disorders1992;16(5):391-5. ">Stinson 1992</a>; <a href="./references#CD011688-bbs2-0002" title="BagiellaE , CairellaM , DelB , GodiR . Changes in attitude toward food by obese patients treated with placebo and serotoninergic agents. Current Therapeutic Research, Clinical and Experimental1991;50(2):205-10. ">Bagiella 1991</a>; <a href="./references#CD011688-bbs2-0015" title="PijlH , KoppeschaarH , WillekensF , Op de KampI , VeldhuisH , MeindersA . Effect of serotonin re-uptake inhibition by fluoxetine on body weight and spontaneous food choice in obesity. International Journal of Obesity1991;15(3):237-42. ">Pijl 1991</a>; <a href="./references#CD011688-bbs2-0013" title="LevineL , EnasG , ThompsonW , ByynyR , DauerA , KirbyR , et al. Use of fluoxetine, a selective serotonin-uptake inhibitor, in the treatment of obesity: a dose-response study. International Journal of Obesity1989;13(5):635-45. ">Levine 1989</a>). The most common outcome was a weight loss in kilograms (<a href="./references#CD011688-bbs2-0017" title="SuplicyH , BoguszewskiC , Dos SantosC , Do DesterroM , CunhaD , RadomiskiR . A comparative study of five centrally acting drugs on the pharmacological treatment of obesity. International Journal of Obesity2014;38(8):1097-103. ">Suplicy 2014</a>; <a href="./references#CD011688-bbs2-0008" title="GuimarãesC , PereiraL , Lucif JúniorN , CesarinoE , AlmeidaC , CarvalhoD , et al. Tolerability and effectiveness of fluoxetine, metformin and sibutramine in reducing anthropometric and metabolic parameters in obese patients. Arquivos Brasileiros de Endocrinologia e Metabologia2006;50(6):1020-5. ">Guimaraes 2006</a>; <a href="./references#CD011688-bbs2-0003" title="BondiM , MenozziR , BertoliniM , VenneriM , RioG . Metabolic effects of fluoxetine in obese menopausal women. Journal of Endocrinological Investigation2000;23(5):280-6. ">Bondi 2000</a>; <a href="./references#CD011688-bbs2-0006" title="GoldsteinD , RampeyA , DornseifB , LevineL , PotvinJ , FludzinskiL . Fluoxetine: a randomized clinical trial in the maintenance of weight loss. Obesity Research1993;1(2):92-8. ">Goldstein 1993</a>; <a href="./references#CD011688-bbs2-0019" title="WurtmanJ , WurtmanR , BerryE , GleasonR , GoldbergH , McDermottJ , et al. Dexfenfluramine, fluoxetine, and weight loss among female carbohydrate cravers. Neuropsychopharmacology1993;9(3):201-10. ">Wurtman 1993</a>; <a href="./references#CD011688-bbs2-0013" title="LevineL , EnasG , ThompsonW , ByynyR , DauerA , KirbyR , et al. Use of fluoxetine, a selective serotonin-uptake inhibitor, in the treatment of obesity: a dose-response study. International Journal of Obesity1989;13(5):635-45. ">Levine 1989</a>). </p> <p>Fifteen trials had a median of six outcomes (<a href="./references#CD011688-bbs2-0001" title="Al-HelliA , Al-AbbassiM , JasimG , Al-BayatyM . Effects of fluoxetine, omega 3, or their combination on serum leptin in Iraqi obese subjects. International Journal of Pharmaceutical Sciences Review and Research2015;35(1):90-5. ">Al‐Helli 2015</a>; <a href="./references#CD011688-bbs2-0017" title="SuplicyH , BoguszewskiC , Dos SantosC , Do DesterroM , CunhaD , RadomiskiR . A comparative study of five centrally acting drugs on the pharmacological treatment of obesity. International Journal of Obesity2014;38(8):1097-103. ">Suplicy 2014</a>; <a href="./references#CD011688-bbs2-0008" title="GuimarãesC , PereiraL , Lucif JúniorN , CesarinoE , AlmeidaC , CarvalhoD , et al. Tolerability and effectiveness of fluoxetine, metformin and sibutramine in reducing anthropometric and metabolic parameters in obese patients. Arquivos Brasileiros de Endocrinologia e Metabologia2006;50(6):1020-5. ">Guimaraes 2006</a>; <a href="./references#CD011688-bbs2-0003" title="BondiM , MenozziR , BertoliniM , VenneriM , RioG . Metabolic effects of fluoxetine in obese menopausal women. Journal of Endocrinological Investigation2000;23(5):280-6. ">Bondi 2000</a>; <a href="./references#CD011688-bbs2-0009" title="HuangC , ChianC , LinJ . Short-term treatment of obesity with fluoxetine as a supplement to a low calorie diet. Changgeng Yi Xue za Zhi [Chang Gung Medical Journal]1998;21(1):50-6. ">Huang 1998</a>; <a href="./references#CD011688-bbs2-0004" title="BrossR , HofferL . Fluoxetine increases resting energy expenditure and basal body temperature in humans. American Journal of Clinical Nutrition1995;61(5):1020-5. ">Bross 1995</a>; <a href="./references#CD011688-bbs2-0005" title="Fernández-SotoM , González-JiménezA , Barredo-AcedoF , Luna del CastilloJ , Escobar-JiménezF . Comparison of fluoxetine and placebo in the treatment of obesity. Annals of Nutrition &amp; Metabolism1995;39(3):159-63. ">Fernández‐Soto 1995</a>; <a href="./references#CD011688-bbs2-0011" title="LawtonC , WalesJ , HillA , BlundellJ . Serotoninergic manipulation, meal-induced satiety and eating pattern: effect of fluoxetine in obese female subjects. Obesity Research1995;3(4):345-56. ">Lawton 1995</a>; <a href="./references#CD011688-bbs2-0007" title="DargaL , Carroll-MichalsL , BotsfordS , LucasC . Fluoxetine's effect on weight loss in obese subjects. American Journal of Clinical Nutrition1991;54(2):321-5. GoldsteinD , RampeyA , EnasG , PotvinJ , FludzinskiL , LevineL . Fluoxetine: a randomized clinical trial in the treatment of obesity. International Journal of Obesity and Related Metabolic Disorders1994;18(3):129-35. ">Goldstein 1994</a>; <a href="./references#CD011688-bbs2-0006" title="GoldsteinD , RampeyA , DornseifB , LevineL , PotvinJ , FludzinskiL . Fluoxetine: a randomized clinical trial in the maintenance of weight loss. Obesity Research1993;1(2):92-8. ">Goldstein 1993</a>; <a href="./references#CD011688-bbs2-0019" title="WurtmanJ , WurtmanR , BerryE , GleasonR , GoldbergH , McDermottJ , et al. Dexfenfluramine, fluoxetine, and weight loss among female carbohydrate cravers. Neuropsychopharmacology1993;9(3):201-10. ">Wurtman 1993</a>; <a href="./references#CD011688-bbs2-0010" title="KopelmanP , ElliottM , SimondsA , CramerD , WardS , WedzichaJ . Short-term use of fluoxetine in asymptomatic obese subjects with sleep-related hypoventilation. International Journal of Obesity and Related Metabolic Disorders1992;16(10):825-30. ">Kopelman 1992</a>; <a href="./references#CD011688-bbs2-0016" title="StinsonJ , MurphyC , AndrewsJ , TomkinG . An assessment of the thermogenic effects of fluoxetine in obese subjects. International Journal of Obesity and Related Metabolic Disorders1992;16(5):391-5. ">Stinson 1992</a>; <a href="./references#CD011688-bbs2-0015" title="PijlH , KoppeschaarH , WillekensF , Op de KampI , VeldhuisH , MeindersA . Effect of serotonin re-uptake inhibition by fluoxetine on body weight and spontaneous food choice in obesity. International Journal of Obesity1991;15(3):237-42. ">Pijl 1991</a>; <a href="./references#CD011688-bbs2-0012" title="LevineL , RosenblattS , BosomworthJ . Use of a serotonin re-uptake inhibitor, fluoxetine, in the treatment of obesity. International Journal of Obesity1987;11(Suppl 3):185-90. ">Levine 1987</a>), with a range of six (<a href="./references#CD011688-bbs2-0003" title="BondiM , MenozziR , BertoliniM , VenneriM , RioG . Metabolic effects of fluoxetine in obese menopausal women. Journal of Endocrinological Investigation2000;23(5):280-6. ">Bondi 2000</a>; <a href="./references#CD011688-bbs2-0006" title="GoldsteinD , RampeyA , DornseifB , LevineL , PotvinJ , FludzinskiL . Fluoxetine: a randomized clinical trial in the maintenance of weight loss. Obesity Research1993;1(2):92-8. ">Goldstein 1993</a>; <a href="./references#CD011688-bbs2-0010" title="KopelmanP , ElliottM , SimondsA , CramerD , WardS , WedzichaJ . Short-term use of fluoxetine in asymptomatic obese subjects with sleep-related hypoventilation. International Journal of Obesity and Related Metabolic Disorders1992;16(10):825-30. ">Kopelman 1992</a>; <a href="./references#CD011688-bbs2-0016" title="StinsonJ , MurphyC , AndrewsJ , TomkinG . An assessment of the thermogenic effects of fluoxetine in obese subjects. International Journal of Obesity and Related Metabolic Disorders1992;16(5):391-5. ">Stinson 1992</a>; <a href="./references#CD011688-bbs2-0015" title="PijlH , KoppeschaarH , WillekensF , Op de KampI , VeldhuisH , MeindersA . Effect of serotonin re-uptake inhibition by fluoxetine on body weight and spontaneous food choice in obesity. International Journal of Obesity1991;15(3):237-42. ">Pijl 1991</a>; <a href="./references#CD011688-bbs2-0012" title="LevineL , RosenblattS , BosomworthJ . Use of a serotonin re-uptake inhibitor, fluoxetine, in the treatment of obesity. International Journal of Obesity1987;11(Suppl 3):185-90. ">Levine 1987</a>) to 26 outcomes (<a href="./references#CD011688-bbs2-0019" title="WurtmanJ , WurtmanR , BerryE , GleasonR , GoldbergH , McDermottJ , et al. Dexfenfluramine, fluoxetine, and weight loss among female carbohydrate cravers. Neuropsychopharmacology1993;9(3):201-10. ">Wurtman 1993</a>). See <a href="./appendices#CD011688-sec-0128">Appendix 8</a> for details. </p> <p>Fourteen trials reported adverse events (<a href="./references#CD011688-bbs2-0005" title="Fernández-SotoM , González-JiménezA , Barredo-AcedoF , Luna del CastilloJ , Escobar-JiménezF . Comparison of fluoxetine and placebo in the treatment of obesity. Annals of Nutrition &amp; Metabolism1995;39(3):159-63. ">Fernández‐Soto 1995</a>; <a href="./references#CD011688-bbs2-0006" title="GoldsteinD , RampeyA , DornseifB , LevineL , PotvinJ , FludzinskiL . Fluoxetine: a randomized clinical trial in the maintenance of weight loss. Obesity Research1993;1(2):92-8. ">Goldstein 1993</a>; <a href="./references#CD011688-bbs2-0007" title="DargaL , Carroll-MichalsL , BotsfordS , LucasC . Fluoxetine's effect on weight loss in obese subjects. American Journal of Clinical Nutrition1991;54(2):321-5. GoldsteinD , RampeyA , EnasG , PotvinJ , FludzinskiL , LevineL . Fluoxetine: a randomized clinical trial in the treatment of obesity. International Journal of Obesity and Related Metabolic Disorders1994;18(3):129-35. ">Goldstein 1994</a>; <a href="./references#CD011688-bbs2-0008" title="GuimarãesC , PereiraL , Lucif JúniorN , CesarinoE , AlmeidaC , CarvalhoD , et al. Tolerability and effectiveness of fluoxetine, metformin and sibutramine in reducing anthropometric and metabolic parameters in obese patients. Arquivos Brasileiros de Endocrinologia e Metabologia2006;50(6):1020-5. ">Guimaraes 2006</a>; <a href="./references#CD011688-bbs2-0009" title="HuangC , ChianC , LinJ . Short-term treatment of obesity with fluoxetine as a supplement to a low calorie diet. Changgeng Yi Xue za Zhi [Chang Gung Medical Journal]1998;21(1):50-6. ">Huang 1998</a>; <a href="./references#CD011688-bbs2-0010" title="KopelmanP , ElliottM , SimondsA , CramerD , WardS , WedzichaJ . Short-term use of fluoxetine in asymptomatic obese subjects with sleep-related hypoventilation. International Journal of Obesity and Related Metabolic Disorders1992;16(10):825-30. ">Kopelman 1992</a>; <a href="./references#CD011688-bbs2-0011" title="LawtonC , WalesJ , HillA , BlundellJ . Serotoninergic manipulation, meal-induced satiety and eating pattern: effect of fluoxetine in obese female subjects. Obesity Research1995;3(4):345-56. ">Lawton 1995</a>; <a href="./references#CD011688-bbs2-0012" title="LevineL , RosenblattS , BosomworthJ . Use of a serotonin re-uptake inhibitor, fluoxetine, in the treatment of obesity. International Journal of Obesity1987;11(Suppl 3):185-90. ">Levine 1987</a>; <a href="./references#CD011688-bbs2-0013" title="LevineL , EnasG , ThompsonW , ByynyR , DauerA , KirbyR , et al. Use of fluoxetine, a selective serotonin-uptake inhibitor, in the treatment of obesity: a dose-response study. International Journal of Obesity1989;13(5):635-45. ">Levine 1989</a>; <a href="./references#CD011688-bbs2-0014" title="PedrinolaF , RissoW , LimaN , MedeirosG . Fluoxetine induced weight loss in overweight subjects: a double-blind placebo-controlled trial. Arquivos Brasileiros de Endocrinologia e Metabologia1993;37:31-3. ">Pedrinola 1993</a>; <a href="./references#CD011688-bbs2-0015" title="PijlH , KoppeschaarH , WillekensF , Op de KampI , VeldhuisH , MeindersA . Effect of serotonin re-uptake inhibition by fluoxetine on body weight and spontaneous food choice in obesity. International Journal of Obesity1991;15(3):237-42. ">Pijl 1991</a>; <a href="./references#CD011688-bbs2-0017" title="SuplicyH , BoguszewskiC , Dos SantosC , Do DesterroM , CunhaD , RadomiskiR . A comparative study of five centrally acting drugs on the pharmacological treatment of obesity. International Journal of Obesity2014;38(8):1097-103. ">Suplicy 2014</a>; <a href="./references#CD011688-bbs2-0018" title="VisserM , SeidellJ , KoppeschaarH , SmitsP . No specific effect of fluoxetine treatment on fasting glucose, insulin, lipid levels, and blood pressure in healthy men with abdominal obesity. Obesity Research1994;2(2):152-9. VisserM , SeidellJ , KoppeschaarH , SmitsP . The effect of fluoxetine on body weight, body composition and visceral fat accumulation. International Journal of Obesity and Related Metabolic Disorders1993;17(5):247-53. ">Visser 1993</a>; <a href="./references#CD011688-bbs2-0019" title="WurtmanJ , WurtmanR , BerryE , GleasonR , GoldbergH , McDermottJ , et al. Dexfenfluramine, fluoxetine, and weight loss among female carbohydrate cravers. Neuropsychopharmacology1993;9(3):201-10. ">Wurtman 1993</a>). One trial investigated health‐related quality of life but did not report results (<a href="./references#CD011688-bbs2-0017" title="SuplicyH , BoguszewskiC , Dos SantosC , Do DesterroM , CunhaD , RadomiskiR . A comparative study of five centrally acting drugs on the pharmacological treatment of obesity. International Journal of Obesity2014;38(8):1097-103. ">Suplicy 2014</a>); nine trials evaluated anthropometric measurements other than weight loss in kilograms (<a href="./references#CD011688-bbs2-0001" title="Al-HelliA , Al-AbbassiM , JasimG , Al-BayatyM . Effects of fluoxetine, omega 3, or their combination on serum leptin in Iraqi obese subjects. International Journal of Pharmaceutical Sciences Review and Research2015;35(1):90-5. ">Al‐Helli 2015</a>; <a href="./references#CD011688-bbs2-0007" title="DargaL , Carroll-MichalsL , BotsfordS , LucasC . Fluoxetine's effect on weight loss in obese subjects. American Journal of Clinical Nutrition1991;54(2):321-5. GoldsteinD , RampeyA , EnasG , PotvinJ , FludzinskiL , LevineL . Fluoxetine: a randomized clinical trial in the treatment of obesity. International Journal of Obesity and Related Metabolic Disorders1994;18(3):129-35. ">Goldstein 1994</a>; <a href="./references#CD011688-bbs2-0008" title="GuimarãesC , PereiraL , Lucif JúniorN , CesarinoE , AlmeidaC , CarvalhoD , et al. Tolerability and effectiveness of fluoxetine, metformin and sibutramine in reducing anthropometric and metabolic parameters in obese patients. Arquivos Brasileiros de Endocrinologia e Metabologia2006;50(6):1020-5. ">Guimaraes 2006</a>; <a href="./references#CD011688-bbs2-0009" title="HuangC , ChianC , LinJ . Short-term treatment of obesity with fluoxetine as a supplement to a low calorie diet. Changgeng Yi Xue za Zhi [Chang Gung Medical Journal]1998;21(1):50-6. ">Huang 1998</a>; <a href="./references#CD011688-bbs2-0010" title="KopelmanP , ElliottM , SimondsA , CramerD , WardS , WedzichaJ . Short-term use of fluoxetine in asymptomatic obese subjects with sleep-related hypoventilation. International Journal of Obesity and Related Metabolic Disorders1992;16(10):825-30. ">Kopelman 1992</a>; <a href="./references#CD011688-bbs2-0012" title="LevineL , RosenblattS , BosomworthJ . Use of a serotonin re-uptake inhibitor, fluoxetine, in the treatment of obesity. International Journal of Obesity1987;11(Suppl 3):185-90. ">Levine 1987</a>; <a href="./references#CD011688-bbs2-0013" title="LevineL , EnasG , ThompsonW , ByynyR , DauerA , KirbyR , et al. Use of fluoxetine, a selective serotonin-uptake inhibitor, in the treatment of obesity: a dose-response study. International Journal of Obesity1989;13(5):635-45. ">Levine 1989</a>; <a href="./references#CD011688-bbs2-0014" title="PedrinolaF , RissoW , LimaN , MedeirosG . Fluoxetine induced weight loss in overweight subjects: a double-blind placebo-controlled trial. Arquivos Brasileiros de Endocrinologia e Metabologia1993;37:31-3. ">Pedrinola 1993</a>; <a href="./references#CD011688-bbs2-0017" title="SuplicyH , BoguszewskiC , Dos SantosC , Do DesterroM , CunhaD , RadomiskiR . A comparative study of five centrally acting drugs on the pharmacological treatment of obesity. International Journal of Obesity2014;38(8):1097-103. ">Suplicy 2014</a>) (see <a href="./appendices#CD011688-sec-0128">Appendix 8</a> for detail). Three trials investigated morbidity (depression as psychiatric disorder) (<a href="./references#CD011688-bbs2-0017" title="SuplicyH , BoguszewskiC , Dos SantosC , Do DesterroM , CunhaD , RadomiskiR . A comparative study of five centrally acting drugs on the pharmacological treatment of obesity. International Journal of Obesity2014;38(8):1097-103. ">Suplicy 2014</a>; <a href="./references#CD011688-bbs2-0006" title="GoldsteinD , RampeyA , DornseifB , LevineL , PotvinJ , FludzinskiL . Fluoxetine: a randomized clinical trial in the maintenance of weight loss. Obesity Research1993;1(2):92-8. ">Goldstein 1993</a>; <a href="./references#CD011688-bbs2-0012" title="LevineL , RosenblattS , BosomworthJ . Use of a serotonin re-uptake inhibitor, fluoxetine, in the treatment of obesity. International Journal of Obesity1987;11(Suppl 3):185-90. ">Levine 1987</a>); 13 trials investigated laboratory parameters (<a href="./references#CD011688-bbs2-0002" title="BagiellaE , CairellaM , DelB , GodiR . Changes in attitude toward food by obese patients treated with placebo and serotoninergic agents. Current Therapeutic Research, Clinical and Experimental1991;50(2):205-10. ">Bagiella 1991</a>; <a href="./references#CD011688-bbs2-0003" title="BondiM , MenozziR , BertoliniM , VenneriM , RioG . Metabolic effects of fluoxetine in obese menopausal women. Journal of Endocrinological Investigation2000;23(5):280-6. ">Bondi 2000</a>; <a href="./references#CD011688-bbs2-0005" title="Fernández-SotoM , González-JiménezA , Barredo-AcedoF , Luna del CastilloJ , Escobar-JiménezF . Comparison of fluoxetine and placebo in the treatment of obesity. Annals of Nutrition &amp; Metabolism1995;39(3):159-63. ">Fernández‐Soto 1995</a>; <a href="./references#CD011688-bbs2-0006" title="GoldsteinD , RampeyA , DornseifB , LevineL , PotvinJ , FludzinskiL . Fluoxetine: a randomized clinical trial in the maintenance of weight loss. Obesity Research1993;1(2):92-8. ">Goldstein 1993</a>; <a href="./references#CD011688-bbs2-0007" title="DargaL , Carroll-MichalsL , BotsfordS , LucasC . Fluoxetine's effect on weight loss in obese subjects. American Journal of Clinical Nutrition1991;54(2):321-5. GoldsteinD , RampeyA , EnasG , PotvinJ , FludzinskiL , LevineL . Fluoxetine: a randomized clinical trial in the treatment of obesity. International Journal of Obesity and Related Metabolic Disorders1994;18(3):129-35. ">Goldstein 1994</a>; <a href="./references#CD011688-bbs2-0008" title="GuimarãesC , PereiraL , Lucif JúniorN , CesarinoE , AlmeidaC , CarvalhoD , et al. Tolerability and effectiveness of fluoxetine, metformin and sibutramine in reducing anthropometric and metabolic parameters in obese patients. Arquivos Brasileiros de Endocrinologia e Metabologia2006;50(6):1020-5. ">Guimaraes 2006</a>; <a href="./references#CD011688-bbs2-0009" title="HuangC , ChianC , LinJ . Short-term treatment of obesity with fluoxetine as a supplement to a low calorie diet. Changgeng Yi Xue za Zhi [Chang Gung Medical Journal]1998;21(1):50-6. ">Huang 1998</a>; <a href="./references#CD011688-bbs2-0012" title="LevineL , RosenblattS , BosomworthJ . Use of a serotonin re-uptake inhibitor, fluoxetine, in the treatment of obesity. International Journal of Obesity1987;11(Suppl 3):185-90. ">Levine 1987</a>; <a href="./references#CD011688-bbs2-0013" title="LevineL , EnasG , ThompsonW , ByynyR , DauerA , KirbyR , et al. Use of fluoxetine, a selective serotonin-uptake inhibitor, in the treatment of obesity: a dose-response study. International Journal of Obesity1989;13(5):635-45. ">Levine 1989</a>; <a href="./references#CD011688-bbs2-0014" title="PedrinolaF , RissoW , LimaN , MedeirosG . Fluoxetine induced weight loss in overweight subjects: a double-blind placebo-controlled trial. Arquivos Brasileiros de Endocrinologia e Metabologia1993;37:31-3. ">Pedrinola 1993</a>; <a href="./references#CD011688-bbs2-0016" title="StinsonJ , MurphyC , AndrewsJ , TomkinG . An assessment of the thermogenic effects of fluoxetine in obese subjects. International Journal of Obesity and Related Metabolic Disorders1992;16(5):391-5. ">Stinson 1992</a>; <a href="./references#CD011688-bbs2-0017" title="SuplicyH , BoguszewskiC , Dos SantosC , Do DesterroM , CunhaD , RadomiskiR . A comparative study of five centrally acting drugs on the pharmacological treatment of obesity. International Journal of Obesity2014;38(8):1097-103. ">Suplicy 2014</a>; <a href="./references#CD011688-bbs2-0019" title="WurtmanJ , WurtmanR , BerryE , GleasonR , GoldbergH , McDermottJ , et al. Dexfenfluramine, fluoxetine, and weight loss among female carbohydrate cravers. Neuropsychopharmacology1993;9(3):201-10. ">Wurtman 1993</a>). No trial investigated all‐cause mortality or socioeconomic effects. </p> </section> </section> <section id="CD011688-sec-0068"> <h4 class="title">Excluded studies</h4> <p>After examination of 52 full‐text studies and records, we excluded 34 records. The reasons for exclusion were that the trial design was not a clinical trial (seven publications), participants did not meet the specified inclusion criteria (23 publications) and the participants did not receive the right intervention or comparator (four publications). For further details see <a href="./references#CD011688-sec-0147" title="">Characteristics of excluded studies</a>. </p> </section> </section> <section id="CD011688-sec-0069"> <h3 class="title">Risk of bias in included studies</h3> <p>For details on the risk of bias of the included trials see <a href="./references#CD011688-sec-0146" title="">Characteristics of included studies</a>. For an overview of the review authors' judgments about the risk of bias for individual trials and across all studies see <a href="#CD011688-fig-0002">Figure 2</a> and <a href="#CD011688-fig-0003">Figure 3</a>. </p> <section id="CD011688-sec-0070"> <h4 class="title">Allocation</h4> <p>Only <a href="./references#CD011688-bbs2-0015" title="PijlH , KoppeschaarH , WillekensF , Op de KampI , VeldhuisH , MeindersA . Effect of serotonin re-uptake inhibition by fluoxetine on body weight and spontaneous food choice in obesity. International Journal of Obesity1991;15(3):237-42. ">Pijl 1991</a> and <a href="./references#CD011688-bbs2-0017" title="SuplicyH , BoguszewskiC , Dos SantosC , Do DesterroM , CunhaD , RadomiskiR . A comparative study of five centrally acting drugs on the pharmacological treatment of obesity. International Journal of Obesity2014;38(8):1097-103. ">Suplicy 2014</a> reported the method used for random sequence generation and described details of allocation concealment; hence we judged these studies at low risk of selection bias. We considered the risk of selection bias uncertain for all other trials. </p> </section> <section id="CD011688-sec-0071"> <h4 class="title">Blinding</h4> <p>We judged four trials to be at high risk of performance bias for most of the reported outcomes (<a href="./references#CD011688-bbs2-0008" title="GuimarãesC , PereiraL , Lucif JúniorN , CesarinoE , AlmeidaC , CarvalhoD , et al. Tolerability and effectiveness of fluoxetine, metformin and sibutramine in reducing anthropometric and metabolic parameters in obese patients. Arquivos Brasileiros de Endocrinologia e Metabologia2006;50(6):1020-5. ">Guimaraes 2006</a>; <a href="./references#CD011688-bbs2-0009" title="HuangC , ChianC , LinJ . Short-term treatment of obesity with fluoxetine as a supplement to a low calorie diet. Changgeng Yi Xue za Zhi [Chang Gung Medical Journal]1998;21(1):50-6. ">Huang 1998</a>; <a href="./references#CD011688-bbs2-0012" title="LevineL , RosenblattS , BosomworthJ . Use of a serotonin re-uptake inhibitor, fluoxetine, in the treatment of obesity. International Journal of Obesity1987;11(Suppl 3):185-90. ">Levine 1987</a>; <a href="./references#CD011688-bbs2-0017" title="SuplicyH , BoguszewskiC , Dos SantosC , Do DesterroM , CunhaD , RadomiskiR . A comparative study of five centrally acting drugs on the pharmacological treatment of obesity. International Journal of Obesity2014;38(8):1097-103. ">Suplicy 2014</a>). The remaining trials reported sufficient information on how the blinding was performed, with the exception of two trials which described blinding methods in little detail, so we judged them as unclear risk of bias (<a href="./references#CD011688-bbs2-0007" title="DargaL , Carroll-MichalsL , BotsfordS , LucasC . Fluoxetine's effect on weight loss in obese subjects. American Journal of Clinical Nutrition1991;54(2):321-5. GoldsteinD , RampeyA , EnasG , PotvinJ , FludzinskiL , LevineL . Fluoxetine: a randomized clinical trial in the treatment of obesity. International Journal of Obesity and Related Metabolic Disorders1994;18(3):129-35. ">Goldstein 1994</a>; <a href="./references#CD011688-bbs2-0014" title="PedrinolaF , RissoW , LimaN , MedeirosG . Fluoxetine induced weight loss in overweight subjects: a double-blind placebo-controlled trial. Arquivos Brasileiros de Endocrinologia e Metabologia1993;37:31-3. ">Pedrinola 1993</a>). See <a href="./references#CD011688-sec-0146" title="">Characteristics of included studies</a> for details. </p> <p>All included trials did not provide adequate information to evaluate blinding of outcome assessment for any outcome measure, with the exception of <a href="./references#CD011688-bbs2-0014" title="PedrinolaF , RissoW , LimaN , MedeirosG . Fluoxetine induced weight loss in overweight subjects: a double-blind placebo-controlled trial. Arquivos Brasileiros de Endocrinologia e Metabologia1993;37:31-3. ">Pedrinola 1993</a> who reported that there was no blinding of outcome assessment. </p> </section> <section id="CD011688-sec-0072"> <h4 class="title">Incomplete outcome data</h4> <p>For the outcome measure 'weight loss', 12 of 17 trials investigating this outcome reported attrition rates from 4.2% to 22% during the follow‐up; hence we judged these at low risk of selection bias (<a href="./references#CD011688-bbs2-0003" title="BondiM , MenozziR , BertoliniM , VenneriM , RioG . Metabolic effects of fluoxetine in obese menopausal women. Journal of Endocrinological Investigation2000;23(5):280-6. ">Bondi 2000</a>; <a href="./references#CD011688-bbs2-0004" title="BrossR , HofferL . Fluoxetine increases resting energy expenditure and basal body temperature in humans. American Journal of Clinical Nutrition1995;61(5):1020-5. ">Bross 1995</a>; <a href="./references#CD011688-bbs2-0005" title="Fernández-SotoM , González-JiménezA , Barredo-AcedoF , Luna del CastilloJ , Escobar-JiménezF . Comparison of fluoxetine and placebo in the treatment of obesity. Annals of Nutrition &amp; Metabolism1995;39(3):159-63. ">Fernández‐Soto 1995</a>; <a href="./references#CD011688-bbs2-0008" title="GuimarãesC , PereiraL , Lucif JúniorN , CesarinoE , AlmeidaC , CarvalhoD , et al. Tolerability and effectiveness of fluoxetine, metformin and sibutramine in reducing anthropometric and metabolic parameters in obese patients. Arquivos Brasileiros de Endocrinologia e Metabologia2006;50(6):1020-5. ">Guimaraes 2006</a>; <a href="./references#CD011688-bbs2-0009" title="HuangC , ChianC , LinJ . Short-term treatment of obesity with fluoxetine as a supplement to a low calorie diet. Changgeng Yi Xue za Zhi [Chang Gung Medical Journal]1998;21(1):50-6. ">Huang 1998</a>; <a href="./references#CD011688-bbs2-0010" title="KopelmanP , ElliottM , SimondsA , CramerD , WardS , WedzichaJ . Short-term use of fluoxetine in asymptomatic obese subjects with sleep-related hypoventilation. International Journal of Obesity and Related Metabolic Disorders1992;16(10):825-30. ">Kopelman 1992</a>; <a href="./references#CD011688-bbs2-0011" title="LawtonC , WalesJ , HillA , BlundellJ . Serotoninergic manipulation, meal-induced satiety and eating pattern: effect of fluoxetine in obese female subjects. Obesity Research1995;3(4):345-56. ">Lawton 1995</a>; <a href="./references#CD011688-bbs2-0012" title="LevineL , RosenblattS , BosomworthJ . Use of a serotonin re-uptake inhibitor, fluoxetine, in the treatment of obesity. International Journal of Obesity1987;11(Suppl 3):185-90. ">Levine 1987</a>; <a href="./references#CD011688-bbs2-0014" title="PedrinolaF , RissoW , LimaN , MedeirosG . Fluoxetine induced weight loss in overweight subjects: a double-blind placebo-controlled trial. Arquivos Brasileiros de Endocrinologia e Metabologia1993;37:31-3. ">Pedrinola 1993</a>; <a href="./references#CD011688-bbs2-0015" title="PijlH , KoppeschaarH , WillekensF , Op de KampI , VeldhuisH , MeindersA . Effect of serotonin re-uptake inhibition by fluoxetine on body weight and spontaneous food choice in obesity. International Journal of Obesity1991;15(3):237-42. ">Pijl 1991</a>; <a href="./references#CD011688-bbs2-0016" title="StinsonJ , MurphyC , AndrewsJ , TomkinG . An assessment of the thermogenic effects of fluoxetine in obese subjects. International Journal of Obesity and Related Metabolic Disorders1992;16(5):391-5. ">Stinson 1992</a>; <a href="./references#CD011688-bbs2-0018" title="VisserM , SeidellJ , KoppeschaarH , SmitsP . No specific effect of fluoxetine treatment on fasting glucose, insulin, lipid levels, and blood pressure in healthy men with abdominal obesity. Obesity Research1994;2(2):152-9. VisserM , SeidellJ , KoppeschaarH , SmitsP . The effect of fluoxetine on body weight, body composition and visceral fat accumulation. International Journal of Obesity and Related Metabolic Disorders1993;17(5):247-53. ">Visser 1993</a>). We identified a high risk of attrition bias in five trials, with attrition rates ranging from 26.5% to 55% (<a href="./references#CD011688-bbs2-0006" title="GoldsteinD , RampeyA , DornseifB , LevineL , PotvinJ , FludzinskiL . Fluoxetine: a randomized clinical trial in the maintenance of weight loss. Obesity Research1993;1(2):92-8. ">Goldstein 1993</a>; <a href="./references#CD011688-bbs2-0007" title="DargaL , Carroll-MichalsL , BotsfordS , LucasC . Fluoxetine's effect on weight loss in obese subjects. American Journal of Clinical Nutrition1991;54(2):321-5. GoldsteinD , RampeyA , EnasG , PotvinJ , FludzinskiL , LevineL . Fluoxetine: a randomized clinical trial in the treatment of obesity. International Journal of Obesity and Related Metabolic Disorders1994;18(3):129-35. ">Goldstein 1994</a>; <a href="./references#CD011688-bbs2-0013" title="LevineL , EnasG , ThompsonW , ByynyR , DauerA , KirbyR , et al. Use of fluoxetine, a selective serotonin-uptake inhibitor, in the treatment of obesity: a dose-response study. International Journal of Obesity1989;13(5):635-45. ">Levine 1989</a>; <a href="./references#CD011688-bbs2-0017" title="SuplicyH , BoguszewskiC , Dos SantosC , Do DesterroM , CunhaD , RadomiskiR . A comparative study of five centrally acting drugs on the pharmacological treatment of obesity. International Journal of Obesity2014;38(8):1097-103. ">Suplicy 2014</a>; <a href="./references#CD011688-bbs2-0019" title="WurtmanJ , WurtmanR , BerryE , GleasonR , GoldbergH , McDermottJ , et al. Dexfenfluramine, fluoxetine, and weight loss among female carbohydrate cravers. Neuropsychopharmacology1993;9(3):201-10. ">Wurtman 1993</a>). We judged the only trial evaluating health‐related quality of life with an attrition rate of 28.3% to be at high risk of attrition bias (<a href="./references#CD011688-bbs2-0017" title="SuplicyH , BoguszewskiC , Dos SantosC , Do DesterroM , CunhaD , RadomiskiR . A comparative study of five centrally acting drugs on the pharmacological treatment of obesity. International Journal of Obesity2014;38(8):1097-103. ">Suplicy 2014</a>). We judged five out of 14 trials investigating adverse events to be at high risk of attrition bias (<a href="./references#CD011688-bbs2-0006" title="GoldsteinD , RampeyA , DornseifB , LevineL , PotvinJ , FludzinskiL . Fluoxetine: a randomized clinical trial in the maintenance of weight loss. Obesity Research1993;1(2):92-8. ">Goldstein 1993</a>; <a href="./references#CD011688-bbs2-0007" title="DargaL , Carroll-MichalsL , BotsfordS , LucasC . Fluoxetine's effect on weight loss in obese subjects. American Journal of Clinical Nutrition1991;54(2):321-5. GoldsteinD , RampeyA , EnasG , PotvinJ , FludzinskiL , LevineL . Fluoxetine: a randomized clinical trial in the treatment of obesity. International Journal of Obesity and Related Metabolic Disorders1994;18(3):129-35. ">Goldstein 1994</a>; <a href="./references#CD011688-bbs2-0013" title="LevineL , EnasG , ThompsonW , ByynyR , DauerA , KirbyR , et al. Use of fluoxetine, a selective serotonin-uptake inhibitor, in the treatment of obesity: a dose-response study. International Journal of Obesity1989;13(5):635-45. ">Levine 1989</a>; <a href="./references#CD011688-bbs2-0017" title="SuplicyH , BoguszewskiC , Dos SantosC , Do DesterroM , CunhaD , RadomiskiR . A comparative study of five centrally acting drugs on the pharmacological treatment of obesity. International Journal of Obesity2014;38(8):1097-103. ">Suplicy 2014</a>; <a href="./references#CD011688-bbs2-0019" title="WurtmanJ , WurtmanR , BerryE , GleasonR , GoldbergH , McDermottJ , et al. Dexfenfluramine, fluoxetine, and weight loss among female carbohydrate cravers. Neuropsychopharmacology1993;9(3):201-10. ">Wurtman 1993</a>). We judged three out of nine trials investigating anthropometric measurements other than weight loss with attrition rates of 26.5% to 43.4% to be at high risk of attrition bias (<a href="./references#CD011688-bbs2-0007" title="DargaL , Carroll-MichalsL , BotsfordS , LucasC . Fluoxetine's effect on weight loss in obese subjects. American Journal of Clinical Nutrition1991;54(2):321-5. GoldsteinD , RampeyA , EnasG , PotvinJ , FludzinskiL , LevineL . Fluoxetine: a randomized clinical trial in the treatment of obesity. International Journal of Obesity and Related Metabolic Disorders1994;18(3):129-35. ">Goldstein 1994</a>; <a href="./references#CD011688-bbs2-0013" title="LevineL , EnasG , ThompsonW , ByynyR , DauerA , KirbyR , et al. Use of fluoxetine, a selective serotonin-uptake inhibitor, in the treatment of obesity: a dose-response study. International Journal of Obesity1989;13(5):635-45. ">Levine 1989</a>; <a href="./references#CD011688-bbs2-0017" title="SuplicyH , BoguszewskiC , Dos SantosC , Do DesterroM , CunhaD , RadomiskiR . A comparative study of five centrally acting drugs on the pharmacological treatment of obesity. International Journal of Obesity2014;38(8):1097-103. ">Suplicy 2014</a>). Three trials reported on morbidity and we judged two of them with attrition rates of 28.3% to 36.3% to be at high risk of attrition bias (<a href="./references#CD011688-bbs2-0006" title="GoldsteinD , RampeyA , DornseifB , LevineL , PotvinJ , FludzinskiL . Fluoxetine: a randomized clinical trial in the maintenance of weight loss. Obesity Research1993;1(2):92-8. ">Goldstein 1993</a>; <a href="./references#CD011688-bbs2-0017" title="SuplicyH , BoguszewskiC , Dos SantosC , Do DesterroM , CunhaD , RadomiskiR . A comparative study of five centrally acting drugs on the pharmacological treatment of obesity. International Journal of Obesity2014;38(8):1097-103. ">Suplicy 2014</a>). </p> </section> <section id="CD011688-sec-0073"> <h4 class="title">Selective reporting</h4> <p>With respect to the Outcome Reporting Bias in Trials classification (ORBIT), we judged nine trials to have a high risk of selection bias because their outcomes were incompletely reported or not reported at all: for weight loss two trials (<a href="./references#CD011688-bbs2-0006" title="GoldsteinD , RampeyA , DornseifB , LevineL , PotvinJ , FludzinskiL . Fluoxetine: a randomized clinical trial in the maintenance of weight loss. Obesity Research1993;1(2):92-8. ">Goldstein 1993</a>; <a href="./references#CD011688-bbs2-0013" title="LevineL , EnasG , ThompsonW , ByynyR , DauerA , KirbyR , et al. Use of fluoxetine, a selective serotonin-uptake inhibitor, in the treatment of obesity: a dose-response study. International Journal of Obesity1989;13(5):635-45. ">Levine 1989</a>), for adverse events three trials (<a href="./references#CD011688-bbs2-0008" title="GuimarãesC , PereiraL , Lucif JúniorN , CesarinoE , AlmeidaC , CarvalhoD , et al. Tolerability and effectiveness of fluoxetine, metformin and sibutramine in reducing anthropometric and metabolic parameters in obese patients. Arquivos Brasileiros de Endocrinologia e Metabologia2006;50(6):1020-5. ">Guimaraes 2006</a>; <a href="./references#CD011688-bbs2-0010" title="KopelmanP , ElliottM , SimondsA , CramerD , WardS , WedzichaJ . Short-term use of fluoxetine in asymptomatic obese subjects with sleep-related hypoventilation. International Journal of Obesity and Related Metabolic Disorders1992;16(10):825-30. ">Kopelman 1992</a>; <a href="./references#CD011688-bbs2-0014" title="PedrinolaF , RissoW , LimaN , MedeirosG . Fluoxetine induced weight loss in overweight subjects: a double-blind placebo-controlled trial. Arquivos Brasileiros de Endocrinologia e Metabologia1993;37:31-3. ">Pedrinola 1993</a>), for anthropometric measurements other than weight loss in kilograms three trials (<a href="./references#CD011688-bbs2-0001" title="Al-HelliA , Al-AbbassiM , JasimG , Al-BayatyM . Effects of fluoxetine, omega 3, or their combination on serum leptin in Iraqi obese subjects. International Journal of Pharmaceutical Sciences Review and Research2015;35(1):90-5. ">Al‐Helli 2015</a>; <a href="./references#CD011688-bbs2-0007" title="DargaL , Carroll-MichalsL , BotsfordS , LucasC . Fluoxetine's effect on weight loss in obese subjects. American Journal of Clinical Nutrition1991;54(2):321-5. GoldsteinD , RampeyA , EnasG , PotvinJ , FludzinskiL , LevineL . Fluoxetine: a randomized clinical trial in the treatment of obesity. International Journal of Obesity and Related Metabolic Disorders1994;18(3):129-35. ">Goldstein 1994</a>; <a href="./references#CD011688-bbs2-0012" title="LevineL , RosenblattS , BosomworthJ . Use of a serotonin re-uptake inhibitor, fluoxetine, in the treatment of obesity. International Journal of Obesity1987;11(Suppl 3):185-90. ">Levine 1987</a>), and for health‐related quality of life one trial (<a href="./references#CD011688-bbs2-0017" title="SuplicyH , BoguszewskiC , Dos SantosC , Do DesterroM , CunhaD , RadomiskiR . A comparative study of five centrally acting drugs on the pharmacological treatment of obesity. International Journal of Obesity2014;38(8):1097-103. ">Suplicy 2014</a>). The remaining 10 trials were judged to have low risk of reporting bias. For details see <a href="./appendices#CD011688-sec-0129">Appendix 9</a>. </p> </section> <section id="CD011688-sec-0074"> <h4 class="title">Other potential sources of bias</h4> <p>We judged six trials to have an unclear risk of other bias, mainly because of possible sponsor bias (<a href="./references#CD011688-bbs2-0004" title="BrossR , HofferL . Fluoxetine increases resting energy expenditure and basal body temperature in humans. American Journal of Clinical Nutrition1995;61(5):1020-5. ">Bross 1995</a>; <a href="./references#CD011688-bbs2-0007" title="DargaL , Carroll-MichalsL , BotsfordS , LucasC . Fluoxetine's effect on weight loss in obese subjects. American Journal of Clinical Nutrition1991;54(2):321-5. GoldsteinD , RampeyA , EnasG , PotvinJ , FludzinskiL , LevineL . Fluoxetine: a randomized clinical trial in the treatment of obesity. International Journal of Obesity and Related Metabolic Disorders1994;18(3):129-35. ">Goldstein 1994</a>; <a href="./references#CD011688-bbs2-0011" title="LawtonC , WalesJ , HillA , BlundellJ . Serotoninergic manipulation, meal-induced satiety and eating pattern: effect of fluoxetine in obese female subjects. Obesity Research1995;3(4):345-56. ">Lawton 1995</a>; <a href="./references#CD011688-bbs2-0012" title="LevineL , RosenblattS , BosomworthJ . Use of a serotonin re-uptake inhibitor, fluoxetine, in the treatment of obesity. International Journal of Obesity1987;11(Suppl 3):185-90. ">Levine 1987</a>; <a href="./references#CD011688-bbs2-0016" title="StinsonJ , MurphyC , AndrewsJ , TomkinG . An assessment of the thermogenic effects of fluoxetine in obese subjects. International Journal of Obesity and Related Metabolic Disorders1992;16(5):391-5. ">Stinson 1992</a>; <a href="./references#CD011688-bbs2-0017" title="SuplicyH , BoguszewskiC , Dos SantosC , Do DesterroM , CunhaD , RadomiskiR . A comparative study of five centrally acting drugs on the pharmacological treatment of obesity. International Journal of Obesity2014;38(8):1097-103. ">Suplicy 2014</a>). </p> </section> </section> <section id="CD011688-sec-0075"> <h3 class="title" id="CD011688-sec-0075">Effects of interventions</h3> <p>See: <a href="./full#CD011688-tbl-0001"><b>Summary of findings 1</b> Summary of findings: fluoxetine compared with placebo</a> </p> <p>Because there were very limited data comparing fluoxetine with other anti‐obesity drugs we only established a 'Summary of findings' table for the comparison 'fluoxetine with placebo'. </p> <section id="CD011688-sec-0076"> <h4 class="title">Baseline characteristics</h4> <p>For details of baseline characteristics, see <a href="./appendices#CD011688-sec-0126">Appendix 6</a> and <a href="./appendices#CD011688-sec-0127">Appendix 7</a>. Only three trials included non‐obese participants (<a href="./references#CD011688-bbs2-0012" title="LevineL , RosenblattS , BosomworthJ . Use of a serotonin re-uptake inhibitor, fluoxetine, in the treatment of obesity. International Journal of Obesity1987;11(Suppl 3):185-90. ">Levine 1987</a>; <a href="./references#CD011688-bbs2-0013" title="LevineL , EnasG , ThompsonW , ByynyR , DauerA , KirbyR , et al. Use of fluoxetine, a selective serotonin-uptake inhibitor, in the treatment of obesity: a dose-response study. International Journal of Obesity1989;13(5):635-45. ">Levine 1989</a>; <a href="./references#CD011688-bbs2-0018" title="VisserM , SeidellJ , KoppeschaarH , SmitsP . No specific effect of fluoxetine treatment on fasting glucose, insulin, lipid levels, and blood pressure in healthy men with abdominal obesity. Obesity Research1994;2(2):152-9. VisserM , SeidellJ , KoppeschaarH , SmitsP . The effect of fluoxetine on body weight, body composition and visceral fat accumulation. International Journal of Obesity and Related Metabolic Disorders1993;17(5):247-53. ">Visser 1993</a>). </p> </section> <section id="CD011688-sec-0077"> <h4 class="title">Fluoxetine versus placebo</h4> <p>For a summary of findings see <a href="./full#CD011688-tbl-0001">summary of findings Table 1</a>. </p> <section id="CD011688-sec-0078"> <h5 class="title">Primary outcomes</h5> <section id="CD011688-sec-0079"> <h6 class="title">Weight loss (kg)</h6> <p>Ten trials with extractable data compared fluoxetine with placebo (<a href="#CD011688-fig-0004">Figure 4</a>). Seven trials used a dose of 60 mg/d (<a href="./references#CD011688-bbs2-0003" title="BondiM , MenozziR , BertoliniM , VenneriM , RioG . Metabolic effects of fluoxetine in obese menopausal women. Journal of Endocrinological Investigation2000;23(5):280-6. ">Bondi 2000</a>; <a href="./references#CD011688-bbs2-0007" title="DargaL , Carroll-MichalsL , BotsfordS , LucasC . Fluoxetine's effect on weight loss in obese subjects. American Journal of Clinical Nutrition1991;54(2):321-5. GoldsteinD , RampeyA , EnasG , PotvinJ , FludzinskiL , LevineL . Fluoxetine: a randomized clinical trial in the treatment of obesity. International Journal of Obesity and Related Metabolic Disorders1994;18(3):129-35. ">Goldstein 1994</a>; <a href="./references#CD011688-bbs2-0008" title="GuimarãesC , PereiraL , Lucif JúniorN , CesarinoE , AlmeidaC , CarvalhoD , et al. Tolerability and effectiveness of fluoxetine, metformin and sibutramine in reducing anthropometric and metabolic parameters in obese patients. Arquivos Brasileiros de Endocrinologia e Metabologia2006;50(6):1020-5. ">Guimaraes 2006</a>; <a href="./references#CD011688-bbs2-0012" title="LevineL , RosenblattS , BosomworthJ . Use of a serotonin re-uptake inhibitor, fluoxetine, in the treatment of obesity. International Journal of Obesity1987;11(Suppl 3):185-90. ">Levine 1987</a>; <a href="./references#CD011688-bbs2-0013" title="LevineL , EnasG , ThompsonW , ByynyR , DauerA , KirbyR , et al. Use of fluoxetine, a selective serotonin-uptake inhibitor, in the treatment of obesity: a dose-response study. International Journal of Obesity1989;13(5):635-45. ">Levine 1989</a>; <a href="./references#CD011688-bbs2-0015" title="PijlH , KoppeschaarH , WillekensF , Op de KampI , VeldhuisH , MeindersA . Effect of serotonin re-uptake inhibition by fluoxetine on body weight and spontaneous food choice in obesity. International Journal of Obesity1991;15(3):237-42. ">Pijl 1991</a>; <a href="./references#CD011688-bbs2-0018" title="VisserM , SeidellJ , KoppeschaarH , SmitsP . No specific effect of fluoxetine treatment on fasting glucose, insulin, lipid levels, and blood pressure in healthy men with abdominal obesity. Obesity Research1994;2(2):152-9. VisserM , SeidellJ , KoppeschaarH , SmitsP . The effect of fluoxetine on body weight, body composition and visceral fat accumulation. International Journal of Obesity and Related Metabolic Disorders1993;17(5):247-53. ">Visser 1993</a>), two trials used a dose of 40 mg/d (<a href="./references#CD011688-bbs2-0013" title="LevineL , EnasG , ThompsonW , ByynyR , DauerA , KirbyR , et al. Use of fluoxetine, a selective serotonin-uptake inhibitor, in the treatment of obesity: a dose-response study. International Journal of Obesity1989;13(5):635-45. ">Levine 1989</a>; <a href="./references#CD011688-bbs2-0014" title="PedrinolaF , RissoW , LimaN , MedeirosG . Fluoxetine induced weight loss in overweight subjects: a double-blind placebo-controlled trial. Arquivos Brasileiros de Endocrinologia e Metabologia1993;37:31-3. ">Pedrinola 1993</a>) and three trials used a dose of 20 mg/d (<a href="./references#CD011688-bbs2-0013" title="LevineL , EnasG , ThompsonW , ByynyR , DauerA , KirbyR , et al. Use of fluoxetine, a selective serotonin-uptake inhibitor, in the treatment of obesity: a dose-response study. International Journal of Obesity1989;13(5):635-45. ">Levine 1989</a>; <a href="./references#CD011688-bbs2-0017" title="SuplicyH , BoguszewskiC , Dos SantosC , Do DesterroM , CunhaD , RadomiskiR . A comparative study of five centrally acting drugs on the pharmacological treatment of obesity. International Journal of Obesity2014;38(8):1097-103. ">Suplicy 2014</a>; <a href="./references#CD011688-bbs2-0019" title="WurtmanJ , WurtmanR , BerryE , GleasonR , GoldbergH , McDermottJ , et al. Dexfenfluramine, fluoxetine, and weight loss among female carbohydrate cravers. Neuropsychopharmacology1993;9(3):201-10. ">Wurtman 1993</a>). </p> <div class="figure" id="CD011688-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Forest plot of comparison: Fluoxetine versus placebo (parallel RCTs), outcome: 1.1 Weight loss, end of trial weight [kg]." data-id="CD011688-fig-0004" src="/cdsr/doi/10.1002/14651858.CD011688.pub2/media/CDSR/CD011688/image_n/nCD011688-FIG-04.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: Fluoxetine versus placebo (parallel RCTs), outcome: 1.1 Weight loss, end of trial weight [kg]. </p> </div> </div> </div> <p>Across all fluoxetine dosages and durations of treatment the MD was −2.7 kg (95% CI −4 to −1.4; P &lt; 0.001; 10 trials (without <a href="./references#CD011688-bbs2-0013" title="LevineL , EnasG , ThompsonW , ByynyR , DauerA , KirbyR , et al. Use of fluoxetine, a selective serotonin-uptake inhibitor, in the treatment of obesity: a dose-response study. International Journal of Obesity1989;13(5):635-45. ">Levine 1989</a> and fluoxetine 20 mg/d and 40 mg/d to avoid a unit of analysis error), 956 participants; low certainty evidence in favour of fluoxetine; <a href="./references#CD011688-fig-0005" title="">Analysis 1.1</a>). The 95% prediction interval ranged between −7.1 kg and 1.7 kg. </p> <p>The different fluoxetine dosages showed the following results (<a href="./references#CD011688-fig-0005" title="">Analysis 1.1</a>). </p> <p> <ul id="CD011688-list-0014"> <li> <p>For fluoxetine 60 mg/d, the MD was −2.5 kg (95% CI −3.8 to −1.2; P &lt; 0.001; 7 trials, 819 participants; low certainty evidence in favour of fluoxetine; <a href="./references#CD011688-fig-0005" title="">Analysis 1.1</a>). The 95% prediction interval ranged between −6.4 kg and 1.4 kg. </p> </li> <li> <p>For fluoxetine 40 mg/d, the MD was −4 kg (95% CI −8.8 to 0.8; P = 0.10; 2 trials, 182 participants; very low certainty; <a href="./references#CD011688-fig-0005" title="">Analysis 1.1</a>). Fixed‐effect meta‐analysis performed because of the low number of trials showed a MD of −2.3 kg (95% CI −3 to −1.6; P &lt; 0.001 in favour of fluoxetine). </p> </li> <li> <p>For fluoxetine 20 mg/d, the MD was −1.5 kg (95% CI −3.5 to 0.5; P = 0.15; 3 trials, 279 participants; very low certainty evidence; <a href="./references#CD011688-fig-0005" title="">Analysis 1.1</a>). Fixed‐effect meta‐analysis performed because of the low number of trials showed an MD of −1.4 kg (95% CI −2.1 to −0.6; P &lt; 0.001 in favour of fluoxetine). The 95% prediction interval did not provide a meaningful estimate. </p> </li> </ul> </p> <p>Of the seven trials that administered fluoxetine 60 mg/d, five trials reported weight loss from zero to three months (<a href="./references#CD011688-bbs2-0003" title="BondiM , MenozziR , BertoliniM , VenneriM , RioG . Metabolic effects of fluoxetine in obese menopausal women. Journal of Endocrinological Investigation2000;23(5):280-6. ">Bondi 2000</a>; <a href="./references#CD011688-bbs2-0012" title="LevineL , RosenblattS , BosomworthJ . Use of a serotonin re-uptake inhibitor, fluoxetine, in the treatment of obesity. International Journal of Obesity1987;11(Suppl 3):185-90. ">Levine 1987</a>; <a href="./references#CD011688-bbs2-0013" title="LevineL , EnasG , ThompsonW , ByynyR , DauerA , KirbyR , et al. Use of fluoxetine, a selective serotonin-uptake inhibitor, in the treatment of obesity: a dose-response study. International Journal of Obesity1989;13(5):635-45. ">Levine 1989</a>; <a href="./references#CD011688-bbs2-0015" title="PijlH , KoppeschaarH , WillekensF , Op de KampI , VeldhuisH , MeindersA . Effect of serotonin re-uptake inhibition by fluoxetine on body weight and spontaneous food choice in obesity. International Journal of Obesity1991;15(3):237-42. ">Pijl 1991</a>; <a href="./references#CD011688-bbs2-0018" title="VisserM , SeidellJ , KoppeschaarH , SmitsP . No specific effect of fluoxetine treatment on fasting glucose, insulin, lipid levels, and blood pressure in healthy men with abdominal obesity. Obesity Research1994;2(2):152-9. VisserM , SeidellJ , KoppeschaarH , SmitsP . The effect of fluoxetine on body weight, body composition and visceral fat accumulation. International Journal of Obesity and Related Metabolic Disorders1993;17(5):247-53. ">Visser 1993</a>); and two reported weight loss from four to six months (<a href="./references#CD011688-bbs2-0007" title="DargaL , Carroll-MichalsL , BotsfordS , LucasC . Fluoxetine's effect on weight loss in obese subjects. American Journal of Clinical Nutrition1991;54(2):321-5. GoldsteinD , RampeyA , EnasG , PotvinJ , FludzinskiL , LevineL . Fluoxetine: a randomized clinical trial in the treatment of obesity. International Journal of Obesity and Related Metabolic Disorders1994;18(3):129-35. ">Goldstein 1994</a>; <a href="./references#CD011688-bbs2-0008" title="GuimarãesC , PereiraL , Lucif JúniorN , CesarinoE , AlmeidaC , CarvalhoD , et al. Tolerability and effectiveness of fluoxetine, metformin and sibutramine in reducing anthropometric and metabolic parameters in obese patients. Arquivos Brasileiros de Endocrinologia e Metabologia2006;50(6):1020-5. ">Guimaraes 2006</a>) (<a href="./references#CD011688-fig-0006" title="">Analysis 1.2</a>). The test for subgroup differences did not indicate a statistically significant difference (P = 0.62). </p> <p>The two trials with the longest duration of follow‐up (52 weeks) did not show a clear difference between fluoxetine and placebo (<a href="./references#CD011688-bbs2-0006" title="GoldsteinD , RampeyA , DornseifB , LevineL , PotvinJ , FludzinskiL . Fluoxetine: a randomized clinical trial in the maintenance of weight loss. Obesity Research1993;1(2):92-8. ">Goldstein 1993</a>; <a href="./references#CD011688-bbs2-0007" title="DargaL , Carroll-MichalsL , BotsfordS , LucasC . Fluoxetine's effect on weight loss in obese subjects. American Journal of Clinical Nutrition1991;54(2):321-5. GoldsteinD , RampeyA , EnasG , PotvinJ , FludzinskiL , LevineL . Fluoxetine: a randomized clinical trial in the treatment of obesity. International Journal of Obesity and Related Metabolic Disorders1994;18(3):129-35. ">Goldstein 1994</a>). </p> <p>Three cross‐over trials compared fluoxetine 60 mg/d with placebo (<a href="./references#CD011688-bbs2-0005" title="Fernández-SotoM , González-JiménezA , Barredo-AcedoF , Luna del CastilloJ , Escobar-JiménezF . Comparison of fluoxetine and placebo in the treatment of obesity. Annals of Nutrition &amp; Metabolism1995;39(3):159-63. ">Fernández‐Soto 1995</a>; <a href="./references#CD011688-bbs2-0011" title="LawtonC , WalesJ , HillA , BlundellJ . Serotoninergic manipulation, meal-induced satiety and eating pattern: effect of fluoxetine in obese female subjects. Obesity Research1995;3(4):345-56. ">Lawton 1995</a>; <a href="./references#CD011688-bbs2-0016" title="StinsonJ , MurphyC , AndrewsJ , TomkinG . An assessment of the thermogenic effects of fluoxetine in obese subjects. International Journal of Obesity and Related Metabolic Disorders1992;16(5):391-5. ">Stinson 1992</a>). Only <a href="./references#CD011688-bbs2-0011" title="LawtonC , WalesJ , HillA , BlundellJ . Serotoninergic manipulation, meal-induced satiety and eating pattern: effect of fluoxetine in obese female subjects. Obesity Research1995;3(4):345-56. ">Lawton 1995</a> provided adequate information to calculate a weight loss of 1.9 kg (95% CI 0.6 to 3.2; P = 0.004; 24 participants in favour of fluoxetine) (<a href="./references#CD011688-fig-0007" title="">Analysis 1.3</a>). </p> </section> <section id="CD011688-sec-0080"> <h6 class="title">Health‐related quality of life</h6> <p>Only <a href="./references#CD011688-bbs2-0017" title="SuplicyH , BoguszewskiC , Dos SantosC , Do DesterroM , CunhaD , RadomiskiR . A comparative study of five centrally acting drugs on the pharmacological treatment of obesity. International Journal of Obesity2014;38(8):1097-103. ">Suplicy 2014</a> planned to assess health‐related quality of life but did not report findings. </p> </section> <section id="CD011688-sec-0081"> <h6 class="title">Adverse events</h6> <p>Nine trials reported adverse events in the comparison of fluoxetine with placebo (<a href="./references#CD011688-bbs2-0006" title="GoldsteinD , RampeyA , DornseifB , LevineL , PotvinJ , FludzinskiL . Fluoxetine: a randomized clinical trial in the maintenance of weight loss. Obesity Research1993;1(2):92-8. ">Goldstein 1993</a>; <a href="./references#CD011688-bbs2-0007" title="DargaL , Carroll-MichalsL , BotsfordS , LucasC . Fluoxetine's effect on weight loss in obese subjects. American Journal of Clinical Nutrition1991;54(2):321-5. GoldsteinD , RampeyA , EnasG , PotvinJ , FludzinskiL , LevineL . Fluoxetine: a randomized clinical trial in the treatment of obesity. International Journal of Obesity and Related Metabolic Disorders1994;18(3):129-35. ">Goldstein 1994</a>; <a href="./references#CD011688-bbs2-0008" title="GuimarãesC , PereiraL , Lucif JúniorN , CesarinoE , AlmeidaC , CarvalhoD , et al. Tolerability and effectiveness of fluoxetine, metformin and sibutramine in reducing anthropometric and metabolic parameters in obese patients. Arquivos Brasileiros de Endocrinologia e Metabologia2006;50(6):1020-5. ">Guimaraes 2006</a>; <a href="./references#CD011688-bbs2-0012" title="LevineL , RosenblattS , BosomworthJ . Use of a serotonin re-uptake inhibitor, fluoxetine, in the treatment of obesity. International Journal of Obesity1987;11(Suppl 3):185-90. ">Levine 1987</a>; <a href="./references#CD011688-bbs2-0013" title="LevineL , EnasG , ThompsonW , ByynyR , DauerA , KirbyR , et al. Use of fluoxetine, a selective serotonin-uptake inhibitor, in the treatment of obesity: a dose-response study. International Journal of Obesity1989;13(5):635-45. ">Levine 1989</a>; <a href="./references#CD011688-bbs2-0015" title="PijlH , KoppeschaarH , WillekensF , Op de KampI , VeldhuisH , MeindersA . Effect of serotonin re-uptake inhibition by fluoxetine on body weight and spontaneous food choice in obesity. International Journal of Obesity1991;15(3):237-42. ">Pijl 1991</a>; <a href="./references#CD011688-bbs2-0017" title="SuplicyH , BoguszewskiC , Dos SantosC , Do DesterroM , CunhaD , RadomiskiR . A comparative study of five centrally acting drugs on the pharmacological treatment of obesity. International Journal of Obesity2014;38(8):1097-103. ">Suplicy 2014</a>; <a href="./references#CD011688-bbs2-0018" title="VisserM , SeidellJ , KoppeschaarH , SmitsP . No specific effect of fluoxetine treatment on fasting glucose, insulin, lipid levels, and blood pressure in healthy men with abdominal obesity. Obesity Research1994;2(2):152-9. VisserM , SeidellJ , KoppeschaarH , SmitsP . The effect of fluoxetine on body weight, body composition and visceral fat accumulation. International Journal of Obesity and Related Metabolic Disorders1993;17(5):247-53. ">Visser 1993</a>; <a href="./references#CD011688-bbs2-0019" title="WurtmanJ , WurtmanR , BerryE , GleasonR , GoldbergH , McDermottJ , et al. Dexfenfluramine, fluoxetine, and weight loss among female carbohydrate cravers. Neuropsychopharmacology1993;9(3):201-10. ">Wurtman 1993</a>). The types of events and the fluoxetine dose differed between trials. A total of 399 out of 627 participants (63.6%) receiving fluoxetine compared with 352 out of 626 participants (56.2%) receiving placebo experienced an adverse event. Pooling the trials in a random‐effects meta‐analysis showed an increase in the risk of having at least one adverse event of any type in the fluoxetine groups compared with placebo: RR 1.18, 95% CI 0.99 to 1.42; P = 0.07; 9 trials; 1253 participants; low certainty evidence; <a href="./references#CD011688-fig-0008" title="">Analysis 1.4</a>. The 95% prediction interval ranged between 0.74 and 1.88. </p> <p>The most frequently reported adverse events comparing fluoxetine with placebo were the following (see <a href="./references#CD011688-fig-0009" title="">Analysis 1.5</a>). </p> <p> <ul id="CD011688-list-0015"> <li> <p>Abdominal pain: RR 1.51, 95% CI 0.58 to 3.90; P = 0.40; 5 trials, 504 participants.</p> </li> <li> <p>Allergy: RR 0.17, 95% CI 0.03 to 0.98; P = 0.05; 3 trials, 780 participants.</p> </li> <li> <p>Amnesia: RR 12.89, 95% CI 0.73 to 227.44; P = 0.08; 1 trial, 458 participants.</p> </li> <li> <p>Anorexia: RR 8.89, 95% CI 1.36 to 57.89; P = 0.02; 1 trial, 19 participants in favour of placebo. </p> </li> <li> <p>Anxiety: RR 1.07, 95% CI 0.56 to 2.03; P = 0.83; 7 trials, 1210 participants.</p> </li> <li> <p>Constipation: RR 2.83, 95% CI 0.58 to 13.90; P = 0.20; 3 trials, 381 participants.</p> </li> <li> <p>Diarrhoea: RR 1.44, 95% CI 0.97 to 2.13; P = 0.07; 7 trials, 1191 participants.</p> </li> <li> <p>Dizziness: RR 2.40, 95% CI 1.03 to 5.60; P = 0.04; 5 trials, 693 participants in favour of placebo. </p> </li> <li> <p>Drowsiness: RR 2.67, 95% CI 1.68 to 4.24; P &lt; 0.001; 9 trials, 1253 participants in favour of placebo. </p> </li> <li> <p>Dry mouth: RR 1.23, 95% CI 0.66 to 2.30; P = 0.52; 6 trials, 896 participants.</p> </li> <li> <p>Dyspepsia: RR 1.99, 95% CI 0.71 to 5.55; P = 0.19; 4 trials, 501 participants.</p> </li> <li> <p>Fatigue: RR 2.50, 95% CI 1.62 to 3.85; P &lt; 0.001; 5 trials, 1112 participants in favour of placebo. </p> </li> <li> <p>Headache: RR 1.17, 95% CI 0.94 to 1.47; P = 0.16; 8 trials, 1234 participants.</p> </li> <li> <p>Insomnia: RR 2.23, 95% CI 1.22 to 4.08; P = 0.009; 7 trials, 1191 participants in favour of placebo. </p> </li> <li> <p>Irritability: RR 1.41, 95% CI 0.63 to 3.15; P = 0.40; 3 trials, 442 participants.</p> </li> <li> <p>Malaise: RR 0.60, 95% CI 0.15 to 2.46; P = 0.48; 2 trials, 322 participants.</p> </li> <li> <p>Nausea: RR 1.99, 95% CI 1.35 to 2.91; P &lt; 0.001; 7 trials, 1016 participants in favour of placebo. </p> </li> <li> <p>Palpitations: RR 2.81, 95% CI 0.12 to 66.40; P = 0.52; 1 trial, 60 participants.</p> </li> <li> <p>Rhinitis: RR 0.99, 95% CI 0.75 to 1.30; P = 0.94; 3 trials, 933 participants.</p> </li> </ul> </p> <p>The adverse events dizziness, drowsiness, fatigue, insomnia and nausea were observed approximately twice as often following fluoxetine treatment. </p> <p>Across all fluoxetine dosages and durations of treatment the RR for the outcome 'any adverse event' was 1.18 (95% CI 0.99 to 1.42; P = 0.07; 9 trials (without <a href="./references#CD011688-bbs2-0013" title="LevineL , EnasG , ThompsonW , ByynyR , DauerA , KirbyR , et al. Use of fluoxetine, a selective serotonin-uptake inhibitor, in the treatment of obesity: a dose-response study. International Journal of Obesity1989;13(5):635-45. ">Levine 1989</a> and fluoxetine 20 mg/d and 40 mg/d, and <a href="./references#CD011688-bbs2-0006" title="GoldsteinD , RampeyA , DornseifB , LevineL , PotvinJ , FludzinskiL . Fluoxetine: a randomized clinical trial in the maintenance of weight loss. Obesity Research1993;1(2):92-8. ">Goldstein 1993</a> and fluoxetine 20 mg/d to avoid a unit of analysis error), 1253 participants; low certainty evidence; <a href="./references#CD011688-fig-0010" title="">Analysis 1.6</a>). </p> <p>Subgroup analyses of different fluoxetine doses for adverse events did not show statistically significant subgroup differences (<a href="./references#CD011688-fig-0010" title="">Analysis 1.6</a>). </p> <p> <ul id="CD011688-list-0016"> <li> <p>For fluoxetine 60 mg/d the RR was 1.16, 95% CI 0.93 to 1.44; P = 0.18; 7 trials, 1134 participants. </p> </li> <li> <p>For fluoxetine 40 mg/d the RR was 1.07, 95% CI 0.93 to 1.24; P = 0.32; 1 trial, 262 participants. </p> </li> <li> <p>For fluoxetine 20 mg/d, the RR was 1.10, 95% CI 0.92 to 1.31; P = 0.30; 4 trials, 592 participants. </p> </li> <li> <p>For fluoxetine 10 mg/d, the RR was 0.96, 95% CI 0.82 to 1.12; P = 0.59; 1 trial, 262 participants. </p> </li> </ul> </p> <p>Of the seven trials administering fluoxetine 60 mg/d, four trials reported the outcome 'any adverse event' from zero to three months (<a href="./references#CD011688-bbs2-0012" title="LevineL , RosenblattS , BosomworthJ . Use of a serotonin re-uptake inhibitor, fluoxetine, in the treatment of obesity. International Journal of Obesity1987;11(Suppl 3):185-90. ">Levine 1987</a>; <a href="./references#CD011688-bbs2-0013" title="LevineL , EnasG , ThompsonW , ByynyR , DauerA , KirbyR , et al. Use of fluoxetine, a selective serotonin-uptake inhibitor, in the treatment of obesity: a dose-response study. International Journal of Obesity1989;13(5):635-45. ">Levine 1989</a>; <a href="./references#CD011688-bbs2-0015" title="PijlH , KoppeschaarH , WillekensF , Op de KampI , VeldhuisH , MeindersA . Effect of serotonin re-uptake inhibition by fluoxetine on body weight and spontaneous food choice in obesity. International Journal of Obesity1991;15(3):237-42. ">Pijl 1991</a>; <a href="./references#CD011688-bbs2-0018" title="VisserM , SeidellJ , KoppeschaarH , SmitsP . No specific effect of fluoxetine treatment on fasting glucose, insulin, lipid levels, and blood pressure in healthy men with abdominal obesity. Obesity Research1994;2(2):152-9. VisserM , SeidellJ , KoppeschaarH , SmitsP . The effect of fluoxetine on body weight, body composition and visceral fat accumulation. International Journal of Obesity and Related Metabolic Disorders1993;17(5):247-53. ">Visser 1993</a>); two reported 'any adverse event' from four to six months (<a href="./references#CD011688-bbs2-0007" title="DargaL , Carroll-MichalsL , BotsfordS , LucasC . Fluoxetine's effect on weight loss in obese subjects. American Journal of Clinical Nutrition1991;54(2):321-5. GoldsteinD , RampeyA , EnasG , PotvinJ , FludzinskiL , LevineL . Fluoxetine: a randomized clinical trial in the treatment of obesity. International Journal of Obesity and Related Metabolic Disorders1994;18(3):129-35. ">Goldstein 1994</a>; <a href="./references#CD011688-bbs2-0008" title="GuimarãesC , PereiraL , Lucif JúniorN , CesarinoE , AlmeidaC , CarvalhoD , et al. Tolerability and effectiveness of fluoxetine, metformin and sibutramine in reducing anthropometric and metabolic parameters in obese patients. Arquivos Brasileiros de Endocrinologia e Metabologia2006;50(6):1020-5. ">Guimaraes 2006</a>); and one reported 'any adverse event' from 7 to 12 months (<a href="./references#CD011688-bbs2-0006" title="GoldsteinD , RampeyA , DornseifB , LevineL , PotvinJ , FludzinskiL . Fluoxetine: a randomized clinical trial in the maintenance of weight loss. Obesity Research1993;1(2):92-8. ">Goldstein 1993</a>) (<a href="./references#CD011688-fig-0011" title="">Analysis 1.7</a>). The test for subgroup differences did not indicate a statistical significant difference. </p> <p>Two cross‐over trials reported adverse events in the comparison of fluoxetine 60 mg/d with placebo (<a href="./references#CD011688-bbs2-0005" title="Fernández-SotoM , González-JiménezA , Barredo-AcedoF , Luna del CastilloJ , Escobar-JiménezF . Comparison of fluoxetine and placebo in the treatment of obesity. Annals of Nutrition &amp; Metabolism1995;39(3):159-63. ">Fernández‐Soto 1995</a>; <a href="./references#CD011688-bbs2-0011" title="LawtonC , WalesJ , HillA , BlundellJ . Serotoninergic manipulation, meal-induced satiety and eating pattern: effect of fluoxetine in obese female subjects. Obesity Research1995;3(4):345-56. ">Lawton 1995</a>). Adverse events were comparable between intervention and control groups. For further details see <a href="./appendices#CD011688-sec-0131">Appendix 11</a>; <a href="./appendices#CD011688-sec-0132">Appendix 12</a>; <a href="./appendices#CD011688-sec-0133">Appendix 13</a>. </p> <p>Discontinuation of the trial due to an adverse event comparing fluoxetine therapy with placebo had an RR of 1.88 (95% CI 0.87 to 4.06; P = 0.11; 8 trials, 1188 participants; <a href="./references#CD011688-fig-0012" title="">Analysis 1.8</a>). The 95% prediction interval ranged between 0.26 and 13.61. </p> </section> </section> <section id="CD011688-sec-0082"> <h5 class="title">Secondary outcomes</h5> <section id="CD011688-sec-0083"> <h6 class="title">Anthropometric measurements other than weight loss in kilograms (reduction in BMI)</h6> <p>Three trials compared fluoxetine with placebo. The MD in BMI reduction across all fluoxetine doses compared with placebo was −1.1 kg/m² (95% CI −3.7 to 1.4; 3 trials, 97 participants; very low certainty evidence; <a href="./references#CD011688-fig-0013" title="">Analysis 1.9</a>). Calculation of the 95% prediction interval did not provide a meaningful estimate. </p> <p>Subgroup analyses of different fluoxetine doses did not show statistically significant subgroup differences; <a href="./references#CD011688-fig-0013" title="">Analysis 1.9</a>. </p> <p> <ul id="CD011688-list-0017"> <li> <p>For fluoxetine 60 mg/d the MD was −3.3 kg/m² (95% CI −7.3 to 0.7; P = 0.10; 1 trial, 19 participants (<a href="./references#CD011688-bbs2-0008" title="GuimarãesC , PereiraL , Lucif JúniorN , CesarinoE , AlmeidaC , CarvalhoD , et al. Tolerability and effectiveness of fluoxetine, metformin and sibutramine in reducing anthropometric and metabolic parameters in obese patients. Arquivos Brasileiros de Endocrinologia e Metabologia2006;50(6):1020-5. ">Guimaraes 2006</a>)). </p> </li> <li> <p>For fluoxetine 40 mg/d the MD was −2.8 kg/m² (95% CI −8.7 to 3.1; P = 0.35; 1 trial, 18 participants (<a href="./references#CD011688-bbs2-0014" title="PedrinolaF , RissoW , LimaN , MedeirosG . Fluoxetine induced weight loss in overweight subjects: a double-blind placebo-controlled trial. Arquivos Brasileiros de Endocrinologia e Metabologia1993;37:31-3. ">Pedrinola 1993</a>)). </p> </li> <li> <p>For fluoxetine 20 mg/d the MD was 0.2 kg/m² (95% CI −0.6 to 1; P = 0.62; 1 trial, 60 participants (<a href="./references#CD011688-bbs2-0017" title="SuplicyH , BoguszewskiC , Dos SantosC , Do DesterroM , CunhaD , RadomiskiR . A comparative study of five centrally acting drugs on the pharmacological treatment of obesity. International Journal of Obesity2014;38(8):1097-103. ">Suplicy 2014</a>)). </p> </li> </ul> </p> </section> <section id="CD011688-sec-0084"> <h6 class="title">Morbidity (depression)</h6> <p>Three trials compared fluoxetine with placebo on the incidence of depression (<a href="./references#CD011688-bbs2-0006" title="GoldsteinD , RampeyA , DornseifB , LevineL , PotvinJ , FludzinskiL . Fluoxetine: a randomized clinical trial in the maintenance of weight loss. Obesity Research1993;1(2):92-8. ">Goldstein 1993</a>; <a href="./references#CD011688-bbs2-0012" title="LevineL , RosenblattS , BosomworthJ . Use of a serotonin re-uptake inhibitor, fluoxetine, in the treatment of obesity. International Journal of Obesity1987;11(Suppl 3):185-90. ">Levine 1987</a>; <a href="./references#CD011688-bbs2-0017" title="SuplicyH , BoguszewskiC , Dos SantosC , Do DesterroM , CunhaD , RadomiskiR . A comparative study of five centrally acting drugs on the pharmacological treatment of obesity. International Journal of Obesity2014;38(8):1097-103. ">Suplicy 2014</a>). A total of 15 out of 197 participants (7.6%) receiving fluoxetine compared with 12 out of 196 participants (6.1%) receiving placebo experienced depression. The risk ratio across all fluoxetine doses compared with placebo was 1.20 (95% CI 0.57 to 2.52; P = 0.62; 3 trials, 393 participants; very low certainty evidence; <a href="./references#CD011688-fig-0014" title="">Analysis 1.10</a>). Calculation of the 95% prediction interval did not provide a meaningful estimate. </p> <p>Three trials with four trial arms provided data for different doses of fluoxetine (<a href="./references#CD011688-fig-0015" title="">Analysis 1.11</a>). Subgroup analysis did not show a statistically significant subgroup difference. </p> <p> <ul id="CD011688-list-0018"> <li> <p>For fluoxetine 60 mg/d, the RR was 1.41 (95% CI 0.53 to 3.79; P = 0.49; 2 trials, 333 participants) (<a href="./references#CD011688-bbs2-0006" title="GoldsteinD , RampeyA , DornseifB , LevineL , PotvinJ , FludzinskiL . Fluoxetine: a randomized clinical trial in the maintenance of weight loss. Obesity Research1993;1(2):92-8. ">Goldstein 1993</a>; <a href="./references#CD011688-bbs2-0012" title="LevineL , RosenblattS , BosomworthJ . Use of a serotonin re-uptake inhibitor, fluoxetine, in the treatment of obesity. International Journal of Obesity1987;11(Suppl 3):185-90. ">Levine 1987</a>). </p> </li> <li> <p>For fluoxetine 20 mg/d, the RR was 0.58 (95% CI 0.23 to 1.48; P = 0.25; 2 trials, 271 participants) (<a href="./references#CD011688-bbs2-0006" title="GoldsteinD , RampeyA , DornseifB , LevineL , PotvinJ , FludzinskiL . Fluoxetine: a randomized clinical trial in the maintenance of weight loss. Obesity Research1993;1(2):92-8. ">Goldstein 1993</a>; <a href="./references#CD011688-bbs2-0017" title="SuplicyH , BoguszewskiC , Dos SantosC , Do DesterroM , CunhaD , RadomiskiR . A comparative study of five centrally acting drugs on the pharmacological treatment of obesity. International Journal of Obesity2014;38(8):1097-103. ">Suplicy 2014</a>). </p> </li> </ul> </p> </section> <section id="CD011688-sec-0085"> <h6 class="title">All‐cause mortality</h6> <p>None of the trials reported on all‐cause mortality.</p> </section> <section id="CD011688-sec-0086"> <h6 class="title">Socioeconomic effects</h6> <p>None of the trials reported on socioeconomic effects.</p> </section> </section> </section> <section id="CD011688-sec-0087"> <h4 class="title">Fluoxetine compared with another anti‐obesity agent</h4> <p>The certainty of the evidence for all outcomes was very low because of high risk of performance bias, attrition bias and selective reporting, and very serious imprecision (CI consistent with benefit and harm, small number of trials and small number of participants). </p> <section id="CD011688-sec-0088"> <h5 class="title">Primary outcomes</h5> <section id="CD011688-sec-0089"> <h6 class="title">Weight loss (kg)</h6> <p>Three trials (234 participants) compared different doses of fluoxetine with six types of anti‐obesity agents (sibutramine, metformin, dexfenfluramine, diethylpropion, fenproporex and mazindol) (<a href="./references#CD011688-fig-0016" title="">Analysis 2.1</a>). </p> <p> <ul id="CD011688-list-0019"> <li> <p>For fluoxetine 60 mg/d versus sibutramine the MD was 4.3 kg (95% CI −3.2 to 11.8; P = 0.26; 1 trial, 17 participants) (<a href="./references#CD011688-bbs2-0008" title="GuimarãesC , PereiraL , Lucif JúniorN , CesarinoE , AlmeidaC , CarvalhoD , et al. Tolerability and effectiveness of fluoxetine, metformin and sibutramine in reducing anthropometric and metabolic parameters in obese patients. Arquivos Brasileiros de Endocrinologia e Metabologia2006;50(6):1020-5. ">Guimaraes 2006</a>). </p> </li> <li> <p>For fluoxetine 60 mg/d versus metformin the MD was −8.9 kg (95% CI −19.9 to 2.1; P = 0.11; 1 trial, 17 participants) (<a href="./references#CD011688-bbs2-0008" title="GuimarãesC , PereiraL , Lucif JúniorN , CesarinoE , AlmeidaC , CarvalhoD , et al. Tolerability and effectiveness of fluoxetine, metformin and sibutramine in reducing anthropometric and metabolic parameters in obese patients. Arquivos Brasileiros de Endocrinologia e Metabologia2006;50(6):1020-5. ">Guimaraes 2006</a>). </p> </li> <li> <p>For fluoxetine 20 mg/d versus sibutramine the MD was 7 kg (95% CI 4.4 to 9.6; P &lt; 0.001; 1 trial, 61 participants) (<a href="./references#CD011688-bbs2-0017" title="SuplicyH , BoguszewskiC , Dos SantosC , Do DesterroM , CunhaD , RadomiskiR . A comparative study of five centrally acting drugs on the pharmacological treatment of obesity. International Journal of Obesity2014;38(8):1097-103. ">Suplicy 2014</a>). </p> </li> <li> <p>For fluoxetine 20 mg/d versus dexfenfluramine the MD was −0.5 kg (95% CI −3.4 to 2.4; P = 0.73; 1 trial, 58 participants) (<a href="./references#CD011688-bbs2-0019" title="WurtmanJ , WurtmanR , BerryE , GleasonR , GoldbergH , McDermottJ , et al. Dexfenfluramine, fluoxetine, and weight loss among female carbohydrate cravers. Neuropsychopharmacology1993;9(3):201-10. ">Wurtman 1993</a>). </p> </li> <li> <p>For fluoxetine 20 mg/d versus diethylpropion the MD was 7.5 kg (95% CI 4.7 to 10.3; P &lt; 0.001; 1 trial, 61 participants) (<a href="./references#CD011688-bbs2-0017" title="SuplicyH , BoguszewskiC , Dos SantosC , Do DesterroM , CunhaD , RadomiskiR . A comparative study of five centrally acting drugs on the pharmacological treatment of obesity. International Journal of Obesity2014;38(8):1097-103. ">Suplicy 2014</a>). </p> </li> <li> <p>For fluoxetine 20 mg/d versus fenproporex the MD was 5.3 kg (95% CI 2.4 to 8.2; P &lt; 0.001; 1 trial, 62 participants) (<a href="./references#CD011688-bbs2-0017" title="SuplicyH , BoguszewskiC , Dos SantosC , Do DesterroM , CunhaD , RadomiskiR . A comparative study of five centrally acting drugs on the pharmacological treatment of obesity. International Journal of Obesity2014;38(8):1097-103. ">Suplicy 2014</a>). </p> </li> <li> <p>For fluoxetine 20 mg/d versus mazindol the MD was 4.9 kg, 95% CI 2.6 to 7.3; P &lt; 0.001; 1 trial; 60 participants (<a href="./references#CD011688-bbs2-0017" title="SuplicyH , BoguszewskiC , Dos SantosC , Do DesterroM , CunhaD , RadomiskiR . A comparative study of five centrally acting drugs on the pharmacological treatment of obesity. International Journal of Obesity2014;38(8):1097-103. ">Suplicy 2014</a>). </p> </li> </ul> </p> </section> <section id="CD011688-sec-0090"> <h6 class="title">Health‐related quality of life</h6> <p>None of the trials assessed health‐related quality of life.</p> </section> <section id="CD011688-sec-0091"> <h6 class="title">Adverse events</h6> <p>Three trials compared different doses of fluoxetine with six anti‐obesity agents (sibutramine, metformin, dexfenfluramine, diethylpropion, fenproporex and mazindol) for any adverse event (<a href="./references#CD011688-fig-0017" title="">Analysis 2.2</a>). </p> <p> <ul id="CD011688-list-0020"> <li> <p>For fluoxetine 60 mg/d versus sibutramine the RR was 1.19 (95% CI 0.75 to 1.88; P = 0.47; 1 trial, 17 participants) (<a href="./references#CD011688-bbs2-0008" title="GuimarãesC , PereiraL , Lucif JúniorN , CesarinoE , AlmeidaC , CarvalhoD , et al. Tolerability and effectiveness of fluoxetine, metformin and sibutramine in reducing anthropometric and metabolic parameters in obese patients. Arquivos Brasileiros de Endocrinologia e Metabologia2006;50(6):1020-5. ">Guimaraes 2006</a>). </p> </li> <li> <p>For fluoxetine 60 mg/d versus metformin the RR was 1.78 (95% CI 0.86 to 3.69; P = 0.12; 1 trial, 17 participants) (<a href="./references#CD011688-bbs2-0008" title="GuimarãesC , PereiraL , Lucif JúniorN , CesarinoE , AlmeidaC , CarvalhoD , et al. Tolerability and effectiveness of fluoxetine, metformin and sibutramine in reducing anthropometric and metabolic parameters in obese patients. Arquivos Brasileiros de Endocrinologia e Metabologia2006;50(6):1020-5. ">Guimaraes 2006</a>). </p> </li> <li> <p>For fluoxetine 20 mg/d versus sibutramine the RR was 1.58 (95% CI 0.91 to 2.77; P = 0.11; 1 trial, 61 participants) (<a href="./references#CD011688-bbs2-0017" title="SuplicyH , BoguszewskiC , Dos SantosC , Do DesterroM , CunhaD , RadomiskiR . A comparative study of five centrally acting drugs on the pharmacological treatment of obesity. International Journal of Obesity2014;38(8):1097-103. ">Suplicy 2014</a>). </p> </li> <li> <p>For fluoxetine 20 mg/d versus dexfenfluramine the RR was 1.09 (95% CI 0.89 to 1.33; P = 0.42; 1 trial, 59 participants) (<a href="./references#CD011688-bbs2-0019" title="WurtmanJ , WurtmanR , BerryE , GleasonR , GoldbergH , McDermottJ , et al. Dexfenfluramine, fluoxetine, and weight loss among female carbohydrate cravers. Neuropsychopharmacology1993;9(3):201-10. ">Wurtman 1993</a>). </p> </li> <li> <p>For fluoxetine 20 mg/d versus diethylpropion the RR was 1.58 (95% CI 0.91 to 2.77; P = 0.11; 1 trial, 61 participants) (<a href="./references#CD011688-bbs2-0017" title="SuplicyH , BoguszewskiC , Dos SantosC , Do DesterroM , CunhaD , RadomiskiR . A comparative study of five centrally acting drugs on the pharmacological treatment of obesity. International Journal of Obesity2014;38(8):1097-103. ">Suplicy 2014</a>). </p> </li> <li> <p>For fluoxetine 20 mg/d versus fenproporex the RR was 1.20 (95% CI 0.75 to 1.92; P = 0.45; 1 trial, 62 participants) (<a href="./references#CD011688-bbs2-0017" title="SuplicyH , BoguszewskiC , Dos SantosC , Do DesterroM , CunhaD , RadomiskiR . A comparative study of five centrally acting drugs on the pharmacological treatment of obesity. International Journal of Obesity2014;38(8):1097-103. ">Suplicy 2014</a>). </p> </li> <li> <p>For fluoxetine 20 mg/d versus mazindol the RR was 1.05 (95% CI 0.68 to 1.64; P = 0.82; 1 trial, 60 participants) (<a href="./references#CD011688-bbs2-0017" title="SuplicyH , BoguszewskiC , Dos SantosC , Do DesterroM , CunhaD , RadomiskiR . A comparative study of five centrally acting drugs on the pharmacological treatment of obesity. International Journal of Obesity2014;38(8):1097-103. ">Suplicy 2014</a>). </p> </li> </ul> </p> <p>The comparisons of the various anti‐obesity agents with fluoxetine with regard to specific adverse events showed inconclusive findings (<a href="./references#CD011688-fig-0018" title="">Analysis 2.3</a>; <a href="./references#CD011688-fig-0019" title="">Analysis 2.4</a>; <a href="./references#CD011688-fig-0020" title="">Analysis 2.5</a>; <a href="./references#CD011688-fig-0021" title="">Analysis 2.6</a>; <a href="./references#CD011688-fig-0022" title="">Analysis 2.7</a>; <a href="./references#CD011688-fig-0023" title="">Analysis 2.8</a>; <a href="./references#CD011688-fig-0024" title="">Analysis 2.9</a>; <a href="./references#CD011688-fig-0025" title="">Analysis 2.10</a>; <a href="./references#CD011688-fig-0026" title="">Analysis 2.11</a>; <a href="./references#CD011688-fig-0027" title="">Analysis 2.12</a>; <a href="./references#CD011688-fig-0028" title="">Analysis 2.13</a>; <a href="./references#CD011688-fig-0029" title="">Analysis 2.14</a>; <a href="./references#CD011688-fig-0030" title="">Analysis 2.15</a>; <a href="./references#CD011688-fig-0031" title="">Analysis 2.16</a>; <a href="./references#CD011688-fig-0032" title="">Analysis 2.17</a>; <a href="./references#CD011688-fig-0033" title="">Analysis 2.18</a>; <a href="./references#CD011688-fig-0034" title="">Analysis 2.19</a>; <a href="./references#CD011688-fig-0035" title="">Analysis 2.20</a>; <a href="./references#CD011688-fig-0036" title="">Analysis 2.21</a>). </p> </section> </section> <section id="CD011688-sec-0092"> <h5 class="title">Secondary outcomes</h5> <section id="CD011688-sec-0093"> <h6 class="title">Anthropometric measurements other than weight loss in kilograms (reduction in BMI)</h6> <p>Two trials compared different dose of fluoxetine with five types of anti‐obesity agents (sibutramine, metformin, diethylpropion, fenproporex and mazindol); <a href="./references#CD011688-fig-0037" title="">Analysis 2.22</a>. </p> <p> <ul id="CD011688-list-0021"> <li> <p>For fluoxetine 60 mg/d versus sibutramine the MD was −1.5 kg/m² (95% CI −5.2 to 2.2; P = 0.42; 1 trial, 17 participants) (<a href="./references#CD011688-bbs2-0008" title="GuimarãesC , PereiraL , Lucif JúniorN , CesarinoE , AlmeidaC , CarvalhoD , et al. Tolerability and effectiveness of fluoxetine, metformin and sibutramine in reducing anthropometric and metabolic parameters in obese patients. Arquivos Brasileiros de Endocrinologia e Metabologia2006;50(6):1020-5. ">Guimaraes 2006</a>). </p> </li> <li> <p>For fluoxetine 60 mg/d versus metformin the MD was −2.2 kg/m² (95% CI −8.4 to 4; P = 0.48; 1 trial, 17 participants) (<a href="./references#CD011688-bbs2-0008" title="GuimarãesC , PereiraL , Lucif JúniorN , CesarinoE , AlmeidaC , CarvalhoD , et al. Tolerability and effectiveness of fluoxetine, metformin and sibutramine in reducing anthropometric and metabolic parameters in obese patients. Arquivos Brasileiros de Endocrinologia e Metabologia2006;50(6):1020-5. ">Guimaraes 2006</a>). </p> </li> <li> <p>For fluoxetine 20 mg/d versus sibutramine the MD was 2.4 kg/m² (95% CI 1.4 to 3.4; P &lt; 0.001; 1 trial, 61 participants) (<a href="./references#CD011688-bbs2-0017" title="SuplicyH , BoguszewskiC , Dos SantosC , Do DesterroM , CunhaD , RadomiskiR . A comparative study of five centrally acting drugs on the pharmacological treatment of obesity. International Journal of Obesity2014;38(8):1097-103. ">Suplicy 2014</a>). </p> </li> <li> <p>For fluoxetine 20 mg/d versus diethylpropion the MD was 2.9 kg/m² (95% CI 1.8 to 4; P &lt; 0.001; 1 trial, 61 participants) (<a href="./references#CD011688-bbs2-0017" title="SuplicyH , BoguszewskiC , Dos SantosC , Do DesterroM , CunhaD , RadomiskiR . A comparative study of five centrally acting drugs on the pharmacological treatment of obesity. International Journal of Obesity2014;38(8):1097-103. ">Suplicy 2014</a>). </p> </li> <li> <p>For fluoxetine 20 mg/d versus fenproporex the MD was 2 kg/m² (95% CI 0.9 to 3.1; P &lt; 0.001; 1 trial, 62 participants) (<a href="./references#CD011688-bbs2-0017" title="SuplicyH , BoguszewskiC , Dos SantosC , Do DesterroM , CunhaD , RadomiskiR . A comparative study of five centrally acting drugs on the pharmacological treatment of obesity. International Journal of Obesity2014;38(8):1097-103. ">Suplicy 2014</a>). </p> </li> <li> <p>For fluoxetine 20 mg/d versus mazindol the MD was 2 kg/m² (95% CI 1.1 to 2.9; P &lt; 0.001; 1 trial, 60 participants) (<a href="./references#CD011688-bbs2-0017" title="SuplicyH , BoguszewskiC , Dos SantosC , Do DesterroM , CunhaD , RadomiskiR . A comparative study of five centrally acting drugs on the pharmacological treatment of obesity. International Journal of Obesity2014;38(8):1097-103. ">Suplicy 2014</a>). </p> </li> </ul> </p> </section> <section id="CD011688-sec-0094"> <h6 class="title">Morbidity (depression)</h6> <p>Only <a href="./references#CD011688-bbs2-0017" title="SuplicyH , BoguszewskiC , Dos SantosC , Do DesterroM , CunhaD , RadomiskiR . A comparative study of five centrally acting drugs on the pharmacological treatment of obesity. International Journal of Obesity2014;38(8):1097-103. ">Suplicy 2014</a> compared fluoxetine 20 mg/d with four types of anti‐obesity agents (sibutramine, diethylpropion, fenproporex and mazindol). Two comparisons provided data for the outcome depression (<a href="./references#CD011688-fig-0038" title="">Analysis 2.23</a>). </p> <p> <ul id="CD011688-list-0022"> <li> <p>For fluoxetine versus sibutramine the RR was 0.32 (95% CI 0.01 to 7.63; P = 0.48; 1 trial, 61 participants). </p> </li> <li> <p>For fluoxetine versus diethylpropion the RR was 0.19 (95% CI 0.01 to 3.88; P = 0.28; 1 trial, 61 participants). </p> </li> </ul> </p> </section> <section id="CD011688-sec-0095"> <h6 class="title">All‐cause mortality</h6> <p>None of the trials reported on all‐cause mortality.</p> </section> <section id="CD011688-sec-0096"> <h6 class="title">Socioeconomic effects</h6> <p>None of the trials reported on socioeconomic effects.</p> </section> </section> </section> <section id="CD011688-sec-0097"> <h4 class="title">Fluoxetine versus non‐pharmacological therapy</h4> <p>One trial (48 participants) consisting of four trial arms included omega‐3 gel as monotherapy and in combination with fluoxetine (<a href="./references#CD011688-bbs2-0001" title="Al-HelliA , Al-AbbassiM , JasimG , Al-BayatyM . Effects of fluoxetine, omega 3, or their combination on serum leptin in Iraqi obese subjects. International Journal of Pharmaceutical Sciences Review and Research2015;35(1):90-5. ">Al‐Helli 2015</a>). None of the primary or secondary outcomes were reported. </p> </section> <section id="CD011688-sec-0098"> <h4 class="title">Fluoxetine versus no treatment</h4> <p>The certainty of the evidence for all outcomes was very low because of high risk of performance bias and very serious imprecision (one trial only with 60 participants). </p> <section id="CD011688-sec-0099"> <h5 class="title">Primary outcomes</h5> <section id="CD011688-sec-0100"> <h6 class="title">Weight loss (kg)</h6> <p>One trial compared fluoxetine 60 mg/d with no treatment (<a href="./references#CD011688-bbs2-0009" title="HuangC , ChianC , LinJ . Short-term treatment of obesity with fluoxetine as a supplement to a low calorie diet. Changgeng Yi Xue za Zhi [Chang Gung Medical Journal]1998;21(1):50-6. ">Huang 1998</a>). The treatment showed a weight loss from 0 to 3 months with an MD of −2.7 kg in favour of fluoxetine (95% CI −3 to −2.4; P &lt; 0.001; 60 participants, 1 trial) (<a href="./references#CD011688-fig-0039" title="">Analysis 3.1</a>). </p> </section> <section id="CD011688-sec-0101"> <h6 class="title">Health‐related quality of life</h6> <p>This outcome was not reported.</p> </section> <section id="CD011688-sec-0102"> <h6 class="title">Adverse events</h6> <p>There was an increase in the risk of at least one adverse event in the fluoxetine 60 mg/d group compared with the no‐treatment group (RR 8.67, 95% CI 2.94 to 25.59; P &lt; 0.001; 60 participants, 1 trial) (<a href="./references#CD011688-fig-0040" title="">Analysis 3.2</a>). </p> <p>Comparisons for allergy, diarrhoea, headache, insomnia, malaise and drowsiness showed inconclusive results. Fluoxetine was associated with increased anorexia (RR 26.00, 95% CI 3.77 to 179.51; P &lt; 0.001; 1 trial, 60 participants) and nausea (RR 8.00, 95% CI 1.07 to 60.09; P = 0.04; 1 trial, 60 participants) (<a href="./references#CD011688-fig-0040" title="">Analysis 3.2</a>). </p> </section> </section> <section id="CD011688-sec-0103"> <h5 class="title">Secondary outcomes</h5> <p>Morbidity, all‐cause mortality or socioeconomic effects were not reported.</p> <section id="CD011688-sec-0104"> <h6 class="title">Anthropometric measurements other than weight loss in kilograms (reduction in BMI)</h6> <p>The MD was −0.5 kg/m² in favour of fluoxetine (95% CI −0.6 to −0.3; P &lt; 0.001; 1 trial, 60 participants) (<a href="./references#CD011688-fig-0041" title="">Analysis 3.3</a>). </p> </section> </section> </section> <section id="CD011688-sec-0105"> <h4 class="title">Subgroup analyses</h4> <p>We only performed subgroup analyses for fluoxetine doses and duration of intervention for the outcome measures 'weight loss and adverse events' for fluoxetine versus placebo, because there were not enough trials to estimate effects for the other subgroups. </p> </section> <section id="CD011688-sec-0106"> <h4 class="title">Sensitivity analyses</h4> <p>We did not perform sensitivity analyses because we could not include enough trials.</p> </section> <section id="CD011688-sec-0107"> <h4 class="title">Assessment of reporting bias</h4> <p>We did not draw funnel plots because of the limited number of trials for a particular outcome. </p> </section> <section id="CD011688-sec-0108"> <h4 class="title">Ongoing trials</h4> <p>We did not find ongoing trials.</p> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD011688-sec-0109" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD011688-sec-0109"></div> <section id="CD011688-sec-0110"> <h3 class="title" id="CD011688-sec-0110">Summary of main results</h3> <p>We included 19 published trials in this review (one record is awaiting assessment), out of which 15 were parallel trials, and four had a cross‐over design. There were a total of 2216 overweight or obese participants without depression, mental illness or abnormal eating patterns who were followed up for between three weeks and one year. In 16 trials BMI was the diagnostic criterion. </p> <p>The 19 included trials in the review had a great variety of interventions with overall 56 trial arms. Out of the total number of participants entered in completed studies, 1280 were assigned to four fluoxetine groups according to the dose administered (60 mg/d, 40 mg/d, 20 mg/d and 10 mg/d) and 936 participants were randomly assigned to 12 comparison groups: A) placebo, our main comparison, in 18 trials; B) anti‐obesity agents (diethylpropion, fenproporex, mazindol, sibutramine, metformin, fenfluramine, dexfenfluramine, fluvoxamine and 5‐hydroxy‐tryptophan) in four trials; C) no treatment in one trial; and D) non‐pharmacological treatment (omega‐3 gel) in another trial. </p> <p>The outcomes assessed also varied among the included trials as: biochemical parameters (glucose, urea, uric acid, serum lipids, cholesterol, triglycerides, fasting glucose, fasting insulin, glycated haemoglobin, insulin resistance, HOMA, glucose‐induced thermogenesis, nitrogen balance, resting energy expenditure); anthropometric measurements (waist circumference, abdominal circumference, fatty tissue); cardiovascular parameters (blood pressure, heart rate, oxygen consumption, arterial oxygen saturation, changes in the electrocardiogram); and others composite outcomes (appetite, energy intake, macronutrient intake, resting metabolic rate, satiety, resting respiratory quotient, sleep‐breathing patterns). </p> <p>Overall, the results of this systematic review suggest that 60 mg/d fluoxetine compared with placebo decreased weight by 2.5 kg; however the 95% prediction interval ranged between a 6.4 kg weight loss and a 1.4 kg weight increase. The adverse events of dizziness, drowsiness, fatigue, insomnia and nausea were observed approximately twice as often following treatment. There were no clear differences between fluoxetine and placebo with regard to morbidity (depression). All‐cause mortality, health‐related quality of life and socioeconomic effects were not reported. The comparisons of fluoxetine with other anti‐obesity agents (3 trials, 234 participants), omega‐3 gel (1 trial, 48 participants) and no treatment (1 trial, 60 participants) showed inconclusive results (very low certainty evidence). </p> </section> <section id="CD011688-sec-0111"> <h3 class="title" id="CD011688-sec-0111">Overall completeness and applicability of evidence</h3> <p>This review included 19 trials with the main comparison being fluoxetine versus placebo. Our included trials did not report on 'all‐cause mortality', 'health‐related quality of life' and 'socioeconomic effects' and there is a high degree of uncertainty regarding these outcome measures. Also, limited data were available for depression as a morbidity outcome. </p> </section> <section id="CD011688-sec-0112"> <h3 class="title" id="CD011688-sec-0112">Quality of the evidence</h3> <p>We identified a great variety of doses and durations of treatment in the intervention groups, many different groups of comparators, and variation in the diagnostic criteria and characteristics of the grade of obesity in the participants, which limited comparability and increased the heterogeneity between trials. </p> <p>In most trials, the risk of selection bias was unclear, because their reports did not mention in detail the methods of random sequence generation and concealment of allocation. Blinding of outcome assessment was unclear in almost all trials. Approximately one‐third of the trials had a high risk of bias due to attrition rates of up 20% of their participants and almost half of the trials had a high risk of reporting bias. </p> <p>The certainty of the evidence for all outcomes was overall low or very low, mainly because of risk of bias and serious imprecision due to low number of trials and participants, and CIs being consistent with benefit and harm. </p> </section> <section id="CD011688-sec-0113"> <h3 class="title" id="CD011688-sec-0113">Potential biases in the review process</h3> <p>This review was performed using standard Cochrane methodology and without any restrictions regarding the language or date of publication. All included trials were selected and assessed, and data were extracted by three review authors to minimise biases in the process of the review. When we identified substantial heterogeneity, we tried to reduce it by data stratification. When data were missing, we attempted to contact the trial authors. However, most of the trials were conducted in the late 1980s and early 1990s and information obtained from trial authors was very limited. </p> </section> <section id="CD011688-sec-0114"> <h3 class="title" id="CD011688-sec-0114">Agreements and disagreements with other studies or reviews</h3> <p>The finding of our review are consistent with those of previous systematic reviews conducted in other populations, which demonstrated a weight loss of 5.1 kg (95% CI 3.4 to 6.83; 4 trials, 97 participants) compared with placebo in participants with type 2 diabetes who received fluoxetine for 24 weeks to 26 weeks (<a href="./references#CD011688-bbs2-0094" title="NorrisSL , ZhangX , AvenellA , GreggE , SchmidCH , LauJ . Pharmacotherapy for weight loss in adults with type 2 diabetes mellitus. Cochrane Database of Systematic Reviews2005, Issue 1. Art. No: CD004096. [DOI: 10.1002/14651858.CD004096.pub2]">Norris 2005</a>); and 4.3 kg (95% CI 2.6 to 6; 5 trials, 213 participants) compared with placebo in participants who received fluoxetine for up to 12 months (<a href="./references#CD011688-bbs2-0111" title="YeZ , ChenL , YangZ , LiQ , HuangY , HeM , et al. Metabolic effects of fluoxetine in adults with type 2 diabetes mellitus: a meta-analysis of randomised placebo-controlled trials. PloS One2011;6(7):e21551. [DOI: 10.1371/journal.pone.0021551]">Ye 2011</a>). Another systematic review reported a weight loss of 1.3 kg (95% CI 0.2 to 2.4; 19 trials) in overweight or obese adults (BMI of 26 kg/m² to 39 kg/m²) treated with fluoxetine between 4 and 12 months compared with placebo (<a href="./references#CD011688-bbs2-0066" title="DomecqJP , PrutskyG , LeppinA , SonbolMB , AltayarO , UndavalliC , et al. Clinical review: drugs commonly associated with weight change: a systematic review and meta-analysis. Journal of Clinical Endocrinology and Metabolism2015;100(2):363-70. [DOI: 10.1210/jc.2014-3421]">Domecq 2015</a>). </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD011688-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011688.pub2/media/CDSR/CD011688/urn:x-wiley:14651858:media:CD011688:CD011688-FIG-01" target="_blank"><b></b></a></p> </div><img alt="Trial flow diagram." data-id="CD011688-fig-0001" src="/cdsr/doi/10.1002/14651858.CD011688.pub2/media/CDSR/CD011688/image_n/nCD011688-FIG-01.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011688.pub2/media/CDSR/CD011688/image_t/tCD011688-FIG-01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Trial flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011688.pub2/full#CD011688-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011688.pub2/media/CDSR/CD011688/image_n/nCD011688-FIG-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011688-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011688.pub2/media/CDSR/CD011688/urn:x-wiley:14651858:media:CD011688:CD011688-FIG-02" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included trials (blank cells indicate that the particular outcome was not measured in some trials)." data-id="CD011688-fig-0002" src="/cdsr/doi/10.1002/14651858.CD011688.pub2/media/CDSR/CD011688/image_n/nCD011688-FIG-02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011688.pub2/media/CDSR/CD011688/image_t/tCD011688-FIG-02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included trials (blank cells indicate that the particular outcome was not measured in some trials). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011688.pub2/full#CD011688-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011688.pub2/media/CDSR/CD011688/image_n/nCD011688-FIG-02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011688-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011688.pub2/media/CDSR/CD011688/urn:x-wiley:14651858:media:CD011688:CD011688-FIG-03" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included trial ((blank cells indicate that the particular outcome was not measured in some trials)." data-id="CD011688-fig-0003" src="/cdsr/doi/10.1002/14651858.CD011688.pub2/media/CDSR/CD011688/image_n/nCD011688-FIG-03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011688.pub2/media/CDSR/CD011688/image_t/tCD011688-FIG-03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included trial ((blank cells indicate that the particular outcome was not measured in some trials). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011688.pub2/full#CD011688-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011688.pub2/media/CDSR/CD011688/image_n/nCD011688-FIG-03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011688-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011688.pub2/media/CDSR/CD011688/urn:x-wiley:14651858:media:CD011688:CD011688-FIG-04" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: Fluoxetine versus placebo (parallel RCTs), outcome: 1.1 Weight loss, end of trial weight [kg]." data-id="CD011688-fig-0004" src="/cdsr/doi/10.1002/14651858.CD011688.pub2/media/CDSR/CD011688/image_n/nCD011688-FIG-04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011688.pub2/media/CDSR/CD011688/image_t/tCD011688-FIG-04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Forest plot of comparison: Fluoxetine versus placebo (parallel RCTs), outcome: 1.1 Weight loss, end of trial weight [kg]. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011688.pub2/full#CD011688-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011688.pub2/media/CDSR/CD011688/image_n/nCD011688-FIG-04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011688-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011688.pub2/media/CDSR/CD011688/urn:x-wiley:14651858:media:CD011688:CD011688-CMP-001.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Fluoxetine versus placebo, Outcome 1: Weight loss (end of trial weight)" data-id="CD011688-fig-0005" src="/cdsr/doi/10.1002/14651858.CD011688.pub2/media/CDSR/CD011688/image_n/nCD011688-CMP-001.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011688.pub2/media/CDSR/CD011688/image_t/tCD011688-CMP-001.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1: Fluoxetine versus placebo, Outcome 1: Weight loss (end of trial weight)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011688.pub2/references#CD011688-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011688.pub2/media/CDSR/CD011688/image_n/nCD011688-CMP-001.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011688-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011688.pub2/media/CDSR/CD011688/urn:x-wiley:14651858:media:CD011688:CD011688-CMP-001.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Fluoxetine versus placebo, Outcome 2: Weight loss (duration of intervention)" data-id="CD011688-fig-0006" src="/cdsr/doi/10.1002/14651858.CD011688.pub2/media/CDSR/CD011688/image_n/nCD011688-CMP-001.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011688.pub2/media/CDSR/CD011688/image_t/tCD011688-CMP-001.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1: Fluoxetine versus placebo, Outcome 2: Weight loss (duration of intervention)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011688.pub2/references#CD011688-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011688.pub2/media/CDSR/CD011688/image_n/nCD011688-CMP-001.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011688-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011688.pub2/media/CDSR/CD011688/urn:x-wiley:14651858:media:CD011688:CD011688-CMP-001.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Fluoxetine versus placebo, Outcome 3: Weight loss (cross‐over trial)" data-id="CD011688-fig-0007" src="/cdsr/doi/10.1002/14651858.CD011688.pub2/media/CDSR/CD011688/image_n/nCD011688-CMP-001.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011688.pub2/media/CDSR/CD011688/image_t/tCD011688-CMP-001.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1: Fluoxetine versus placebo, Outcome 3: Weight loss (cross‐over trial)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011688.pub2/references#CD011688-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011688.pub2/media/CDSR/CD011688/image_n/nCD011688-CMP-001.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011688-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011688.pub2/media/CDSR/CD011688/urn:x-wiley:14651858:media:CD011688:CD011688-CMP-001.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Fluoxetine versus placebo, Outcome 4: Any adverse event" data-id="CD011688-fig-0008" src="/cdsr/doi/10.1002/14651858.CD011688.pub2/media/CDSR/CD011688/image_n/nCD011688-CMP-001.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011688.pub2/media/CDSR/CD011688/image_t/tCD011688-CMP-001.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1: Fluoxetine versus placebo, Outcome 4: Any adverse event</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011688.pub2/references#CD011688-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011688.pub2/media/CDSR/CD011688/image_n/nCD011688-CMP-001.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011688-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011688.pub2/media/CDSR/CD011688/urn:x-wiley:14651858:media:CD011688:CD011688-CMP-001.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Fluoxetine versus placebo, Outcome 5: Specific adverse events" data-id="CD011688-fig-0009" src="/cdsr/doi/10.1002/14651858.CD011688.pub2/media/CDSR/CD011688/image_n/nCD011688-CMP-001.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011688.pub2/media/CDSR/CD011688/image_t/tCD011688-CMP-001.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1: Fluoxetine versus placebo, Outcome 5: Specific adverse events</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011688.pub2/references#CD011688-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011688.pub2/media/CDSR/CD011688/image_n/nCD011688-CMP-001.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011688-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011688.pub2/media/CDSR/CD011688/urn:x-wiley:14651858:media:CD011688:CD011688-CMP-001.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Fluoxetine versus placebo, Outcome 6: Participants with any adverse event (per dose)" data-id="CD011688-fig-0010" src="/cdsr/doi/10.1002/14651858.CD011688.pub2/media/CDSR/CD011688/image_n/nCD011688-CMP-001.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011688.pub2/media/CDSR/CD011688/image_t/tCD011688-CMP-001.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1: Fluoxetine versus placebo, Outcome 6: Participants with any adverse event (per dose) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011688.pub2/references#CD011688-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011688.pub2/media/CDSR/CD011688/image_n/nCD011688-CMP-001.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011688-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011688.pub2/media/CDSR/CD011688/urn:x-wiley:14651858:media:CD011688:CD011688-CMP-001.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Fluoxetine versus placebo, Outcome 7: Participants with any adverse event (duration of intervention)" data-id="CD011688-fig-0011" src="/cdsr/doi/10.1002/14651858.CD011688.pub2/media/CDSR/CD011688/image_n/nCD011688-CMP-001.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011688.pub2/media/CDSR/CD011688/image_t/tCD011688-CMP-001.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1: Fluoxetine versus placebo, Outcome 7: Participants with any adverse event (duration of intervention) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011688.pub2/references#CD011688-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011688.pub2/media/CDSR/CD011688/image_n/nCD011688-CMP-001.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011688-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011688.pub2/media/CDSR/CD011688/urn:x-wiley:14651858:media:CD011688:CD011688-CMP-001.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Fluoxetine versus placebo, Outcome 8: Participants discontinuing due to adverse events" data-id="CD011688-fig-0012" src="/cdsr/doi/10.1002/14651858.CD011688.pub2/media/CDSR/CD011688/image_n/nCD011688-CMP-001.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011688.pub2/media/CDSR/CD011688/image_t/tCD011688-CMP-001.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1: Fluoxetine versus placebo, Outcome 8: Participants discontinuing due to adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011688.pub2/references#CD011688-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011688.pub2/media/CDSR/CD011688/image_n/nCD011688-CMP-001.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011688-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011688.pub2/media/CDSR/CD011688/urn:x-wiley:14651858:media:CD011688:CD011688-CMP-001.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Fluoxetine versus placebo, Outcome 9: Anthropometric measurements other than weight loss (BMI)" data-id="CD011688-fig-0013" src="/cdsr/doi/10.1002/14651858.CD011688.pub2/media/CDSR/CD011688/image_n/nCD011688-CMP-001.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011688.pub2/media/CDSR/CD011688/image_t/tCD011688-CMP-001.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1: Fluoxetine versus placebo, Outcome 9: Anthropometric measurements other than weight loss (BMI) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011688.pub2/references#CD011688-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011688.pub2/media/CDSR/CD011688/image_n/nCD011688-CMP-001.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011688-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011688.pub2/media/CDSR/CD011688/urn:x-wiley:14651858:media:CD011688:CD011688-CMP-001.10" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Fluoxetine versus placebo, Outcome 10: Morbidity (depression)" data-id="CD011688-fig-0014" src="/cdsr/doi/10.1002/14651858.CD011688.pub2/media/CDSR/CD011688/image_n/nCD011688-CMP-001.10.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011688.pub2/media/CDSR/CD011688/image_t/tCD011688-CMP-001.10.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.10</div> <div class="figure-caption"> <p>Comparison 1: Fluoxetine versus placebo, Outcome 10: Morbidity (depression)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011688.pub2/references#CD011688-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011688.pub2/media/CDSR/CD011688/image_n/nCD011688-CMP-001.10.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011688-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011688.pub2/media/CDSR/CD011688/urn:x-wiley:14651858:media:CD011688:CD011688-CMP-001.11" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Fluoxetine versus placebo, Outcome 11: Morbidity (depression per dose)" data-id="CD011688-fig-0015" src="/cdsr/doi/10.1002/14651858.CD011688.pub2/media/CDSR/CD011688/image_n/nCD011688-CMP-001.11.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011688.pub2/media/CDSR/CD011688/image_t/tCD011688-CMP-001.11.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.11</div> <div class="figure-caption"> <p>Comparison 1: Fluoxetine versus placebo, Outcome 11: Morbidity (depression per dose)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011688.pub2/references#CD011688-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011688.pub2/media/CDSR/CD011688/image_n/nCD011688-CMP-001.11.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011688-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011688.pub2/media/CDSR/CD011688/urn:x-wiley:14651858:media:CD011688:CD011688-CMP-002.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Fluoxetine versus another anti‐obesity agent, Outcome 1: Weight loss, end of trial weight" data-id="CD011688-fig-0016" src="/cdsr/doi/10.1002/14651858.CD011688.pub2/media/CDSR/CD011688/image_n/nCD011688-CMP-002.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011688.pub2/media/CDSR/CD011688/image_t/tCD011688-CMP-002.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2: Fluoxetine versus another anti‐obesity agent, Outcome 1: Weight loss, end of trial weight </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011688.pub2/references#CD011688-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011688.pub2/media/CDSR/CD011688/image_n/nCD011688-CMP-002.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011688-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011688.pub2/media/CDSR/CD011688/urn:x-wiley:14651858:media:CD011688:CD011688-CMP-002.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Fluoxetine versus another anti‐obesity agent, Outcome 2: Any adverse event" data-id="CD011688-fig-0017" src="/cdsr/doi/10.1002/14651858.CD011688.pub2/media/CDSR/CD011688/image_n/nCD011688-CMP-002.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011688.pub2/media/CDSR/CD011688/image_t/tCD011688-CMP-002.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2: Fluoxetine versus another anti‐obesity agent, Outcome 2: Any adverse event </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011688.pub2/references#CD011688-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011688.pub2/media/CDSR/CD011688/image_n/nCD011688-CMP-002.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011688-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011688.pub2/media/CDSR/CD011688/urn:x-wiley:14651858:media:CD011688:CD011688-CMP-002.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Fluoxetine versus another anti‐obesity agent, Outcome 3: Adverse events (abdominal pain)" data-id="CD011688-fig-0018" src="/cdsr/doi/10.1002/14651858.CD011688.pub2/media/CDSR/CD011688/image_n/nCD011688-CMP-002.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011688.pub2/media/CDSR/CD011688/image_t/tCD011688-CMP-002.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2: Fluoxetine versus another anti‐obesity agent, Outcome 3: Adverse events (abdominal pain) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011688.pub2/references#CD011688-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011688.pub2/media/CDSR/CD011688/image_n/nCD011688-CMP-002.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011688-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011688.pub2/media/CDSR/CD011688/urn:x-wiley:14651858:media:CD011688:CD011688-CMP-002.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Fluoxetine versus another anti‐obesity agent, Outcome 4: Adverse events (allergy)" data-id="CD011688-fig-0019" src="/cdsr/doi/10.1002/14651858.CD011688.pub2/media/CDSR/CD011688/image_n/nCD011688-CMP-002.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011688.pub2/media/CDSR/CD011688/image_t/tCD011688-CMP-002.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2: Fluoxetine versus another anti‐obesity agent, Outcome 4: Adverse events (allergy) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011688.pub2/references#CD011688-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011688.pub2/media/CDSR/CD011688/image_n/nCD011688-CMP-002.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011688-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011688.pub2/media/CDSR/CD011688/urn:x-wiley:14651858:media:CD011688:CD011688-CMP-002.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Fluoxetine versus another anti‐obesity agent, Outcome 5: Adverse events (anorexia)" data-id="CD011688-fig-0020" src="/cdsr/doi/10.1002/14651858.CD011688.pub2/media/CDSR/CD011688/image_n/nCD011688-CMP-002.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011688.pub2/media/CDSR/CD011688/image_t/tCD011688-CMP-002.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2: Fluoxetine versus another anti‐obesity agent, Outcome 5: Adverse events (anorexia) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011688.pub2/references#CD011688-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011688.pub2/media/CDSR/CD011688/image_n/nCD011688-CMP-002.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011688-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011688.pub2/media/CDSR/CD011688/urn:x-wiley:14651858:media:CD011688:CD011688-CMP-002.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Fluoxetine versus another anti‐obesity agent, Outcome 6: Adverse events (anxiety)" data-id="CD011688-fig-0021" src="/cdsr/doi/10.1002/14651858.CD011688.pub2/media/CDSR/CD011688/image_n/nCD011688-CMP-002.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011688.pub2/media/CDSR/CD011688/image_t/tCD011688-CMP-002.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.6</div> <div class="figure-caption"> <p>Comparison 2: Fluoxetine versus another anti‐obesity agent, Outcome 6: Adverse events (anxiety) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011688.pub2/references#CD011688-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011688.pub2/media/CDSR/CD011688/image_n/nCD011688-CMP-002.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011688-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011688.pub2/media/CDSR/CD011688/urn:x-wiley:14651858:media:CD011688:CD011688-CMP-002.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Fluoxetine versus another anti‐obesity agent, Outcome 7: Adverse events (constipation)" data-id="CD011688-fig-0022" src="/cdsr/doi/10.1002/14651858.CD011688.pub2/media/CDSR/CD011688/image_n/nCD011688-CMP-002.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011688.pub2/media/CDSR/CD011688/image_t/tCD011688-CMP-002.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.7</div> <div class="figure-caption"> <p>Comparison 2: Fluoxetine versus another anti‐obesity agent, Outcome 7: Adverse events (constipation) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011688.pub2/references#CD011688-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011688.pub2/media/CDSR/CD011688/image_n/nCD011688-CMP-002.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011688-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011688.pub2/media/CDSR/CD011688/urn:x-wiley:14651858:media:CD011688:CD011688-CMP-002.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Fluoxetine versus another anti‐obesity agent, Outcome 8: Adverse events (diarrhoea)" data-id="CD011688-fig-0023" src="/cdsr/doi/10.1002/14651858.CD011688.pub2/media/CDSR/CD011688/image_n/nCD011688-CMP-002.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011688.pub2/media/CDSR/CD011688/image_t/tCD011688-CMP-002.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.8</div> <div class="figure-caption"> <p>Comparison 2: Fluoxetine versus another anti‐obesity agent, Outcome 8: Adverse events (diarrhoea) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011688.pub2/references#CD011688-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011688.pub2/media/CDSR/CD011688/image_n/nCD011688-CMP-002.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011688-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011688.pub2/media/CDSR/CD011688/urn:x-wiley:14651858:media:CD011688:CD011688-CMP-002.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Fluoxetine versus another anti‐obesity agent, Outcome 9: Adverse events (dizziness)" data-id="CD011688-fig-0024" src="/cdsr/doi/10.1002/14651858.CD011688.pub2/media/CDSR/CD011688/image_n/nCD011688-CMP-002.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011688.pub2/media/CDSR/CD011688/image_t/tCD011688-CMP-002.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.9</div> <div class="figure-caption"> <p>Comparison 2: Fluoxetine versus another anti‐obesity agent, Outcome 9: Adverse events (dizziness) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011688.pub2/references#CD011688-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011688.pub2/media/CDSR/CD011688/image_n/nCD011688-CMP-002.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011688-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011688.pub2/media/CDSR/CD011688/urn:x-wiley:14651858:media:CD011688:CD011688-CMP-002.10" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Fluoxetine versus another anti‐obesity agent, Outcome 10: Adverse events (drowsiness)" data-id="CD011688-fig-0025" src="/cdsr/doi/10.1002/14651858.CD011688.pub2/media/CDSR/CD011688/image_n/nCD011688-CMP-002.10.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011688.pub2/media/CDSR/CD011688/image_t/tCD011688-CMP-002.10.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.10</div> <div class="figure-caption"> <p>Comparison 2: Fluoxetine versus another anti‐obesity agent, Outcome 10: Adverse events (drowsiness) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011688.pub2/references#CD011688-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011688.pub2/media/CDSR/CD011688/image_n/nCD011688-CMP-002.10.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011688-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011688.pub2/media/CDSR/CD011688/urn:x-wiley:14651858:media:CD011688:CD011688-CMP-002.11" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Fluoxetine versus another anti‐obesity agent, Outcome 11: Adverse events (dry mouth)" data-id="CD011688-fig-0026" src="/cdsr/doi/10.1002/14651858.CD011688.pub2/media/CDSR/CD011688/image_n/nCD011688-CMP-002.11.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011688.pub2/media/CDSR/CD011688/image_t/tCD011688-CMP-002.11.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.11</div> <div class="figure-caption"> <p>Comparison 2: Fluoxetine versus another anti‐obesity agent, Outcome 11: Adverse events (dry mouth) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011688.pub2/references#CD011688-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011688.pub2/media/CDSR/CD011688/image_n/nCD011688-CMP-002.11.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011688-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011688.pub2/media/CDSR/CD011688/urn:x-wiley:14651858:media:CD011688:CD011688-CMP-002.12" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Fluoxetine versus another anti‐obesity agent, Outcome 12: Adverse events (dyspepsia)" data-id="CD011688-fig-0027" src="/cdsr/doi/10.1002/14651858.CD011688.pub2/media/CDSR/CD011688/image_n/nCD011688-CMP-002.12.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011688.pub2/media/CDSR/CD011688/image_t/tCD011688-CMP-002.12.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.12</div> <div class="figure-caption"> <p>Comparison 2: Fluoxetine versus another anti‐obesity agent, Outcome 12: Adverse events (dyspepsia) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011688.pub2/references#CD011688-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011688.pub2/media/CDSR/CD011688/image_n/nCD011688-CMP-002.12.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011688-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011688.pub2/media/CDSR/CD011688/urn:x-wiley:14651858:media:CD011688:CD011688-CMP-002.13" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Fluoxetine versus another anti‐obesity agent, Outcome 13: Adverse events (fatigue)" data-id="CD011688-fig-0028" src="/cdsr/doi/10.1002/14651858.CD011688.pub2/media/CDSR/CD011688/image_n/nCD011688-CMP-002.13.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011688.pub2/media/CDSR/CD011688/image_t/tCD011688-CMP-002.13.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.13</div> <div class="figure-caption"> <p>Comparison 2: Fluoxetine versus another anti‐obesity agent, Outcome 13: Adverse events (fatigue) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011688.pub2/references#CD011688-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011688.pub2/media/CDSR/CD011688/image_n/nCD011688-CMP-002.13.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011688-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011688.pub2/media/CDSR/CD011688/urn:x-wiley:14651858:media:CD011688:CD011688-CMP-002.14" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Fluoxetine versus another anti‐obesity agent, Outcome 14: Adverse events (headache)" data-id="CD011688-fig-0029" src="/cdsr/doi/10.1002/14651858.CD011688.pub2/media/CDSR/CD011688/image_n/nCD011688-CMP-002.14.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011688.pub2/media/CDSR/CD011688/image_t/tCD011688-CMP-002.14.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.14</div> <div class="figure-caption"> <p>Comparison 2: Fluoxetine versus another anti‐obesity agent, Outcome 14: Adverse events (headache) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011688.pub2/references#CD011688-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011688.pub2/media/CDSR/CD011688/image_n/nCD011688-CMP-002.14.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011688-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011688.pub2/media/CDSR/CD011688/urn:x-wiley:14651858:media:CD011688:CD011688-CMP-002.15" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Fluoxetine versus another anti‐obesity agent, Outcome 15: Adverse events (insomnia)" data-id="CD011688-fig-0030" src="/cdsr/doi/10.1002/14651858.CD011688.pub2/media/CDSR/CD011688/image_n/nCD011688-CMP-002.15.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011688.pub2/media/CDSR/CD011688/image_t/tCD011688-CMP-002.15.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.15</div> <div class="figure-caption"> <p>Comparison 2: Fluoxetine versus another anti‐obesity agent, Outcome 15: Adverse events (insomnia) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011688.pub2/references#CD011688-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011688.pub2/media/CDSR/CD011688/image_n/nCD011688-CMP-002.15.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011688-fig-0031"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011688.pub2/media/CDSR/CD011688/urn:x-wiley:14651858:media:CD011688:CD011688-CMP-002.16" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Fluoxetine versus another anti‐obesity agent, Outcome 16: Adverse events (irritability)" data-id="CD011688-fig-0031" src="/cdsr/doi/10.1002/14651858.CD011688.pub2/media/CDSR/CD011688/image_n/nCD011688-CMP-002.16.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011688.pub2/media/CDSR/CD011688/image_t/tCD011688-CMP-002.16.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.16</div> <div class="figure-caption"> <p>Comparison 2: Fluoxetine versus another anti‐obesity agent, Outcome 16: Adverse events (irritability) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011688.pub2/references#CD011688-fig-0031">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011688.pub2/media/CDSR/CD011688/image_n/nCD011688-CMP-002.16.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011688-fig-0032"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011688.pub2/media/CDSR/CD011688/urn:x-wiley:14651858:media:CD011688:CD011688-CMP-002.17" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Fluoxetine versus another anti‐obesity agent, Outcome 17: Adverse events (malaise)" data-id="CD011688-fig-0032" src="/cdsr/doi/10.1002/14651858.CD011688.pub2/media/CDSR/CD011688/image_n/nCD011688-CMP-002.17.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011688.pub2/media/CDSR/CD011688/image_t/tCD011688-CMP-002.17.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.17</div> <div class="figure-caption"> <p>Comparison 2: Fluoxetine versus another anti‐obesity agent, Outcome 17: Adverse events (malaise) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011688.pub2/references#CD011688-fig-0032">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011688.pub2/media/CDSR/CD011688/image_n/nCD011688-CMP-002.17.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011688-fig-0033"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011688.pub2/media/CDSR/CD011688/urn:x-wiley:14651858:media:CD011688:CD011688-CMP-002.18" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Fluoxetine versus another anti‐obesity agent, Outcome 18: Adverse events (nausea)" data-id="CD011688-fig-0033" src="/cdsr/doi/10.1002/14651858.CD011688.pub2/media/CDSR/CD011688/image_n/nCD011688-CMP-002.18.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011688.pub2/media/CDSR/CD011688/image_t/tCD011688-CMP-002.18.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.18</div> <div class="figure-caption"> <p>Comparison 2: Fluoxetine versus another anti‐obesity agent, Outcome 18: Adverse events (nausea) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011688.pub2/references#CD011688-fig-0033">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011688.pub2/media/CDSR/CD011688/image_n/nCD011688-CMP-002.18.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011688-fig-0034"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011688.pub2/media/CDSR/CD011688/urn:x-wiley:14651858:media:CD011688:CD011688-CMP-002.19" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Fluoxetine versus another anti‐obesity agent, Outcome 19: Adverse events (palpitation)" data-id="CD011688-fig-0034" src="/cdsr/doi/10.1002/14651858.CD011688.pub2/media/CDSR/CD011688/image_n/nCD011688-CMP-002.19.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011688.pub2/media/CDSR/CD011688/image_t/tCD011688-CMP-002.19.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.19</div> <div class="figure-caption"> <p>Comparison 2: Fluoxetine versus another anti‐obesity agent, Outcome 19: Adverse events (palpitation) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011688.pub2/references#CD011688-fig-0034">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011688.pub2/media/CDSR/CD011688/image_n/nCD011688-CMP-002.19.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011688-fig-0035"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011688.pub2/media/CDSR/CD011688/urn:x-wiley:14651858:media:CD011688:CD011688-CMP-002.20" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Fluoxetine versus another anti‐obesity agent, Outcome 20: Adverse events (sweating)" data-id="CD011688-fig-0035" src="/cdsr/doi/10.1002/14651858.CD011688.pub2/media/CDSR/CD011688/image_n/nCD011688-CMP-002.20.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011688.pub2/media/CDSR/CD011688/image_t/tCD011688-CMP-002.20.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.20</div> <div class="figure-caption"> <p>Comparison 2: Fluoxetine versus another anti‐obesity agent, Outcome 20: Adverse events (sweating) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011688.pub2/references#CD011688-fig-0035">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011688.pub2/media/CDSR/CD011688/image_n/nCD011688-CMP-002.20.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011688-fig-0036"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011688.pub2/media/CDSR/CD011688/urn:x-wiley:14651858:media:CD011688:CD011688-CMP-002.21" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Fluoxetine versus another anti‐obesity agent, Outcome 21: Adverse events (tremor)" data-id="CD011688-fig-0036" src="/cdsr/doi/10.1002/14651858.CD011688.pub2/media/CDSR/CD011688/image_n/nCD011688-CMP-002.21.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011688.pub2/media/CDSR/CD011688/image_t/tCD011688-CMP-002.21.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.21</div> <div class="figure-caption"> <p>Comparison 2: Fluoxetine versus another anti‐obesity agent, Outcome 21: Adverse events (tremor) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011688.pub2/references#CD011688-fig-0036">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011688.pub2/media/CDSR/CD011688/image_n/nCD011688-CMP-002.21.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011688-fig-0037"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011688.pub2/media/CDSR/CD011688/urn:x-wiley:14651858:media:CD011688:CD011688-CMP-002.22" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Fluoxetine versus another anti‐obesity agent, Outcome 22: Anthropometric measurements other than weight loss in kg (BMI)" data-id="CD011688-fig-0037" src="/cdsr/doi/10.1002/14651858.CD011688.pub2/media/CDSR/CD011688/image_n/nCD011688-CMP-002.22.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011688.pub2/media/CDSR/CD011688/image_t/tCD011688-CMP-002.22.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.22</div> <div class="figure-caption"> <p>Comparison 2: Fluoxetine versus another anti‐obesity agent, Outcome 22: Anthropometric measurements other than weight loss in kg (BMI) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011688.pub2/references#CD011688-fig-0037">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011688.pub2/media/CDSR/CD011688/image_n/nCD011688-CMP-002.22.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011688-fig-0038"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011688.pub2/media/CDSR/CD011688/urn:x-wiley:14651858:media:CD011688:CD011688-CMP-002.23" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Fluoxetine versus another anti‐obesity agent, Outcome 23: Morbidity (depression)" data-id="CD011688-fig-0038" src="/cdsr/doi/10.1002/14651858.CD011688.pub2/media/CDSR/CD011688/image_n/nCD011688-CMP-002.23.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011688.pub2/media/CDSR/CD011688/image_t/tCD011688-CMP-002.23.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.23</div> <div class="figure-caption"> <p>Comparison 2: Fluoxetine versus another anti‐obesity agent, Outcome 23: Morbidity (depression) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011688.pub2/references#CD011688-fig-0038">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011688.pub2/media/CDSR/CD011688/image_n/nCD011688-CMP-002.23.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011688-fig-0039"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011688.pub2/media/CDSR/CD011688/urn:x-wiley:14651858:media:CD011688:CD011688-CMP-003.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Fluoxetine versus no treatment, Outcome 1: Weight loss" data-id="CD011688-fig-0039" src="/cdsr/doi/10.1002/14651858.CD011688.pub2/media/CDSR/CD011688/image_n/nCD011688-CMP-003.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011688.pub2/media/CDSR/CD011688/image_t/tCD011688-CMP-003.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3: Fluoxetine versus no treatment, Outcome 1: Weight loss</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011688.pub2/references#CD011688-fig-0039">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011688.pub2/media/CDSR/CD011688/image_n/nCD011688-CMP-003.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011688-fig-0040"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011688.pub2/media/CDSR/CD011688/urn:x-wiley:14651858:media:CD011688:CD011688-CMP-003.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Fluoxetine versus no treatment, Outcome 2: Adverse events" data-id="CD011688-fig-0040" src="/cdsr/doi/10.1002/14651858.CD011688.pub2/media/CDSR/CD011688/image_n/nCD011688-CMP-003.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011688.pub2/media/CDSR/CD011688/image_t/tCD011688-CMP-003.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3: Fluoxetine versus no treatment, Outcome 2: Adverse events</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011688.pub2/references#CD011688-fig-0040">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011688.pub2/media/CDSR/CD011688/image_n/nCD011688-CMP-003.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011688-fig-0041"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011688.pub2/media/CDSR/CD011688/urn:x-wiley:14651858:media:CD011688:CD011688-CMP-003.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Fluoxetine versus no treatment, Outcome 3: Anthropometric measurements other than weight loss in kg (BMI)" data-id="CD011688-fig-0041" src="/cdsr/doi/10.1002/14651858.CD011688.pub2/media/CDSR/CD011688/image_n/nCD011688-CMP-003.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011688.pub2/media/CDSR/CD011688/image_t/tCD011688-CMP-003.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3: Fluoxetine versus no treatment, Outcome 3: Anthropometric measurements other than weight loss in kg (BMI) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011688.pub2/references#CD011688-fig-0041">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011688.pub2/media/CDSR/CD011688/image_n/nCD011688-CMP-003.03.svg" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD011688-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Summary of findings: fluoxetine compared with placebo</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Fluoxetine compared with placebo</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Population:</b> overweight or obese adults </p> <p><b>Settings:</b> outpatients </p> <p><b>Intervention:</b> fluoxetine </p> <p><b>Comparison:</b> placebo </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Placebo</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Fluoxetine</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>No of participants<br/>(trials)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Weight loss (kg)</b> </p> <p>(a) All fluoxetine dosages</p> <p>(b) Fluoxetine 60 mg/d<br/>(c) Fluoxetine 40 mg/d<br/>(d) Fluoxetine 20 mg/d </p> <p>Follow‐up:</p> <p>(a) 11 days to 52 weeks</p> <p>(b) 11 days to 52 weeks</p> <p>(c) 8 &amp; 12 weeks</p> <p>(d) 8 weeks to 52 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>(a) The mean weight loss ranged across placebo groups from −4.9 kg to 0.3 kg</p> <p>(b) The mean weight loss ranged across placebo groups from −4.9 kg to 0.3 kg<br/>(c) The mean weight loss ranged across placebo groups from −1.7 kg to −0.5 kg<br/>(d) The mean weight loss ranged across placebo groups from −3.1 kg to −0.5 kg </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>(a) The mean weight loss in the fluoxetine groups was <b>2.7 kg</b> higher (4 kg higher to 1.4 kg higher) </p> <p>(b) The mean weight loss in the fluoxetine groups was <b>2.5 kg</b> higher (3.8 kg higher to 1.2 kg higher)<br/>(c) The mean weight loss in the fluoxetine groups was <b>4 kg</b> higher (8.8 kg higher to 0.8 kg lower) </p> <p>(d) The mean weight loss in the fluoxetine groups was <b>1.5 kg</b> higher (3.5 kg higher to 0.5 kg lower) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(a) 956 (10)</p> <p>(b) 819 (7)<br/>(c) 182 (2)<br/>(d) 279 (3) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(a) &amp; (b)</p> <p>⊕⊝⊝⊝<br/><b>low</b><sup>a</sup> </p> <p>(c) &amp; (d)<br/>⊝⊝⊝⊝<br/><b>very</b> <b>low</b><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(a) The 95% prediction interval ranged between −7.1 kg and 1.7 kg</p> <p>(b) The 95% prediction interval ranged between −6.4 kg and 1.4 kg</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p><b>Health‐related quality of life</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p><b>Not reported</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Any adverse event (N)</b> </p> <p>Follow‐up: median 3 months, maximum 12 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>562 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>664 per 1000</b> (557 to 798) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.18</b> (0.99 to 1.42) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1253 (9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>l<b>ow</b><sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Only 9/19 trials reported on the outcome 'any adverse event'</p> <p>Adverse events dizziness, drowsiness, fatigue, insomnia and nausea were observed approximately twice as often following fluoxetine treatment </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Anthropometric measurements other than weight loss in kg (BMI reduction measured in</b> <b>kg/m²)</b> </p> <p>Follow‐up: median 3 months, maximum 12 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean BMI ranged across placebo groups from −0.4 kg/m² to −1.2 kg/m²</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean BMI reduction in the fluoxetine groups was <b>1.1 kg/m²</b> higher (3.7 kg/m² higher to 1.4 kg/m² lower) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>97 (3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>very low</b><sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Morbidity: depression (N)</b> </p> <p>Follow‐up: median 9.2 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>61 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>73 per 1000</b> (35 to 154) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.20</b> (0.57 to 2.52) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>393 (3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>very low</b><sup>e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>All‐cause mortality</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p><b>Not reported</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Socioeconomic effects</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p><b>Not reported</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>BMI:</b> boy mass index; <b>CI:</b> confidence interval; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>GRADE Working Group grades of evidence<br/><b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded by 1 level because of reporting bias and by 1 level because of imprecision (small median sample size) ‒ see <a href="./appendices#CD011688-sec-0121">Appendix 1</a><br/><sup>b</sup>Downgraded by 1 level because of reporting bias and attrition bias, by 1 level because of inconsistency (point estimates varied widely) and by 1 level because of imprecision (small median sample size, small number of trials) ‒ see <a href="./appendices#CD011688-sec-0121">Appendix 1</a><br/><sup>c</sup>Downgraded by 1 level because of reporting bias and attrition bias, and by 1 level because of imprecision (small median sample) ‒ see <a href="./appendices#CD011688-sec-0121">Appendix 1</a><br/><sup>d</sup>Downgraded by 1 level because of reporting bias and performance bias and by 2 levels because of imprecision (CI consistent with benefit and harm, small median sample size, small number of trials) ‒ see <a href="./appendices#CD011688-sec-0121">Appendix 1</a><br/><sup>e</sup>Downgraded by 1 level because of reporting bias, performance bias and attrition bias, and by 2 levels because of imprecision (CI consistent with benefit and harm, small median sample size, small number of trials) ‒ see <a href="./appendices#CD011688-sec-0121">Appendix 1</a> </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Summary of findings: fluoxetine compared with placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011688.pub2/full#CD011688-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD011688-tbl-0002"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Overview of trial populations</span></div> <tbody> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Trial ID</b> </p> <p><b>(trial design)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Intervention(s) and comparator(s)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Description of power and sample size calculation</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Screened/eligible<br/>(N)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Randomised<br/>(N)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>ITT<br/>(N)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Analysed<br/>(N)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Finishing trial<br/>(N)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Randomised finishing trial<br/>(%)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Duration of intervention</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="5" valign="top"> <p><a href="./references#CD011688-bbs2-0001" title="Al-HelliA , Al-AbbassiM , JasimG , Al-BayatyM . Effects of fluoxetine, omega 3, or their combination on serum leptin in Iraqi obese subjects. International Journal of Pharmaceutical Sciences Review and Research2015;35(1):90-5. ">Al‐Helli 2015</a><br/>(parallel RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: fluoxetine 20 mg</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>48/48</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="5" valign="top"> <p>2 months</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I2: omega‐3 gel</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I3: fluoxetine 20 mg + omega‐3 gel</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100</p> </td> </tr> <tr> <th align="right" class="headercell" colspan="3" rowspan="1" scope="col" valign="top"> <p><b>total:</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>48</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>48</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>48</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>48</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>100</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="7" valign="top"> <p><a href="./references#CD011688-bbs2-0017" title="SuplicyH , BoguszewskiC , Dos SantosC , Do DesterroM , CunhaD , RadomiskiR . A comparative study of five centrally acting drugs on the pharmacological treatment of obesity. International Journal of Obesity2014;38(8):1097-103. ">Suplicy 2014</a><br/>(parallel RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: diethylpropion</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>"As we had calculated the day to day coefficient of variation of resting metabolic rate for this method to be less than 5% for a given subject, we calculated that it was necessary to study at least 26 subjects to have sufficient power" </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>507/180</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>76.7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="7" valign="top"> <p>52 weeks</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I2: fenproporex</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>74.2</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I3: mazindol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>82.7</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I4: fluoxetine 20 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>64.5</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I5: sibutramine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: placebo</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>51.7</p> </td> </tr> <tr> <th align="right" class="headercell" colspan="3" rowspan="1" scope="col" valign="top"> <p><b>total:</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>180</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>174</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>174</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>129</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>71.7</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="5" valign="top"> <p><a href="./references#CD011688-bbs2-0008" title="GuimarãesC , PereiraL , Lucif JúniorN , CesarinoE , AlmeidaC , CarvalhoD , et al. Tolerability and effectiveness of fluoxetine, metformin and sibutramine in reducing anthropometric and metabolic parameters in obese patients. Arquivos Brasileiros de Endocrinologia e Metabologia2006;50(6):1020-5. ">Guimaraes 2006</a><br/>(parallel RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: sibutramine</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>35/35</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="5" valign="top"> <p>90 days</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I2: metformin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I3: fluoxetine 60 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: placebo</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100</p> </td> </tr> <tr> <th align="right" class="headercell" colspan="3" rowspan="1" scope="col" valign="top"> <p><b>total:</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>35</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>35</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>35</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>35</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>100</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><a href="./references#CD011688-bbs2-0003" title="BondiM , MenozziR , BertoliniM , VenneriM , RioG . Metabolic effects of fluoxetine in obese menopausal women. Journal of Endocrinological Investigation2000;23(5):280-6. ">Bondi 2000</a><br/>(parallel RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: fluoxetine 40 mg</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>32/32</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>12 weeks</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I2: fluoxetine 60 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: placebo</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100</p> </td> </tr> <tr> <th align="right" class="headercell" colspan="3" rowspan="1" scope="col" valign="top"> <p><b>total:</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>32</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>32</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>32</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>32</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>100</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD011688-bbs2-0009" title="HuangC , ChianC , LinJ . Short-term treatment of obesity with fluoxetine as a supplement to a low calorie diet. Changgeng Yi Xue za Zhi [Chang Gung Medical Journal]1998;21(1):50-6. ">Huang 1998</a><br/>(parallel RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: fluoxetine 60 mg</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>60/60</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>93.3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>12 weeks</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: no treatment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>73.3</p> </td> </tr> <tr> <th align="right" class="headercell" colspan="3" rowspan="1" scope="col" valign="top"> <p><b>total:</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>60</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>—</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>50</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>50</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>83.3</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD011688-bbs2-0004" title="BrossR , HofferL . Fluoxetine increases resting energy expenditure and basal body temperature in humans. American Journal of Clinical Nutrition1995;61(5):1020-5. ">Bross 1995</a><br/>(parallel RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: fluoxetine 60 mg</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>20/20</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>3 weeks</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: placebo</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100</p> </td> </tr> <tr> <th align="right" class="headercell" colspan="3" rowspan="1" scope="col" valign="top"> <p><b>total:</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>20</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>20</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>20</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>20</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>100</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD011688-bbs2-0005" title="Fernández-SotoM , González-JiménezA , Barredo-AcedoF , Luna del CastilloJ , Escobar-JiménezF . Comparison of fluoxetine and placebo in the treatment of obesity. Annals of Nutrition &amp; Metabolism1995;39(3):159-63. ">Fernández‐Soto 1995</a> </p> <p>(cross‐over RCT)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: fluoxetine 60 mg</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>42 participants with full cross‐over</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>78.2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>3 months</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: placebo</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>78.9</p> </td> </tr> <tr> <th align="right" class="headercell" colspan="3" rowspan="1" scope="col" valign="top"> <p><b>total:</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>42</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>—</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>33</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>33</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>78.5</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD011688-bbs2-0011" title="LawtonC , WalesJ , HillA , BlundellJ . Serotoninergic manipulation, meal-induced satiety and eating pattern: effect of fluoxetine in obese female subjects. Obesity Research1995;3(4):345-56. ">Lawton 1995</a><br/>(cross‐over RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: fluoxetine 60 mg</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>13 participants with full cross‐over</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>92.3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>2 weeks</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: placebo</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>92.3</p> </td> </tr> <tr> <th align="right" class="headercell" colspan="3" rowspan="1" scope="col" valign="top"> <p><b>total:</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>13</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>12</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>12</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>12</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>92.3</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD011688-bbs2-0007" title="DargaL , Carroll-MichalsL , BotsfordS , LucasC . Fluoxetine's effect on weight loss in obese subjects. American Journal of Clinical Nutrition1991;54(2):321-5. GoldsteinD , RampeyA , EnasG , PotvinJ , FludzinskiL , LevineL . Fluoxetine: a randomized clinical trial in the treatment of obesity. International Journal of Obesity and Related Metabolic Disorders1994;18(3):129-35. ">Goldstein 1994</a><br/>(parallel RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: fluoxetine 60 mg</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>458/458</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>230</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>217</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>217</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>99</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>43</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>52 weeks</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: placebo</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>228</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>217</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>217</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>108</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>47.3</p> </td> </tr> <tr> <th align="right" class="headercell" colspan="3" rowspan="1" scope="col" valign="top"> <p><b>total:</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>458</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>434</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>434</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>207</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>45.1</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><a href="./references#CD011688-bbs2-0006" title="GoldsteinD , RampeyA , DornseifB , LevineL , PotvinJ , FludzinskiL . Fluoxetine: a randomized clinical trial in the maintenance of weight loss. Obesity Research1993;1(2):92-8. ">Goldstein 1993</a><br/>(parallel RCT)<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: fluoxetine 60 mg</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>458/450</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>106</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>61</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>61</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>56.6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>40 weeks</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I2: fluoxetine 20 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>104</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>72</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>72</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>67.3</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: placebo</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>107</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>72</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>72</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>72</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>67.2</p> </td> </tr> <tr> <th align="right" class="headercell" colspan="3" rowspan="1" scope="col" valign="top"> <p><b>total:</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>317</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>205</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>205</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>202</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>63.7</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD011688-bbs2-0014" title="PedrinolaF , RissoW , LimaN , MedeirosG . Fluoxetine induced weight loss in overweight subjects: a double-blind placebo-controlled trial. Arquivos Brasileiros de Endocrinologia e Metabologia1993;37:31-3. ">Pedrinola 1993</a><br/>(parallel RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: fluoxetine 40 mg</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>20/20</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>12 weeks</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: placebo</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80</p> </td> </tr> <tr> <th align="right" class="headercell" colspan="3" rowspan="1" scope="col" valign="top"> <p><b>total:</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>20</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>—</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>18</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>18</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>90</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD011688-bbs2-0018" title="VisserM , SeidellJ , KoppeschaarH , SmitsP . No specific effect of fluoxetine treatment on fasting glucose, insulin, lipid levels, and blood pressure in healthy men with abdominal obesity. Obesity Research1994;2(2):152-9. VisserM , SeidellJ , KoppeschaarH , SmitsP . The effect of fluoxetine on body weight, body composition and visceral fat accumulation. International Journal of Obesity and Related Metabolic Disorders1993;17(5):247-53. ">Visser 1993</a><br/>(parallel RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: fluoxetine 60 mg</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>"Based on earlier studies at our department 40 men in total were selected for detecting a 10% improvement in body weight, fat‐free mass and abdominal fat areas, with 80% probability" </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>132/40</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>90</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>12 weeks</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: placebo</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100</p> </td> </tr> <tr> <th align="right" class="headercell" colspan="3" rowspan="1" scope="col" valign="top"> <p><b>total:</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>40</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>—</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>38</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>38</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>95</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><a href="./references#CD011688-bbs2-0019" title="WurtmanJ , WurtmanR , BerryE , GleasonR , GoldbergH , McDermottJ , et al. Dexfenfluramine, fluoxetine, and weight loss among female carbohydrate cravers. Neuropsychopharmacology1993;9(3):201-10. ">Wurtman 1993</a><br/>(parallel RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: dexfenfluramine</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>87/87</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>75</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>12 weeks</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I2: fluoxetine 20 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: placebo</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>86.2</p> </td> </tr> <tr> <th align="right" class="headercell" colspan="3" rowspan="1" scope="col" valign="top"> <p><b>total:</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>87</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>87</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>87</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>64</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>73.5</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD011688-bbs2-0010" title="KopelmanP , ElliottM , SimondsA , CramerD , WardS , WedzichaJ . Short-term use of fluoxetine in asymptomatic obese subjects with sleep-related hypoventilation. International Journal of Obesity and Related Metabolic Disorders1992;16(10):825-30. ">Kopelman 1992</a><br/>(cross‐over RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: fluoxetine 60 mg</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>11 participants with full cross‐over</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>3 days</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: placebo</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100</p> </td> </tr> <tr> <th align="right" class="headercell" colspan="3" rowspan="1" scope="col" valign="top"> <p><b>total:</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>11</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>11</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>11</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>11</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>100</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD011688-bbs2-0016" title="StinsonJ , MurphyC , AndrewsJ , TomkinG . An assessment of the thermogenic effects of fluoxetine in obese subjects. International Journal of Obesity and Related Metabolic Disorders1992;16(5):391-5. ">Stinson 1992</a><br/>(cross‐over RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: fluoxetine 60 mg</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>"A 12‐wk placebo‐subtracted total weight loss of at least 5% was considered. It was assumed that roughly 10% of participants in the placebo group would have a weight loss of 5% at the end of the study and the magnitude of the effect (the minimum difference between treatment arms to be considered clinically relevant) was assumed to be 40%. </p> <p>"Power was set as 0.8 with an alpha level of 0.05, resulting in an estimate minimum sample size of 26 participants per group" </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>30 participants with full cross‐over</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>2 weeks</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: placebo</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100</p> </td> </tr> <tr> <th align="right" class="headercell" colspan="3" rowspan="1" scope="col" valign="top"> <p><b>total:</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>30</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>30</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>30</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>30</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>100</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="7" valign="top"> <p><a href="./references#CD011688-bbs2-0002" title="BagiellaE , CairellaM , DelB , GodiR . Changes in attitude toward food by obese patients treated with placebo and serotoninergic agents. Current Therapeutic Research, Clinical and Experimental1991;50(2):205-10. ">Bagiella 1991</a><br/>(parallel RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: fenfluramine</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>60/60</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="7" valign="top"> <p>12 weeks</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I2: 5‐hydroxy‐tryptophan</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I3: d‐fenfluramine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I4: fluoxetine 20 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I5: fluvoxamine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: placebo</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <th align="right" class="headercell" colspan="3" rowspan="1" scope="col" valign="top"> <p><b>total:</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>60</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>60</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>60</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>60</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>100</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD011688-bbs2-0015" title="PijlH , KoppeschaarH , WillekensF , Op de KampI , VeldhuisH , MeindersA . Effect of serotonin re-uptake inhibition by fluoxetine on body weight and spontaneous food choice in obesity. International Journal of Obesity1991;15(3):237-42. ">Pijl 1991</a><br/>(parallel RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: fluoxetine 60 mg</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>24/24</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>91.6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>6 weeks</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: placebo</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100</p> </td> </tr> <tr> <th align="right" class="headercell" colspan="3" rowspan="1" scope="col" valign="top"> <p><b>total:</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>24</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>—</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>23</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>23</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>95.8</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><a href="./references#CD011688-bbs2-0013" title="LevineL , EnasG , ThompsonW , ByynyR , DauerA , KirbyR , et al. Use of fluoxetine, a selective serotonin-uptake inhibitor, in the treatment of obesity: a dose-response study. International Journal of Obesity1989;13(5):635-45. ">Levine 1989</a><br/>(parallel RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: fluoxetine 10 mg</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="5" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="5" valign="top"> <p>655/655</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>131</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>131</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>131</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>61</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>8 weeks</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I2: fluoxetine 20 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>131</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>131</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>131</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>86</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>65.6</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I3: fluoxetine 40 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>131</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>131</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>131</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>68.7</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I4: fluoxetine 60 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>131</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>131</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>131</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>87</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>66.4</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: placebo</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>131</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>131</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>131</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>74</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>56.4</p> </td> </tr> <tr> <th align="right" class="headercell" colspan="3" rowspan="1" scope="col" valign="top"> <p><b>total:</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>655</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>655</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>655</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>417</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>63.6</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD011688-bbs2-0012" title="LevineL , RosenblattS , BosomworthJ . Use of a serotonin re-uptake inhibitor, fluoxetine, in the treatment of obesity. International Journal of Obesity1987;11(Suppl 3):185-90. ">Levine 1987</a><br/>(parallel RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: fluoxetine 60 mg</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>120/120</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>59</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>11 days</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: placebo</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>59</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>86.6</p> </td> </tr> <tr> <th align="right" class="headercell" colspan="3" rowspan="1" scope="col" valign="top"> <p><b>total:</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>120</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>118</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>100</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>100</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>83.3</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>Grand total<sup>b</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>All interventions</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="3" valign="top"></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>1280</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="3" valign="top"></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>842</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="3" valign="top"></td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>All comparators</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>936</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>761</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>All interventions and comparators</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>2216</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>1603</b> </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="10"> <div class="table-footnote"> <p>— denotes not reported</p> <p><sup>a</sup>Obese outpatients were randomised who had lost 23.6 kg after 8 weeks of single‐blind fluoxetine 60 mg/d in the "qualification phase"<br/><sup>b</sup>Numbers do not add up correctly because <a href="./references#CD011688-bbs2-0002" title="BagiellaE , CairellaM , DelB , GodiR . Changes in attitude toward food by obese patients treated with placebo and serotoninergic agents. Current Therapeutic Research, Clinical and Experimental1991;50(2):205-10. ">Bagiella 1991</a> did not provide the numbers of randomised participants per intervention and comparator group; <a href="./references#CD011688-bbs2-0005" title="Fernández-SotoM , González-JiménezA , Barredo-AcedoF , Luna del CastilloJ , Escobar-JiménezF . Comparison of fluoxetine and placebo in the treatment of obesity. Annals of Nutrition &amp; Metabolism1995;39(3):159-63. ">Fernández‐Soto 1995</a>, <a href="./references#CD011688-bbs2-0010" title="KopelmanP , ElliottM , SimondsA , CramerD , WardS , WedzichaJ . Short-term use of fluoxetine in asymptomatic obese subjects with sleep-related hypoventilation. International Journal of Obesity and Related Metabolic Disorders1992;16(10):825-30. ">Kopelman 1992</a>, <a href="./references#CD011688-bbs2-0011" title="LawtonC , WalesJ , HillA , BlundellJ . Serotoninergic manipulation, meal-induced satiety and eating pattern: effect of fluoxetine in obese female subjects. Obesity Research1995;3(4):345-56. ">Lawton 1995</a> and <a href="./references#CD011688-bbs2-0016" title="StinsonJ , MurphyC , AndrewsJ , TomkinG . An assessment of the thermogenic effects of fluoxetine in obese subjects. International Journal of Obesity and Related Metabolic Disorders1992;16(5):391-5. ">Stinson 1992</a> were cross‐over trials and were subsumed under all interventions only </p> <p><b>C:</b> comparator; <b>I:</b> Intervention; <b>ITT:</b> intention‐to‐treat; <b>RCT:</b> randomised controlled trial; <b>wk</b>: week. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Overview of trial populations</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011688.pub2/full#CD011688-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011688-tbl-0003"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Fluoxetine versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.1 Weight loss (end of trial weight) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.1 Fluoxetine 60 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>819</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.50 [‐3.78, ‐1.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.2 Fluoxetine 40 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>182</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.97 [‐8.75, 0.81]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.3 Fluoxetine 20 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>279</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.50 [‐3.53, 0.54]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.2 Weight loss (duration of intervention) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1466</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.72 [‐3.73, ‐1.71]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.1 0 to 3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>366</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.34 [‐3.93, ‐2.76]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.2 4 to 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>453</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.75 [‐3.91, ‐1.59]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.3 7 to 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>647</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.34 [‐5.71, 3.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.3 Weight loss (cross‐over trial) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.4 Any adverse event <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1253</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.18 [0.99, 1.42]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.5 Specific adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5.1 Abdominal pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>504</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.51 [0.58, 3.90]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5.2 Allergy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>780</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.17 [0.03, 0.98]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5.3 Amnesia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>458</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>12.89 [0.73, 227.44]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5.4 Anorexia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>8.89 [1.36, 57.89]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5.5 Anxiety</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1210</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.07 [0.56, 2.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5.6 Constipation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>381</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.83 [0.58, 13.90]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5.7 Diarrhoea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1191</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.44 [0.97, 2.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5.8 Dizziness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>693</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.40 [1.03, 5.60]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5.9 Drowsiness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1253</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.67 [1.68, 4.24]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5.10 Dry mouth</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>896</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.23 [0.66, 2.30]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5.11 Dyspepsia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>501</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.99 [0.71, 5.55]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5.12 Fatigue</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1112</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.50 [1.62, 3.85]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5.13 Headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1234</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.17 [0.94, 1.47]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5.14 Insomnia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1191</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.23 [1.22, 4.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5.15 Irritability</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>442</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.41 [0.63, 3.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5.16 Malaise</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>322</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.60 [0.15, 2.46]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5.17 Nausea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1016</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.99 [1.35, 2.91]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5.18 Palpitation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.81 [0.12, 66.40]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5.19 Rhinitis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>933</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.75, 1.30]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.6 Participants with any adverse event (per dose) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.6.1 Fluoxetine 60 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1134</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.16 [0.93, 1.44]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.6.2 Fluoxetine 40 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>262</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.07 [0.93, 1.24]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.6.3 Fluoxetine 20 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>592</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.10 [0.92, 1.31]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.6.4 Fluoxetine 10 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>262</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.82, 1.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.7 Participants with any adverse event (duration of intervention) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.7.1 0 to 3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>444</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.71 [0.87, 3.33]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.7.2 4 to 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>477</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.51 [0.27, 23.63]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.7.3 7 to 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>213</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.54, 1.69]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.8 Participants discontinuing due to adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1188</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.88 [0.87, 4.06]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.9 Anthropometric measurements other than weight loss (BMI) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>97</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.11 [‐3.66, 1.43]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.9.1 Fluoxetine 60 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.30 [‐7.25, 0.65]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.9.2 Fluoxetine 40 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.80 [‐8.71, 3.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.9.3 Fluoxetine 20 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.20 [‐0.60, 1.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.10 Morbidity (depression) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>393</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.20 [0.57, 2.52]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.11 Morbidity (depression per dose) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>604</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.52, 1.73]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.11.1 Fluoxetine 60 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>333</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.41 [0.53, 3.79]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.11.2 Fluoxetine 20 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>271</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.58 [0.23, 1.48]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Fluoxetine versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011688.pub2/references#CD011688-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011688-tbl-0004"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Fluoxetine versus another anti‐obesity agent</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.1 Weight loss, end of trial weight <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1.1 Fluoxetine 60 mg/d vs. sibutramine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1.2 Fluoxetine 60 mg/d vs. metformin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1.3 Fluoxetine 20 mg/d vs. sibutramine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1.4 Fluoxetine 20 mg/d vs. dexfenfluramine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1.5 Fluoxetine 20 mg/d vs. diethylpropion</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1.6 Fluoxetine 20 mg/d vs. fenproporex</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1.7 Fluoxetine 20 mg/d vs. mazindol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.2 Any adverse event <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2.1 Fluoxetine 60 mg/d vs. sibutramine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2.2 Fluoxetine 60 mg/d vs. metformin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2.3 Fluoxetine 20 mg/d vs. sibutramine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2.4 Fluoxetine 20 mg/d vs. dexfenfluramine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2.5 Fluoxetine 20 mg/d vs diethylpropion</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2.6 Fluoxetine 20 mg/d vs. fenproporex</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2.7 Fluoxetine 20 mg/d vs. mazindol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.3 Adverse events (abdominal pain) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3.1 Fluoxetine 20 mg/d vs. sibutramine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3.2 Fluoxetine 20 mg/d vs. diethylpropion</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3.3 Fluoxetine 20 mg/d vs. fenproporex</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3.4 Fluoxetine 20 mg/d vs. mazindol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.4 Adverse events (allergy) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4.1 Fluoxetine 20 mg/d vs. sibutramine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4.2 Fluoxetine 20 mg/d vs. diethylpropion</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4.3 Fluoxetine 20 mg/d vs. fenproporex</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4.4 Fluoxetine 20 mg/d vs. mazindol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.5 Adverse events (anorexia) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.5.1 Fluoxetine 60 mg/d vs. sibutramine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.5.2 Fluoxetine 60 mg/d vs. metformin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.5.3 Fluoxetine 20 mg/d vs. sibutramine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.5.4 Fluoxetine 20 mg/d vs. diethylpropion</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.5.5 Fluoxetine 20 mg/d vs. fenproporex</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.5.6 Fluoxetine 20 mg/d vs. mazindol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.6 Adverse events (anxiety) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.6.1 Fluoxetine 20 mg/d vs. sibutramine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.6.2 Fluoxetine 20 mg/d vs. dexfenfluramine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.6.3 Fluoxetine 20 mg/d vs. diethylpropion</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.6.4 Fluoxetine 20 mg/d vs. fenproporex</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.6.5 Fluoxetine 20 mg/d vs. mazindol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.7 Adverse events (constipation) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.7.1 Fluoxetine 60 mg/d vs. sibutramine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.7.2 Fluoxetine 60 mg/d vs. metformin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.7.3 Fluoxetine 20 mg/d vs. sibutramine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.7.4 Fluoxetine 20 mg/d vs. dexfenfluramine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.7.5 Fluoxetine 20 mg/d vs. diethylpropion</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.7.6 Fluoxetine 20 mg/d vs. fenproporex</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.7.7 Fluoxetine 20 mg/d vs. mazindol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.8 Adverse events (diarrhoea) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.8.1 Fluoxetine 60 mg/d vs. sibutramine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.8.2 Fluoxetine 60 mg/d vs. metformin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.8.3 Fluoxetine 20 mg/d vs. sibutramine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.8.4 Fluoxetine 20 mg/d vs. dexfenfluramine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.8.5 Fluoxetine 20 mg/d vs. diethylpropion</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.8.6 Fluoxetine 20 mg/d vs. fenproporex</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.8.7 Fluoxetine 20 mg/d vs. mazindol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.9 Adverse events (dizziness) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.9.1 Fluoxetine 60 mg/d vs. sibutramine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.9.2 Fluoxetine 60 mg/d vs. metformin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.9.3 Fluoxetine 20 mg/d vs. sibutramine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.9.4 Fluoxetine 20 mg/d vs. diethylpropion</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.9.5 Fluoxetine 20 mg/d vs. fenproporex</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.9.6 Fluoxetine 20 mg/d vs. mazindol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.10 Adverse events (drowsiness) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.10.1 Fluoxetine 60 mg/d vs. sibutramine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.10.2 Fluoxetine 60 mg/d vs. metformin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.10.3 Fluoxetine 20 mg/d vs. sibutramine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.10.4 Fluoxetine 20 mg/d vs. dexfenfluramine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.10.5 Fluoxetine 20 mg/d vs. diethylpropion</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.10.6 Fluoxetine 20 mg/d vs. fenproporex</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.10.7 Fluoxetine 20 mg/d vs. mazindol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.11 Adverse events (dry mouth) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.11.1 Fluoxetine 60 mg/d vs. sibutramine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.11.2 Fluoxetine 60 mg/d vs. metformin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.11.3 Fluoxetine 20 mg/d vs. sibutramine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.11.4 Fluoxetine 20 mg/d vs. dexfenfluramine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.11.5 Fluoxetine 20 mg/d vs. diethylpropion</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.11.6 Fluoxetine 20 mg/d vs. fenproporex</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.11.7 Fluoxetine 20 mg/d vs. mazindol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.12 Adverse events (dyspepsia) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.12.1 Fluoxetine 20 mg/d vs. sibutramine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.12.2 Fluoxetine 20 mg/d vs. dexfenfluramine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.12.3 Fluoxetine 20 mg/d vs. diethylpropion</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.12.4 Fluoxetine 20 mg/d vs. fenproporex</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.12.5 Fluoxetine 20 mg/d vs. mazindol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.13 Adverse events (fatigue) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.13.1 Fluoxetine 20 mg/d vs. sibutramine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.13.2 Fluoxetine 20 mg/d vs. dexfenfluramine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.13.3 Fluoxetine 20 mg/d vs. diethylpropion</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.13.4 Fluoxetine 20 mg/d vs. fenproporex</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.13.5 Fluoxetine 20 mg/d vs. mazindol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.14 Adverse events (headache) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.14.1 Fluoxetine 60 mg/d vs. sibutramine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.14.2 Fluoxetine 60 mg/d vs. metformin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.14.3 Fluoxetine 20 mg/d vs. sibutramine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.14.4 Fluoxetine 20 mg/d vs. dexfenfluramine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.14.5 Fluoxetine 20 mg/d vs. diethylpropion</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.14.6 Fluoxetine 20 mg/d vs. fenproporex</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.14.7 Fluoxetine 20 mg/d vs. mazindol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.15 Adverse events (insomnia) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.15.1 Fluoxetine 60 mg/d vs. sibutramine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.15.2 Fluoxetine 60 mg/d vs. metformin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.15.3 Fluoxetine 20 mg/d vs. sibutramine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.15.4 Fluoxetine 20 mg/d vs. dexfenfluramine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.15.5 Fluoxetine 20 mg/d vs. diethylpropion</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.15.6 Fluoxetine 20 mg/d vs. fenproporex</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.15.7 Fluoxetine 20 mg/d vs. mazindol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.16 Adverse events (irritability) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.16.1 Fluoxetine 20 mg/d vs. sibutramine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.16.2 Fluoxetine 20 mg/d vs diethylpropion</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.16.3 Fluoxetine 20 mg/d vs. fenproporex</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.16.4 Fluoxetine 20 mg/d vs. mazindol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.17 Adverse events (malaise) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.17.1 Fluoxetine 20 mg/d vs. sibutramine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.17.2 Fluoxetine 20 mg/d vs. diethylpropion</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.17.3 Fluoxetine 20 mg/d vs. fenproporex</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.17.4 Fluoxetine 20 mg/d vs. mazindol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.18 Adverse events (nausea) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.18.1 Fluoxetine 60 mg/d vs. sibutramine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.18.2 Fluoxetine 60 mg/d vs. metformin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.18.3 Fluoxetine 20 mg/d vs. sibutramine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.18.4 Fluoxetine 20 mg/d vs. dexfenfluramine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.18.5 Fluoxetine 20 mg/d vs. diethylpropion</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.18.6 Fluoxetine 20 mg/d vs. fenproporex</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.18.7 Fluoxetine 20 mg/d vs. mazindol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.19 Adverse events (palpitation) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.19.1 Fluoxetine 20 mg/d vs. sibutramine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.19.2 Fluoxetine 20 mg/d vs. diethylpropion</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.19.3 Fluoxetine 20 mg/d vs. fenproporex</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.19.4 Fluoxetine 20 mg/d vs. mazindol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.20 Adverse events (sweating) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.20.1 Fluoxetine 60 mg/d vs. sibutramine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.20.2 Fluoxetine 60 mg/d vs. metformin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.20.3 Fluoxetine 20 mg/d vs. sibutramine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.20.4 Fluoxetine 20 mg/d vs. diethylpropion</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.20.5 Fluoxetine 20 mg/d vs. fenproporex</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.20.6 Fluoxetine 20 mg/d vs. mazindol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.21 Adverse events (tremor) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.21.1 Fluoxetine 20 mg/d vs. sibutramine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.21.2 Fluoxetine 20 mg/d vs. diethylpropion</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.21.3 Fluoxetine 20 mg/d vs. fenproporex</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.21.4 Fluoxetine 20 mg/d vs. mazindol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.22 Anthropometric measurements other than weight loss in kg (BMI) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.22.1 Fluoxetine 60 mg/d vs. sibutramine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.22.2 Fluoxetine 60 mg/d vs. metformin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.22.3 Fluoxetine 20 mg/d vs. sibutramine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.22.4 Fluoxetine 20 mg/d vs. diethylpropion</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.22.5 Fluoxetine 20 mg/d vs. fenproporex</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.22.6 Fluoxetine 20 mg/d vs. mazindol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.23 Morbidity (depression) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.23.1 Fluoxetine 20 mg/d vs. sibutramine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.23.2 Fluoxetine 20 mg/d vs. diethylpropion</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.23.3 Fluoxetine 20 mg/d vs. fenproporex</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.23.4 Fluoxetine 20 mg/d vs. mazindol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Fluoxetine versus another anti‐obesity agent</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011688.pub2/references#CD011688-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011688-tbl-0005"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Fluoxetine versus no treatment</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.1 Weight loss <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.2 Adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2.1 Any event</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2.2 Allergy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2.3 Anorexia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2.4 Diarrhoea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2.5 Headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2.6 Insomnia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2.7 Malaise</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2.8 Nauseas</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2.9 Drowsiness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.3 Anthropometric measurements other than weight loss in kg (BMI) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Fluoxetine versus no treatment</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011688.pub2/references#CD011688-tbl-0005">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD011688.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="de#CD011688-note-0006">Deutsch</a> </li> <li class="section-language"> <a class="" href="es#CD011688-note-0017">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD011688-note-0014">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD011688-note-0015">Français</a> </li> <li class="section-language"> <a class="" href="hr#CD011688-note-0013">Hrvatski</a> </li> <li class="section-language"> <a class="" href="ko#CD011688-note-0011">한국어</a> </li> <li class="section-language"> <a class="" href="ms#CD011688-note-0012">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="pl#CD011688-note-0016">Polski</a> </li> <li class="section-language"> <a class="" href="pt#CD011688-note-0010">Português</a> </li> <li class="section-language"> <a class="" href="ru#CD011688-note-0009">Русский</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD011688-note-0007">简体中文</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD011688-note-0008">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738735355000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738735355000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011688\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011688\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011688\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011688\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011688\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011688\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011688\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011688\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011688\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011688\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011688\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011688\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011688\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011688\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011688\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011688\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011688\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011688\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=xNbeAU8n&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011688.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD011688.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD011688.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD011688.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011688.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740716866394"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD011688.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740716866398"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD011688.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918da9f5eb0f1be3',t:'MTc0MDcxNjg2Ny4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 